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Whilst the cultivation of the Amaryllidaceae genus has primarily been for their ornamental 
properties, their use in traditional medicine is also well documented. Although over 100 alkaloids 
from this genus have been isolated, the phenanthridinone analogues narciclasine and 
pancratistatin isolated from the daffodil bulb, are particularly interesting due to their cytostatic and 
cytotoxic properties. They have potent and selective anticancer activity which is seemingly unique 
when compared to currently available chemotherapeutic agents. However, they have yet to be fully 
exploited as therapeutic agents due to their complex total synthesis and scarce availability from 
natural sources. The work described herein demonstrates short synthetic sequences which have 
been developed to gain simple analogues of these natural products. These have been assessed by 
MTS cell proliferation assays in order to gain more understanding of the SARs of narciclasine and 
pancratistatin, which in turn will be used to design additional biologically active compounds. 
 
These natural products share a dihydroisoquinolinone core and a series of AB-ring analogues were 
synthesised using a one-pot procedure previously developed and published by the group. 
Analogues were tested for anticancer activity by MTS cell proliferation assays against HT29 colon 
cancer cell line. Although these analogues were not biologically active their isoquinolinone 
counterparts showed a marked improvement with IC50 values below 300 μM. Functionalisation to 
simulate the C-ring of the natural products had limited success. Allylation gave analogues with IC50 
values below 250 μM, however attempts at subsequent dihydroxylation proved to be capricious. 
Acetylation at the benzylic position showed some potential with the most promising compound 
having an IC50 value of 33 μM. Upon N-methylation of the acetylated lactam some activity was lost 
with the IC50 value increasing to 110 μM. 
Optimisation of preliminary investigations was undertaken in order to synthesise late stage ABC-
ring analogues using Robinson annulation, Curtius rearrangement and Friedel-Craft acylation as key 
reaction steps. A novel methylenedioxy analogue was synthesised and further functionalisation was 
briefly explored with very limited success. Preliminary in-house MTS cell proliferation assays against 
the HT29 cells showed promising biological activity with IC50 values ranging from 9 to 50 μM. These 
selected analogues were sent to the NCI for further analysis.  
In order to improve the water solubility of the natural product a quinazolinone AB-ring core was 
incorporated to generate late stage tricyclic analogues with a basic nitrogen. This utilised a one-
step synthesis from anthranilamide and glutaraldehyde starting materials. Unfortunately these 
compounds were found to be unstable and further functionalisation was problematic due to 
decomposition of the tricyclic compounds. C-ring analogues were also examined which were 
derived from sugars such as L- and D-lyxose, furnishing hydroxylated derivatives with known 
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Members of the Amaryllidaceae family of bulbous plants include Galanthus (snowdrops), Amaryllis 
(Lilly) and Narcissus (daffodils) and interest in this family has primarily been for their cut flowers 
and decorative properties. However, of particular interest is their use in traditional medicine which 
has been well documented around the globe. Indeed, records dating back to ancient Greece show 
that Hippocrates of Kos (ca. B.C. 460 – 370) recommended the use of a pessary of narcissus oil to 
treat uterine tumours.2 To date over 100 alkaloids have been isolated from the Amaryllidaceae 
family and of particular significance are a structurally diverse group such as lycorine 2, crinine 3 and 
montanine 4, shown in Figure 1.01, which share a common biosynthetic pathway from the 
precursors norbelladine 1.3 These alkaloids have so far proved to be a bountiful source of 
biologically active compounds exhibiting a range of different activities. The exciting promise of 
these natural products is demonstrated by galanthamine 5, approved by the FDA for the 
symptomatic relief of Alzheimer’s disease, although it unfortunately remains an incurable disease. 
 
Figure 1.01: Examples of compounds generated from norbelladine 1 
1.1.1. Galanthamine 
The anecdotal use of snowdrops to treat poliomyelitis in the villages of Eastern Europe in addition 
to its similarity to morphine 6, Figure 1.02, led to its development as a drug.4,5 Although 
galanthamine was found to have some analgesic effects, a more exciting property was its ability to 
cross the blood brain barrier and selectively inhibit the enzyme acetylcholinesterase. This enzyme 
is responsible for the removal of acetylcholine (ACh) from the synaptic cleft following neuronal 
firing and it is well established that a decline in ACh neurons is responsible for the diminishing 
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cognitive function of Alzheimer’s patients.4,6 Galanthamine 5 slows the enzymatic breakdown of 
ACh, and so prolongs cholinergic neurotransmission leading to the successful treatment of the 
symptoms of these patients. Galanthamine was licenced in the mid 1990’s as Reminyl in the UK. 
Although galanthamine can be made by organic synthesis it is interesting to note that Reminyl is 
manufactured using galanthamine extracted from commercially grown daffodil bulbs.7  
 
Figure 1.02: Chemical structure of galanthamine 5 and morphine 6 
1.1.2. Narciclasine and related derivatives 
Keen gardeners have long known the irritant nature of daffodil bulbs and how cut Amaryllidaceae 
flowers can hasten the wilting of other flowers within a vase.2 This physiological effect has been 
attributed to a series of molecules which are structurally related to lycorine 2 shown in Figure 
1.01.2,3 Narciclasine 7 was the first to be isolated by Cerrioti et al.8 in 1967 and pancratistatin 8 
isolated in 1984 by the Pettit group,9 both of which are shown in Figure 1.03 with their 7-deoxy 
counterparts 9 and 10. It should be noted that the numbering of the tricyclic building block is 
according to Pettit et al.1 and will be further defined in Section 1.3.3 and is used throughout this 
work. 
 
Figure 1.03: Structure of narciclasine 7 and pancratistatin 8 with 7-deoxy counterparts 9 and 10 
The naming of this series of analogues is much debated. As they are lacking a basic nitrogen they 
are not true alkaloids. They have been widely termed the isocarbostyril group containing the 
- 3 - 
 
indicative isoquinolinone core, however this is misleading as it fails to capture the C-ring of the 
natural products. In addition, they have also been referred to as phenanthridinone derivatives, 
however it should be noted that they lack aromaticity of the C-ring. Within this work they will be 
referred to as phenanthridinone derivatives in order to fully appreciate the tricyclic nature of the 
natural products. 
Since their discovery narciclasine 7 and pancratistatin 8 have subsequently shown moderate 
antiviral activity, albeit at near toxic concentrations.10 However, it is their antineoplastic nature, 
particularly against some treatment-resistant cancer cell lines, which have shown them to be 
excellent lead candidates in our fight against cancer as reviewed by Kornienko and Evidente.2 
1.1.3. The phenanthridinones, cancer and current cancer therapy 
Cancer is well known as one of the leading causes of morbidity and mortality in the western world 
and although surgery and radiotherapy are valuable treatment options chemical and biological 
molecules are still the mainstay of treatment.11 As a consequence much research has been initiated 
into finding agents used for combating the disease. Cancerous cells are known to have lost normal 
cellular control of replication and current chemotherapies exploit this increase in cell division by 
the catastrophic targeting of DNA and/or interfering with the cell division process.12 Broadly 
speaking, chemotherapy can be expressed in terms of a drugs biological mode of action, a brief 
summary of which is highlighted herein.  
Alkylating agents are a prominent feature in current cancer treatment. Interference in cell 
replication and division is caused by the intercalation between nucleotide bases, modifying DNA (in 
addition to some other cellular proteins) by alkylation and/or forming crosslinks between DNA 
strands.13 This damage to the DNA can stimulate cell death providing a valuable treatment option 
for some cancers. The nitrogen mustards were the first to be investigated in the 1940’s when 
chemotherapeutic agents such as chlorambucil and cyclophosphamide were discovered.14 Platinum 
agents are often described as having alkylating-like properties and include drugs such as cisplatin 
and carboplatin.13 The platinum binds to purine nucleotides forming adducts on the DNA strands, 
similar to alkylation, which can then go on to form intrastrand crosslinks, thereby preventing normal 
DNA translation and replication.  
A group of compounds which mimic cellular molecules are termed the antimetabolites. This 
includes pyrimidine analogues 5-fluorouracil, capecitabine and gemcitabine and purine analogues 
such as 6-mercaptopurine. These drug molecules are incorporated into replicating DNA and RNA in 
place of pyrimidine-bases cytosine, uracil and thymine or purine-bases adenine and guanine. This 
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causes replication to fail by preventing chain elongation and subsequently induces apoptosis.13 
Another subset of antimetabolites are the folate antagonists such as methotrexate and 
pemetrexed.14 These inhibit the dihydrofolate reductase enzyme a key component in the 
metabolism of nucleotide bases, again preventing cell division and inducing apoptosis. 
Microtubules are an important component of a cell’s cytoskeleton, in particular they play a key role 
in the cell division process by forming the mitotic spindle.15 Each microtubule is made from a 
polymer of tubulin which is a target for a group of chemotherapeutic compounds termed spindle 
poisons. Tubulin stabilisers, such as paclitaxel, bind to tubulin already in formation preventing the 
disassembly of microtubules thereby causing prolonged mitotic arrest and cell death. Other agents 
work by binding tubulin monomers thereby preventing elongation to microtubules and include the 
vinca alkaloids such as vinblastine. 
During DNA translation and replication topoisomerase enzymes release the build-up of DNA 
torsional strain by instigating controlled single and double strand breaks of the double helix.13 
Topoisomerase poisons form a complex of this DNA-enzyme intermediate preventing religation of 
the strand breaks thereby initiating cell death. Such agents include irinotecan, camptothecin and 
doxorubicin.  
Although the intention of these treatments is to target the cancer specifically it is an unfortunate 
consequence that normal, healthy tissue is also affected. This leads to unwanted side effects 
sometimes so severe that treatment is terminated. In addition, cancer cells have adapted to evade 
cell death becoming resistant to a number of the first line treatments currently available. There is 
therefore an obvious need to continue the development of novel anticancer compounds. They 
require better side effect profiles in addition to the ability to circumvent resistance developed in 
some cancer cells. Narciclasine 7 and pancratistatin 8 have both been shown to have unique 
anticancer activity and will be discussed below in more detail. 
1.2. Biological Mode of Action of the phenanthridinones 
The biological mode of action of the phenanthridinone derivatives has yet to be definitively 
determined although their selectivity for a wide range of cancer cell lines has been proven. Indeed, 
screening of narciclasine 7 and pancratistatin 8 against 60 cancer cell lines by the National Cancer 
Institute (NCI) has shown them to exhibit a mean GI50 of 0.016 μM and 0.091 μM respectively, 
where GI50 is defined as the concentration required to inhibit 50 % of cell growth.1 Preliminary 
investigations suggest that narciclasine and related derivatives have a distinctive and selective 
anticancer activity, which will now be described.  
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1.2.1. The cytostatic effect of narciclasine  
Observations in plant physiology suggest that at low doses the phenanthridinone analogues are 
cytostatic rather than cytotoxic.16 For example, narciclasine is a well-established plant growth 
modulator which has been found to induce dose dependent mitotic cell cycle arrest in lettuce 
seedlings.17 The cytostatic effect has also been observed in vitro, in antiproliferative assays, and 
also in vivo using xenograft animal models of human tumours and is explained below. 
1.2.1.1. Inhibition of protein synthesis 
Ribosomes are complex molecular machines found within cells which are responsible for translating 
genetic information into the corresponding protein. In 1975 Carrasco et al. reported the inhibition 
of protein synthesis by narciclasine which specifically targets the peptidyl-transferase centre of the 
60S subunit in eukaryotic ribosomes.18 Further studies by Jimenez et al. in wild-type and mutated 
yeast confirmed that elongation of the amino acid chain is prevented and suggest that this is due 
to the inability of the amino acyl-tRNA (aa-tRNA) to move from the A-site to the P-site thereby 
preventing peptide bond formation, shown in Figure 1.04.19,20 A recent study probing the structure-
activity relationship (SAR) of eukaryotic ribosome inhibitors used X-ray crystallography to show 
narciclasine specifically binding to the A-site of the peptidyl-transferase centre thereby preventing 
normal entry and progression of the aa-tRNA.21 
 
Figure 1.04: Elongating peptide chain from eukaryotic ribosome 
In addition, narciclasine has been found to be a natural ligand for eEF1A, a protein highly involved 
in the delivery of aa-tRNA to the A-site of the ribosome.22 The eEF1A protein is also an important 
component of cytokinesis by mediating actin organisation and any inhibition would therefore be 
cytostatic. The role of eEF1A in cell migration is of particular interest as it could assist in tackling the 
prognosis of terminal metastatic cancer patients, the significance of which will be highlighted 
further below. 
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1.2.1.2. Prevention of cell migration. 
The disruption of cell migration by narciclasine-mediated inhibition of eEF1A22 is complimented by 
further work by the Lefranc group into xenograft glioblastoma cells.23 Glioblastoma cancer is a 
particularly aggressive and invasive brain cancer which can actively migrate over large distances 
through extracellular spaces in the brain. The cofilin pathway is directly responsible for regulating 
the actin cytoskeleton by controlling the stability of actin filaments and therefore plays a key role 
in cell migration. Narciclasine moderates Rho GTPase activity which in turn prevents the cascade of 
events leading to cofilin activation. Preclinical studies have demonstrated cell cycle arrest and the 
inhibition of cell migration of glioblastoma cells which, in turn increases the survival of xenograft-
bearing mice. It is worth noting here that narciclasine and pancratistatin show particular promise 
against brain cancers and this may also be due, in part, to their lipophilic nature which enables them 
to pass the blood brain barrier.  
1.2.2. The cytotoxic effect of the phenanthridinone derivatives  
1.2.2.1. Cell death and the induction of apoptosis 
Apoptosis is a non-traumatic, highly conserved process of cell death which has been widely 
characterised in the literature. It presents with defined biochemical hallmarks all leading to 
phagocytosis.12 This tight control ensures the protection of surrounding tissue from intracellular 
enzymes and cytokines and may also allow for the recycling of proteins. Conversely, necrosis is an 
uncontrolled form of cell death often resulting from an extreme insult to the cell. It is characterised 
by rupturing of the cell wall leading to secretion of cytoplasmic constituents. Apoptosis is preferred 
and its initiation is the target of many antineoplastic compounds. 
It is generally well established that apoptosis is initiated by two main pathways, the intrinsic 
(mitochondrial) pathway or the extrinsic (death-receptor) pathway.12,24 After stimulation of the 
extrinsic pathway there are thought to be two divergent responses which are cell type specific. 
Narciclasine and pancratistatin have been shown to stimulate both pathways and are described in 
more detail below. 
1.2.2.1.1. Extrinsic pathway 
Dumont et al. showed that narciclasine-mediated apoptosis can occur via the extrinsic pathway.25 
Stimulation of the cell surface TNF death receptors, FAS and DR4 leads to the formation of the 
Death Inducing Signalling Complex (DISC) and the subsequent recruitment and activation of pro-
caspase 8 to caspase 8. A divergence of the downstream signalling cascade then occurs which is 
highlighted in Figure 1.05. 
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Figure 1.05: Diverging pathways of narciclasine-mediated induction of apoptosis25 
Type I cells, such as PC-3 prostate cancer cells used in the study, show a high concentration of 
caspase 8 activation.25 This leads to the direct recruitment and activation of the caspase cascade 
triggering apoptosis. Type II cells, such as MCF7 breast cancer described by Dumont et al., show a 
concentration of caspase 8 activation insufficient to initiate the caspase cascade. Amplification of 
the signal is therefore required and achieved by the permeabilisation of the mitochondrial outer 
membrane. This results in a release of the pro-apoptotic protein cytochrome c and the subsequent 
formation of the cytochrome-c-Apaf-1-procaspase-9 complex, termed the apoptosome, which 
commits the cell to die. 
Complementary work undertaken by Kekre et al shows pancratistatin-promoted stimulation of the 
Fas receptor, albeit with slightly different downstream consequences.26 Apoptosis of Jurkat (human 
T lymphocyte) cancer cells, preferentially to their non-cancerous counterparts, was achieved with 
low concentrations of pancratistatin. At a concentration of 500 nM a third of the Jurkat cells were 
shown to undergo apoptosis, this figure increased to over 70 % at concentrations of 1 μM. 
Interestingly, it was the activation of caspase 3, rather than the previously described caspase 8, and 
the flipping of the membrane bound phosphatidylserine from the cytosol to the outside of the cell 
which induced apoptosis in this study. 
1.2.2.1.2. Intrinsic pathway 
The mitochondrion are extremely important organelles with a dual role of providing energy to the 
cell in the form of ATP as well as playing a crucial role in the management of apoptosis. Pro- and 
anti-apoptotic proteins elicit a response from the mitochondria by either preventing or instigating 
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cell death. The bio-energetic differences between cancerous and non-cancerous cell mitochondria 
and contradictory function of maintaining life and controlling death have led the mitochondria to 
becoming an exciting new target for anticancer therapies, either directly or by the initiation of pro-
apoptotic proteins described above. 
A tumour suppressor protein, p53, is an important regulator in the activation of pro-apoptotic 
members of the Bcl-2 family of proteins. These proteins govern mitochondrial outer membrane 
potential and therefore ultimately control the release if cytochrome c, apoptosome formation and 
the activation of caspase 3.27 Unfortunately, one of the most common genetic defects in human 
cancer causes a mutation of p53.24  
Griffin et al. has shown pancratistatin to induce intrinsic apoptosis in both p53 negative HT29 and 
p53 wild-type HCT116 colon cancer cell lines with IC50 values of 100 nM.28 This is without relative 
toxicity to normal colon cells, CCD-18Co, which have an IC50 > 10 μM. This implies that pancratistatin 
elicits a response in a p53 independent manner which was shown to be the case. A collapse in 
mitochondrial membrane potential was observed with a corresponding loss of membrane integrity 
and the associated release of cytochrome c and subsequent apoptosome formation described 
previously. 
The unique physiological activity of narciclasine and pancratistatin clearly mark them out as good 
clinical candidates. Although narciclasine 7 was first observed as being an antimitotic substance by 
Ceriotti et al. in 1967 it does not share the spindle poison characteristics as shown by paclitaxel or 
vinblastine.8 Rather, it is thought to elicit a response by the inhibition of protein synthesis previously 
described.18-20 Narciclasine 7 and pancratistatin 8 induce apoptosis either by the initiation of the 
extrinsic or intrinsic apoptotic pathway, and not by causing catastrophic interface with DNA or 
associated metabolites as with alkylating agents, platinum agents, antimetabolite or topoisomerase 
inhibitors. This again highlights the unique mode of action exhibited by these natural products. 
Unfortunately, their low natural abundance and complex total synthesis have so far prevented their 
clinical progression. 
1.3. Phenanthridinone derivatives and drug development 
The extraction of narciclasine and pancratistatin from a variety of different Amaryllidaceae bulbs is 
a laborious and costly process, typically producing 100-150 mg of pure compound per kg of bulb.29 
This, in addition to their poor aqueous solubility, has had a prohibitive impact on the development 
of these compounds as clinical candidates. This is at odds to galanthamine 5 which is easily 
extracted from natural sources due to the presence of a basic nitrogen.7 However, their seemingly 
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unique in addition to specific anticancer activity has stimulated research into the total synthesis of 
the natural products and truncated and unnatural analogues in order to gain a thorough 
understanding of the anticancer pharmacophore. Furthermore, research into improving the drug-
like characteristics of the natural products is also in development and a variety of potential prodrug 
analogues will be discussed further in Section 1.3.4. 
1.3.1. Total synthesis of narciclasine 
The first total synthesis of narciclasine was reported by Rigby et al.30 in 1997 (Table 1.01, Entry 1), 
however the total number of steps and disappointingly low overall yield warranted further 
investigation by the research community and is summarised in Table 1.01. It should be noted that 
more recent synthetic work is towards unnatural and truncated analogues of both natural products 
and will be discussed in more detail in Section 1.3.3.  
Entry Research group Year Number of steps Overall yield (%) 
1 Rigby et al.30 1997 23 0.2 
2 Gonzalez et al.31 1999 12 0.6 
3 Keck et al.32 1999 14 16 
4 Elango et al.33 2002 9 19 
Table 1.01: Summary of the total synthesis of narciclasine 
Hudlicky and co-workers approach to the synthesis of narciclasine started from a bio oxidation 
reaction of a benzene derivative (Table 1.01, Entry 2).31 The whole-cell fermentation of 1-3-
dibromobenzene 11, using recombinant Escherichia coli JM109(pDTG601A), gave the 
cyclohexadiene diol 12. This was used to construct part of the of the polyhydroxylated C-ring found 
in narciclasine 7 (Scheme 1.01).31 This was followed by multiple reactions, including the key steps 
of a Suzuki coupling of a boronic acid derivative of o-vanillin with a vinyl-bromide to introduce the 
A-ring moiety, and a modified Bischler-Napieralski reaction to form the B-ring lactam. 
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Scheme 1.01: Enzymatic dihydroxylation reported by Hudlicky et al.31 
In 2002, Elango and Yan also applied microbial arene oxidation in their total synthesis of narciclasine 
7 gaining a cis-dihydrodiol by whole cell fermentation of benzene with Pseudomonas putida 39/D, 
shown in Scheme 1.02.33 Their overall yield was reported as an impressive 19 % over 9 steps (Table 
1.01, Entry 4), although this was later questioned in a review by Rinner and Hudlicky,34 as an 
accurate step count could not be made from the published data. The key synthetic steps are shown 
in Scheme 1.02 and were reported as being stereocontrolled epoxide formation followed by 
intramolecular SnCl4-catalysed arene epoxide coupling to gain late stage analogue 16.33 
 
Scheme 1.02: Key steps in the synthesis reported by Elango et al.33 
Keck et al. presented the total synthesis of enantiomerically pure narciclasine in 14 steps from D-
gulonolactone (Table 1.01, Entry 3).32 After the formation of alkyne 17, intramolecular radical 
cyclisation was carried out using thiophenol under irradiation and gave the key intermediate 18 in 
88 % yield, as shown in Scheme 1.03. Following further steps, B-ring formation occurred by 
aluminium-catalysed cyclisation and subsequent deprotection furnished (+)-narciclasine 7 in 16 % 
yield.  
- 11 - 
 
 
Scheme 1.03: Key steps in the synthesis reported by Keck et al.32 
1.3.2. Total synthesis of pancratistatin 
The first reported synthesis of racemic pancratistatin 8 was by Danishefsky et al. in 1989 over 26 
steps with a 0.13 %.35 The first synthesis of enantiomerically pure (+)-pancratistatin was by Tian et 
al.36 in 1995 (Table 1.02, Entry 1) shortly followed by Trost et al.37 later that year (Table 1.02, Entry 
2). There have been subsequent efforts into the stereoselective synthesis of the enantiomerically 
pure pancratistatin, a selection of which are shown in Table 1.02 and some of which will be 
discussed herein.  
Entry Research group Year Number of steps Overall yield (%) 
1 Tian et al.36 1995 14 2.0 
2 Trost et al.37 1995 15 11.0 
3 Magnus et al.38 1998 19 1.2 
4 Rigby et al.39 2000 22 0.4 
5 Pettit et al.40 2001 10a 3.6 
6 Kim et al.41 2002 16 4.0 
7 Ko et al.42 2004 17 5.8 
8 Li et al.43 2006 12 9.0 
9 Cagide-Fagin et al.44 2012 12 2.7 
Table 1.02: A selection of the total syntheses of pancratistatin (a From narciclasine) 
An interesting approach to the synthesis of pancratistatin was employed by Pettit et al. using the 
more abundantly available narciclasine as a precursor (Table 1.02, Entry 5).40 This involved 10 
synthetic steps from narciclasine 7 and pancratistatin 8 was isolated in a 3.6 % yield. 
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Rigby et al. described a 22 step synthesis of pancratistatin (Table 1.02, Entry 4) with a hydrogen 
bond-controlled aryl enamide photocyclisation as a key step, shown in Scheme 1.04.39 This 
furnished the advanced analogue 20 in 30 % yield, a synthetic approach which was initially used to 
synthesise narciclasine 7 with analogue 20 being the last common intermediate.30  
 
Scheme 1.04: Photocyclisation of analogue 1939 
Li et al. utilised two coupling fragments, bromide 21 and pinitol analogue 22, in order to gain the 
A/C-ring 23.43 They report the total synthesis of pancratistatin from pinitol in 12 steps, 2.7 % yield 
(Table 1.02, Entry 8). Coupling fragments are also employed by Cagide-Fagin et al. (Table 1.02, Entry 
9) who report a [3+3] enantioselective annulation of ketone 24 and methylenedioxy derivative 25 
to get the A/C-ring analogue 26, shown below in Scheme 1.05.44 
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Li et al.43 
 
Cagide-Fagin et al.44 
 
Scheme 1.05: Synthesis of late stage pancratistatin intermediates from coupling fragments 
1.3.3. Structure-activity relationship of the phenanthridinone group 
A thorough understanding of the structure-activity relationship (SAR) of the phenanthridinone 
group will enable investigations into more efficacious clinical candidates and will also provide 
biological probes in order to fully elucidate the true mode of action of this group. The tricyclic 
phenanthridinone building block, which is numbered according to Pettit et al.,1 and shown in Figure 
1.06, is present in a variety of Amaryllidaceae natural products, with various substituents on the 
aromatic A-ring and a polyhydroxylated C-ring. There are a number of structural analogues of 
narciclasine and pancratistatin and only selected examples are discussed here to highlight key 
features in the ring system. 
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Figure 1.06: Numbering of the phenanthridinone narciclasine core1 
1.3.3.1. A-ring 
It has been well established that narciclasine 7 and pancratistatin 8 have a tenfold increase in 
activity compared to that reported for their 7-deoxy counterparts 9 and 10, shown previously in 
Figure 1.03, which is attributed to the free phenolic hydroxy at C(7).1 The anticancer activity was 
also shown to diminish with subsequent removal of oxygen from the A-ring, with a C(9)-methoxy 
analogue of pancratistatin showing very poor activity, with a mean GI50 value of 12.5 μM across a 
minipanel of human cancers. 
 
Figure 1.07: Biological activity of narciclasine 7 and pancratistatin 81 
In order to address the poor bioavailability of the parent compounds, Hudlicky et al. further 
investigated the tolerance for A-ring manipulation by its replacement with an indole moiety to give 
pancratistatin analogue 27, shown in Figure 1.08.45 The H-bond donor-acceptor pairing of the β-
ketoamide moiety was thought to contribute to the anticancer pharmacophore and was emulated 
by the β-carboline-1-one analogue 27 as described in Figure 1.08.  
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Figure 1.08: Spatial similarities of pancratistatin 8 compared to bioisostere 2745 
Pancratistatin 8 and analogue 27 were tested against a small panel of human cancer cell lines with 
analogue 27 being found to have a diminished activity of more than 100 fold.45 Although molecular 
modelling showed spatial similarities the difference in electronic density of the analogue to the 
parent compound was apparent following molecular mapping. The findings complement previous 
work showing the requirement for electronegative oxygenation of the A-ring for activity.45,46 This 
application of the indole group as a bioisostere for a related analogue was reported by our group,47 
which showed only a slight decrease in activity. 
In order to mimic the donor-acceptor functionality of the C(7) phenol the N(7)-oxide 28 was 
synthesised in addition to 7-aza-nornarciclasine 29 and its HCl salt 30, all shown in Figure 1.09.48 
Each analogue was tested against HeLa cervical cancer and MCF7 breast cancer cell lines. No activity 
was observed for analogue 29 with moderate activity (IC50 > 100 μM) being observed for analogues 
28 and 30. Although the analogues are also missing the methylenedioxy bridge these results suggest 
that the C(7) phenol is crucial for preserving cancer cell inhibition.    
 
Figure 1.09: Activity of aza-analogues against HeLa and MCF7 cancer cell lines48 
1.3.3.2. B-ring 
Current understanding suggests that manipulation of the lactam B-ring is poorly tolerated, although 
this has yet to be fully explored. An investigation into the total synthesis of narciclasine by Chretien 
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et al. generated the lactone derivatives 31 and 32, as well as their epi-analogues, all of which were 
found to be inactive against L1210 murine lymphocytic leukaemia cells (Figure 1.10).49 In addition, 
reduction of the lactam to the corresponding basic amine 33 showed biological activity against a 
minipanel of human cancers lines with mean GI50 > 35 μM compared with GI50 < 0.3 M of the C(7)-
deoxy natural product 9.50 Interestingly, the hydrochloride salt 34 performed slightly better with an 
improved activity of GI50 > 16 μM. 
 
Figure 1.10: Manipulation of the B-ring and observed biological activity49-51 
The requirement for a cyclic system was established by the synthesis of seco-analogues of 
narciclasine and lycoricidine.51 Compounds 35 and 36, lacking the C(10a)/C(10b) bond, showed no 
activity against L1210 cells. 
1.3.3.3. C-ring 
The polyoxygenated amino-inositol C-ring of the narciclasine analogues has attracted much 
synthetic attention in order to ascertain the minimum structural requirements for the anticancer 
pharmacophore. The natural product 7-deoxy-trans-dihydronarciclasine 37, often isolated with 
narciclasine 7, retains activity in the same order of magnitude as lycoricidine 9, with a 
corresponding increase in activity for the C(7) phenol 38, as shown in Figure 1.11.52 
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Figure 1.11: C(1) derivatives of the phenanthridinone natural products 
A variety of C(1) derivatives of 7-deoxypancratistatin were developed to further probe the 
possibility for manipulation at this position. The acid 39 and methyl ester 40 were found to be 
inactive however, compound 41 and acetate analogue 42 both had moderate activity, with IC50 
values of 0.09 and 0.06 μM respectively, against prostate cancer HTB-81 (Figure 1.11).53 These 
compounds were also comparable to 7-deoxypancratistatin 10 against P388 cancer cells. In 
addition, the acetate analogue 42 was found to induce apoptosis in Jurkat cells and not in non-
cancerous human fibroblast again showing cancer cell specificity. 
Related work by the McNulty group further elaborated key biological features of the C-ring and 
showed that the C(4) derivative 43 had poor activity against P388 cells (ED50 of 154 μM ) with some 
improvement being observed with the C(2)-C(3) diol 44, ED50 of 1.62 μM, both of which are shown 
in Figure 1.12.54,55 
 
Figure 1.12: Structure of C(4) derivative 43 and C(2)-C(3) diol 44 
Continuing their research in this area the McNulty group also showed no induction of apoptosis or 
cell growth inhibition by the C(2)-C(4) diol 45, proving it to be inactive (Figure 1.13).56 Investigations 
of C-ring substitutions by Rinner et al. generated the C(3)-C(4) diol 46, an analogue of 7-
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deoxypancratistatin 10, which had disappointing biological activity showing a mean GI50 > 36 μM 
against a minipanel of human cancers.46  
 
Figure 1.13: Structure of C(2)-C(4) 45 and C(3)-C(4) diol 46 
In summary, a number of key characteristics have been identified as being essential or increasing 
the anticancer activity of the natural products. Poly-oxygenation of the A-ring is essential for 
maintaining activity, with a ten-fold increase in anticancer activity being observed when the phenol 
at C(7) is present, as highlighted in Figure 1.14. An intact, six-membered B-ring is required with an 
amide moiety. Replacing the lactam with a basic nitrogen or lactone renders the molecule inactive. 
The C(10b) position should be sp2 hybridised, or if saturated, should have a trans B/C-ring junction 
as seen in pancratistatin. Hydroxylation of the C-ring is required to maintain activity although the 
absolute and relative stereochemistry of the C-ring has yet to be determined. It appears that the 
hydroxyl at C(1) is not essential for activity but can be manipulated such as in the formation of pro-
drugs which will now be described. 
 
Figure 1.14: Summary of SAR 
1.3.4. Pro-Drug synthesis and activity 
Salt derivatives have widely been shown to improve water solubility and bioavailability of drug 
molecules, for example galanthamine 5 (Reminyl) is orally delivered as the hydrobromide salt. 
However narciclasine 7 and pancratistatin 8 possess a lactam and are therefore not basic, so simple 
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salt formation of the natural product is not possible. Alternatively, phosphate prodrugs are 
encouraging as they increase water solubility and exploit cytosolic nonspecific phosphatases in 
order to release an active compound and elicit a response. The poor aqueous solubility (53 μg/mL) 
of pancratistatin and related compounds is thought to be responsible for the poor delivery of these 
molecules and has, in part, led to their exclusion from clinical testing. This encouraged a series of 
published works by the Pettit research group into phosphate prodrugs of the phenanthridinone 
natural products. This has proved to be a very successful approach and has subsequently been 
patented and will be discussed in more detail below. 
Initial investigation focused on the phosphorylation of the C(7) hydroxyl of natural product 
pancratistatin 8, and the construction of a series of different counterion analogues was 
examined.57,58 Most of the derivatives had comparable in vitro activity against the standard murine 
P388 leukaemia cell line and minipanel of human cancer cells, however it was the sodium 7-O-
phosphate prodrug 47, shown in Figure 1.15, which was most soluble at 20 mg/mL in water. The 
3,4-O-cyclic phosphate derivatives of pancratistatin were also synthesised in parallel due to the very 
poor yield of their 7-O-phosphate counterparts however decomposition of the cyclic product led to 
an investigation of the 4-O-phosphate series.59 Again it was the sodium phosphate analogues 48 
and 49 which showed the best solubility. This procedure has also been extended to the formation 
of a 3,4-O-cyclic phosphate narciclasine series, with the sodium salt again being the most soluble 
at 60 mg/mL.60 It is proposed that the reduced in vitro anticancer activity of this series is due to the 
lack of endogenous nonspecific phosphatases which will be more efficient in in vivo models.61 
 
Figure 1.15: Disodium 7-O-phosphate 47, sodium 3,4-O-cyclic phosphate 48 and sodium 4-O-
phosphate 49 prodrugs of pancratistatin 
The 3-log improvement in solubility of the 3,4-O-cyclic phosphate prodrug 48 of pancratistatin 8 
allowed for subsequent in vivo investigations using clinically relevant IV administration.62 A 
statistically significant delay in growth of the tumour was observed using a xenograft of DLD-1 colon 
adenocarcinoma cell line in mice, with negligible harm to the host. The effect was found to be a 
reduction in operational vasculature in the tumour 24 hours after exposure with the disruption of 
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mitochondrial function appearing to be the cause, a common mechanism with other vascular 
targeting agents. 
As previously discussed in Section 1.3.3.3 and shown in Figure 1.11, manipulation at C(1) was well 
tolerated with hydroxymethyl 41 and acetate counterpart 42 showing nM activity. The pro-drug 
C(1) benzoate ester 50 (shown in Figure 1.16) which would potentially deliver the natural product 
pancratistatin 8 upon non-specific ester hydrolysis, showed potent biological activity with a GI50 of 
1.33 nM across a minipanel of human cancer cell lines, compared to a GI50 of 66 nM across the same 
panel for pancratistatin 8.40 Manipulation at C(1) therefore shows continued and even improved 
biological activity with the addition of a lipophilic group whereas an increase in polarity is not 
tolerated. It has been postulated that an increase in lipophilicity at C(1) assists in cell penetration 
although it is unclear as to whether intracellular hydrolysis occurs to release the natural product.53 
Further development of C(1) benzoate ester 50 led to the synthesis of the phosphate salt 51. This 
showed good but slightly diminished in vitro activity, GI50 of 244 nM, against the same minipanel of 
human cancer cell lines as analogue 50.59 
 
Figure 1.16: C(1) benzoate ester analogues of pancratistatin40,59 
Narciclasine and pancratistatin have both shown interesting and exciting biological activities, in 
particular against some resistant cancer cell lines and also brain cancers, both of which are 
notoriously difficult to treat. Their low natural abundance and complex total synthesis has led to 
much interest around finding short and efficient syntheses of these natural products as well as 
related and truncated versions in order to probe their SAR.  
1.4. Project aims and objectives 
The aim of this project is to synthesise simplified narciclasine 7 and pancratistatin 8 analogues using 
short synthetic sequences and to explore their biological activity. 
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AB-ring analogues will initially be synthesised building on the dihydroisoquinolinone framework 
present throughout the phenanthridinone natural products. This will be based on published 
synthesis within the group employing conditions for Curtius rearrangement and intramolecular 
Friedel-craft acylation.63 Functionalisation of the AB-ring system will allow for the investigation into 
the need for a cyclised C-ring.  
Late stage narciclasine dimethoxy and dimethoxyhydroxy analogues have been synthesised by the 
group.64 Optimisation of this preliminary work will be done in addition to the synthesis of the novel 
methylenedioxy analogue in order to assess these compounds for biological activity with a view to 
sending them to the NCI for further testing.  
Novel quinazolinone analogues, which would possess a basic nitrogen instead of C(10b) on the late 
stage ABC-ring intermediates, will be investigated which will be of great interest. In addition, 
tricyclic analogues will also be examined which are derived from sugars such as L- and D-lyxose. 
This will give hydroxylated C-ring analogues with known absolute and relative stereochemistry and 
will be of interest in this field of research. 
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2. Synthesis and evaluation of AB-ring analogues 
2.1. Introduction to the isoquinolinone motif 
A common structural motif found throughout the natural world and medicinal chemistry is 
dihydroisoquinolinone 52, which is also present in narciclasine 7 and related derivatives (Figure 
2.01). The Caggiano research group has been interested in developing efficient methods to 
synthesise dihydroisoquinolinones related to the narciclasine structure and examine their biological 
activities. Preliminary work in this area was undertaken by the group, which has been expanded 
and described herein.  
 
Figure 2.01: Dihydroisoquinolinone 52 and highlighted core of narciclasine 7 
2.2. Synthesis of dihydroisoquinolinone 
The Caggiano group developed and reported an efficient one-pot procedure for the synthesis of 
various lactams from the corresponding carboxylic acid precursors (Scheme 2.01).63 This method 
was successfully used to furnish analogues of tetrahydro β-carbolinone 54 and 
dihydroisoquinolinone 55 as shown below in Scheme 2.01. 
 
Scheme 2.01: General synthesis of lactam analogues by Judd et al.63 
The synthesis of three dihydroisoquinolinone analogues were reported by Judd et al.,64 with this 
reported methodology being successfully employed in this work and is now described. 
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Commercially available 3,4-dimethoxy dihydrocinnamic acid 56 was treated with triethylamine 
(Et3N) and diphenylphosphoryl azide (DPPA) to afford the corresponding acyl-azide 57 shown in 
Scheme 2.02.63 Heating the acyl-azide intermediate 57 from room temperature to 90 °C initiated a 
Curtius rearrangement to give the isocyanate 58 with the evolution of N2 gas. Upon the removal of 
toluene, intramolecular Friedel-Crafts acylation was achieved with the addition of neat boron 
trifluoride diethyl etherate (BF3·OEt2), activating the isocyanate which is captured by the electron 
rich aromatic ring giving the dihydroisoquinolinone 59 in 75 % yield (Scheme 2.02).  
 
Scheme 2.02: Isocyanate formation and subsequent cyclisation to afford lactam 59 
Commercially available 3,4-methylenedioxycinnamic acid was first reduced using standard 
conditions to the dihydrocinnamic acid in 93 % yield,65,66 which, when subjected to the previously 
described reaction conditions, gave lactam 60 in 73 % yield (Figure 2.02). When 3,4,5-trimethoxy 
dihydrocinnamic acid was subjected to the same conditions, again the corresponding lactam 
product 61 was obtained, in 54 % yield. It should be noted that selective demethylation was 
observed giving C(8) phenol, shown in Figure 2.02. This is of particular interest as the narciclasine 
and related derivatives also possess a free hydroxyl group at C(8), as described in Section 1.3.3.1, 
which when absent results in diminished biological activity. Toke et al. also show regioselective 
demethylation for a similar phenanthridinone compounds in concentrated BF3·OEt2.67 
 
Figure 2.02: Structure of lactam 60 and lactam 61 
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Selective demethylation is presumably the result of the strong chelation of the lactam to the 
BF3·OEt2 Lewis acid, making the methyl group susceptible to nucleophilic attack, similar to BCl3 
deprotection of aryl ethers68 and is supported by Nicolaou et al.69 who report similar chelated 
structures. Judd et al. obtained an X-ray crystal structure of the isolated of the BF2-adduct 62 and 
determined C(8) demethylation, as shown in Figure 2.03.63  
 
Figure 2.03: BF2 adduct 62 
2.3. Oxidation reaction - background 
Oxidation of the dihydroisoquinolinone to the isoquinolinone derivatives would provide access to 
an interesting motif seen in a wide variety of biologically active molecules and would mimic the sp2 
hybridisation of C(10b) found in narciclasine 7 (Figure 1.03). In addition, the isoquinolinone would 
provide a precursor to further functionalisation.  
The dihydroisoquinolinones 61, 59 and 60 were oxidised to their corresponding isoquinolinones 63, 
64 and 65 using Pd/C following similar reported transformations in the literature,70,71 although the 
yields were poor and often irreproducible. Preliminary anticancer activities of these compounds 
were investigated by the group using an in-house MTS cell proliferation assay with HT29 colon 
cancer cell lines, the results of which are shown in Figure 2.04. The dihydroisoquinolinone 
derivatives 61, 59 and 60 showed relatively poor activity whereas their oxidised counterparts 63, 
64 and 65 showed a marked improvement. As expected, and consistent with data previously 
described in Section 1.3.3.1, the hydroxyl at C(8) improved activity for both series of compounds. 
With this encouraging preliminary data in hand, further investigations were then conducted in 
order to improve the yields and validate the results and are now discussed in more detail. 
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Figure 2.04: Preliminary biological assessment undertaken by the Caggiano group 
2.3.1. Oxidation of the lactams using DDQ 
Due to the irreproducible and low yields obtained with Pd/C in the preliminary investigations, and 
for the potential for palladium contamination effecting the results of the antiproliferative assay, 
alternative strategies for the oxidation of dihydroisoquinolinones were examined. A commonly 
used agent for performing dehydrogenation at the benzylic position is 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) and this was explored as a possible reagent to achieve oxidation of the 
lactams.  
The typical reaction conditions reported for the oxidation of similar compounds used DDQ in 
dioxane heated at reflux, as shown in Scheme 2.03.72,73 When these procedures were applied to 
dihydroisoquinolinones 59, 60 and 61 the desired oxidised isoquinolinone analogues were only 
obtained in small amounts as observed by crude 1H NMR spectroscopic analysis. Unfortunately 
isolation was not possible due to co-eluting of the starting material with the product. No 
improvement was made upon increasing the amount of DDQ or lengthening the reaction time.  
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Dou et al.72 
 
Tsai et al.73 
 
Scheme 2.03: Oxidation of dihydroisoquinolinones by DDQ 
An interesting alternative was described by Estevez et al., in which acetic acid was added dropwise 
to a gently stirring mixture of starting material 70 and DDQ, shown in Scheme 2.04.74 After forming 
and isolating intermediate 71 the reaction was heated to 250 °C for 30 minutes, giving the oxidised 
product 72.  
 
Scheme 2.04: Dehydrogenation of compound 70 using DDQ74 
The method described by Estevez et al. introduces an acetate intermediate which would also 
provide an interesting structure for biological testing, which is shown in Scheme 2.05. When these 
conditions were employed with our substrates we recovered mostly unreacted starting material 
with only trace amounts of the isoquinolinone identified by 1H NMR spectroscopic analysis of the 
crude. Upon resubmitting the dimethoxy material 59 and leaving for 16 hours at 80 °C, the oxidised 
product 64 was observed by crude 1H NMR spectroscopic analysis in a 3 to 1 ratio of starting 
material to product, without the need for heating to 250 °C. Trace amounts of a third product were 
also observed, presumably the acetate 73, but this could not be isolated. 
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Scheme 2.05: Expected outcome following the procedure developed by Estevez et al.74 
This procedure provided some limited success in isolating the oxidised lactams, as shown in Table 
2.01, however these results were not consistent. A significant problem was that reactions did not 
go to completion and therefore required purification. However, the separation of the oxidised 
product from the dihydroisoquinolinone starting material was problematic, as they possess very 
similar retention factors in a variety of solvent systems, resulting in poor yields. Manipulation of 
temperature, reaction time and/or quantity of DDQ failed to improve conversion or yield. In 
addition, the products of the reaction were often contaminated with residual DDQ preventing 
accurate biological analysis. An alternative strategy was therefore sought. 












Table 2.01: Dehydrogenation of lactams using DDQ (a Conducted at room temperature for 18 hours. b 
Conducted 120 °C for 22 hours) 
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2.3.2. Oxidation of the lactams using Pd/C 
Despite the potential for contamination and due to our previous limited success, we investigated 
the oxidation of dihydroisoquinolinones with Pd/C further. Typically used as a hydrogen transfer 
agent, dehydrogenation has been successfully achieved using Pd/C in hydrogen-free conditions at 
elevated temperatures. 
Awuah et al. reported the oxidation of dimethoxy lactam 59 in solvent free conditions.75 The lactam 
59 was ground to a fine powder with Pd/C (10 % wt.) in a mortar prior to being transferred to a 
round bottom flask. This was heated to 150 °C for 30 minutes, giving the oxidised lactam 64 in 98 
% yield, Scheme 2.06. A repeat of these reaction conditions carried out within the group failed to 
provide lactam 64, returning only starting material. However, increasing the reaction temperature 
and time, as reported by McNulty and Still,76 provided the oxidised product 64 in 81 % yield.77 
Despite this success, the reaction proved to be inconsistent and afforded an inseparable mix of 
starting material and oxidised product in various ratios. A similar outcome was also observed for 
the methylenedioxy analogue 65. 
 
Scheme 2.06: Solvent free dehydrogenation of lactam 6475 
Limited success was achieved in obtaining the dimethoxyhydroxy lactam 63 using the reported 
conditions.76 Although crude 1H NMR spectroscopic analysis suggested a ratio of starting material 
to product of 18 to 81 only a 6 % yield was achieved, again due to the co-eluting of compounds. 
Optimisation of the reaction conditions by extending the reaction time, altering the amount of Pd/C 
and using either open or closed systems failed to improve the yield of all three analogues.  
2.4. Cyclisation of cinnamic acid 
Due to the capricious nature of the oxidation reactions, an alternative route to isoquinolinones 63, 
64 and 65 was pursued. Some success had been described in the literature for the cyclisation of 
trans-cinnamic acids to their corresponding isoquinolinone counterparts.78-82 Typical reaction 
conditions describe the formation of the acyl-azide from the carboxylic acid using ethyl 
chloroformate followed by sodium azide. The acyl-azide was then heated in diphenyl ether (Ph2O) 
or diphenyl methane (Ph2Me) at temperatures above 200 °C to facilitate the Curtius rearrangement, 
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isomerisation and subsequent cyclisation to the isoquinolinone. Ray et al. reported that the same 
transformation could be achieved using DPPA with the similar 3-methoxycinnamic acid 76 to afford 
lactam 78 (Scheme 2.07).81  
 
Scheme 2.07: Isocyanate formation and thermal cyclisation of the 3-methoxy cinnamic acid81 
Using DPPA as described by Ray et al.81 and building on expertise within our group, DPPA was added 
dropwise to a stirring solution of methylenedioxycinnamic acid 80 and Et3N in Ph2O at 25 °C.63,81 
The reaction was then heated to 200 °C for one hour. It was interesting to note that as the 
temperature reached approximately 90 °C a violent effervescence was observed, which is 
presumably N2 gas being evolved from the Curtius rearrangement. Analysis by TLC suggested the 
formation of lactam 65, however this was accompanied by a large amount of other unidentified 
products. Optimisation of the reaction was conducted, with the initial formation of the acyl-azide 
in toluene prior to thermal rearrangement,63,81 however the reaction still resulted in complex 
mixtures of unidentifiable compounds by crude 1H NMR spectroscopic analysis. 
The highly reactive nature of the isocyanate group and high temperatures required clearly result in 
alternative products in addition to the desired capture of the isocyanate by the aromatic ring. There 
is potential for carbamic acids and amines resulting from hydrolysis of the isocyanate, which can 
further react forming urea analogues as previously observed within the group. Furthermore, use of 
DPPA and Et3N results in phosphate salts which could also result in side reactions. New et al. 
described the formation of a trimer, but this appears to be an isolated case.83 Some reports isolate 
the acyl-azide prior to isocyanate formation, either by extraction with toluene82 or filtering through 
a plug of silica,84 which we investigated in our system. 
Using modified conditions, incorporating the procedure reported by Ray et al.81 with the successful 
azide formation by Judd et al.63 and isolating the acyl-azide, DPPA was added dropwise to a stirring 
solution of methylenedioxycinnamic acid 80 in toluene and Et3N. After stirring at room temperature 
for 120 minutes the reaction was filtered through a plug of silica and washed with toluene, leaving 
only one spot visible by TLC, Rf [EtOAc] 0.80. After the toluene was removed under reduced 
pressure, Ph2O was added and the reaction heated at 250 °C for 3 hours with the violent evolution 
of N2 gas at approximately 90 °C as the isocyanate is formed. After cooling slowly over 18 hours a 
precipitate was observed and filtered, washed with diethyl ether to give the desired lactam 65 in 
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good yield without the need for further purification (Scheme 2.08). The filtration process was found 
to be crucial for the success of the reaction. This is an important result as the oxidised product could 
be formed in a single step from the cinnamic acid, rather than the previously described method 
that required 1) reduction of the cinnamic acid; 2) DPPA cyclisation and 3) oxidation, especially as 
the third step often resulted in low yields and possible palladium or DDQ contamination. 
Furthermore, the reactions was successfully performed on 25 mmol scale and still afford the 
product in reasonable yield without the need for further purification. It should also be noted that 
many processes occur in this transformation, including i) formation of the acyl-azide; ii) Curtius 
rearrangement; iii) thermal isomerisation to the Z-isomer of the isocyanate and finally iv) thermally-
induced intramolecular Friedel-Crafts acylation, therefore the overall yields obtained are good. 
  
 
Scheme 2.08: Successful cyclisation of cinnamic acid analogues 79 and 80 
As can be seen in Scheme 2.08 the reaction was equally efficient with both the dimethoxy and 
methylenedioxycinnamic acids 79 and 80. In both cases 1H NMR spectroscopic analysis of the 
products show the loss of three aromatic protons seen in the starting material, two doublets and a 
double doublet each integrating for 1H. Instead, there are two aromatic protons, both of which are 
singlets integrating for 1H, suggesting the cyclisation of the B-ring. In addition, the coupling 
constants of the olefin present in cinnamic acids 7985 and 8086 are both 16 Hz, consistent with a 
trans double bond. In products 64 and 65 the coupling constants are 7 Hz which correlates to a cis 
double bond, the correct isomer seen in the AB-ring analogues 64 and 65. Regrettably, using these 
optimised conditions 3,4,5-trimethoxycinnamic acid failed to provide the corresponding lactam 63. 
Instead a complex mixture of unidentifiable products was obtained. Presumably, the additional 
activation caused by the third methoxy group led to other products, possibly due to competing 
inter- as well as intra-molecular attack of the isocyanate intermediate. 
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2.5. Methylation 
We wished to investigate the effect N-methyl derivatives would have on antiproliferative activity 
compared to their N-H precursors as a thorough investigation into the requirements for the intact 
lactam (as previously discussed in Section 1.3.3.2) is yet to be completed. An undergraduate 
summer student under my guidance followed the procedure reported by Maertens et al.87 for a 
similar compound, shown in Scheme 2.09, which was also successfully used previously within the 
group on similar compounds.63  
 
Scheme 2.09: Methylation and ester hydrolysis to gain N-methylindole-3-propionic acid 8287  
Using this procedure with our isoquinolinones, N-methylation was achieved with the dimethoxy 
analogue 64 to get 83 in 65 % yield (Scheme 2.10 using iodomethane (MeI) in the presence of 
potassium hydroxide (KOH), with the addition of THF being required to improve solubility. In 
addition, however, an interesting second compound was also isolated in 23 % yield, identified as 
compound 84 shown in Scheme 2.10. The 1H and 13C NMR spectroscopic data matched that 
previously reported by Seki et al for the same compound 84, albeit isolated via a different synthetic 
process and is shown in Table 2.02.88  
 
Scheme 2.10: Structure of analogues 83 and 84 
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Entry Carbon 
13C Chemical Shift 
(ppm) 
1H Chemical Shift 
(ppm) 
Integration J (Hz) 
1 1 114.2 na na na 
2 2 111.8 7.13 1H d, J 2.0 
3 3 148.8 na na na 
4 4 148.7 na na na 
5 5 111.0 6.88 1H d, J 8.5 
6 6 120.4 7.00 1H dd, J 8.0 and 2.0 
7 1’ 125.6 na na na 
8 2’ 162.5 na na na 
9 3’(N) na na na na 
10 4’ 151.4 na na na 
11 5’(N) na na na na 
12 6’ 139.8 7.27 1H s 
13 OCH3 55.9 3.91 3H s 
14 OCH3 55.9 3.90 3H s 
15 3’(N)CH3 28.3 3.43 3H s 
16 5’(N)CH3 37.1 3.48 3H s 
Table 2.02: 1H and 13C NMR assignment for analogue 84 
This remarkable transformation is difficult to understand as several processes have occurred. The 
1H NMR spectrum clearly shows a tri-substituted aromatic (Table 2.02, Entry 2, 5 and 6) therefore 
the lactam must be cleaved, followed by a proto-decarboxylation. The urea also suggests that the 
product has been obtained from two molecules of the isoquinolinone 64. The methoxy groups 
remain intact (Table 2.02, Entry 13 and 14) furthermore there are an additional two methyl groups 
(Table 2.02, Entry 15 and 16) which were identified as N-methyl moieties. This structure was also 
found to be consistent with HRMS analysis. Presumably, the reaction proceeds via a deprotonated 
enamide which can act as a nucleophile through the C(4) carbon, which is part of the product 
structure (Scheme 2.11).  
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Scheme 2.11: Routes to the observed products 
This methodology was abandoned in order to avoid the side reaction and improve the yield. Using 
sodium hydride (NaH) as the base a series of N-methylated dihydroisoquinolinone and 
isoquinolinone derivatives were synthesised in good yield, as shown in Table 2.03 below.  
It is worthy of note that selective N-methylation of the phenol analogues 85 and 86 (Table 2.03, 
Entry 1 and 4) was achieved using these conditions. Using 6 equivalents of NaH ensured the 
formation of both the phenoxide and amide anions. The ensuing phenoxide anion is stabilised by 
the aromatic ring allowing for regioselective methylation to occur with the more reactive amide 
anion, using 1 equivalent of MeI at 0 °C. HRMS confirmed the addition of a single methyl group with 
1H NMR spectroscopic analysis showing a sharp phenol OH peak consistently found at ~ 13 ppm for 
similar compounds. The regioselectivity was confirmed by NOESY NMR, which showed a strong 
correlation between proton(s) on C(3) and the methyl on the nitrogen atom (Figure 2.05).  
 
Figure 2.05: NOESY correlation between proton(s) on C(3) and N-methyl 
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Entry Starting material Product NaH (eq.) MeI (eq.) Yield (%) 
1 
  
6 1 99 
2 
  
3 3 95 
3 
  
3 3 94 
4 
  
6 1 72 
5 
  
3 3 91 
6 
  
3 3 95 
Table 2.03: Synthesis of N-methylated compounds 
2.6. Functionalisation of the olefin 
With the oxidised isoquinolinones in hand, we wished to investigate further functionalisation of the 
double bond at C(4) and C(3) in order to simulate parts of the oxygenated C-ring of the natural 
product 8. Initial investigations examined acetylation of the nucleophilic C(4) position, which could 
afford hydroxylated products which correspond to positions on the C-ring in pancratistatin 8, as 
shown in Scheme 2.12. 
- 35 - 
 
 
Scheme 2.12: Potential functionalisation at C(4) 
2.6.1. Functionalisation at C(4) 
Chao et al. described the acetylation of an N-alkyl isoquinolinone 88 using acetic anhydride in the 
presence of sulfuric acid, as shown in Scheme 2.13.  
 
Scheme 2.13: Acetylation of isoquinolinone 8989  
Using these reported conditions acetylation of the N-methylated compounds 90 and 91 was 
achieved, although yields were low (Figure 2.06). Acetylation of the dimethoxy N-H isoquinolinone 
92 was also effective even after 16 hours, without possible N-acetylated material being observed. 
Unfortunately, however, no product was observed with the methylenedioxy N-H analogue 65 
despite using the same reaction conditions. Likewise, the dimethoxyhydroxy analogues 63 and 85 
gave complicated mixtures of unidentified products, which could not be isolated. 
 
Figure 2.06: Acetylated isoquinolinone compounds 
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Due to problems with the dimethoxyhydroxy analogue, which would be expected to afford the most 
active narciclasine analogues, and the low yields obtained with the other substrates, we did not 
pursue this reaction with 2-propenoyl chloride. In addition, we observed cleaner transformations 
with the N-methyl derivatives, which again would not be suitable for narciclasine derivatives as N-
H substrates were expected to be more potent. Therefore we explored other biologically active 
compounds which would build on these key observations. 
NSC 314622 94, shown in Figure 2.07, was identified as a lead compound following COMPARE 
analysis of the antiproliferative data of 60 human cancer cell lines by the National Cancer Institute 
(NCI).90 It was found to have a cytotoxic profile similar to camptothecin 93, a known topoisomerase 
I inhibitor. 
 
Figure 2.07: Topoisomerase I inhibitors 
As can be seen, NSC 314622 94 possesses a fused cyclopentanone core. Following our successful 
acetylation of the C(4) position of the N-methyl isoquinolinones 90 and 91, we wished to investigate 
the corresponding benzoylation reaction, which would afford novel analogues of NSC 314622 94 
such as 95, which does not have a cyclic ketone (Figure 2.07). The proposed analogues would be 
more flexible and could be accessed by a Friedel-Crafts benzoylation reaction, as previously 
described.  
Initial investigations were conducted using standard conditions for the acylation of aromatic rings, 
with an acid chloride and either AlCl3 or BF3·OEt2. Unfortunately, none of the expected product was 
observed and crude 1H NMR and TLC analysis showed only starting materials were present. Zhang 
et al. reported that the acylation of 2-chloroethoxy-benzene 97 by piperonylic acid 96 in the 
presence of trifluoroacetic anhydride (TFAA) could be achieved at room temperature over 96 hours 
(Scheme 2.14).91 However, when the N-methyl dimethoxy isoquinolinone 83 was treated with 
piperonylic acid 96 under the same conditions, no product was obtained. 
- 37 - 
 
 
Scheme 2.14: Reported Friedel-Craft benzoylation91 
Dallemagne et al. described the intramolecular cyclisation of dihydrocinnamic acids to the 
corresponding indanones as a one-pot procedure using a 1 to 1 ratio of trifluoroacetic acid (TFA) 
and TFAA, shown in Scheme 2.15.92 Similar work was published by Kolokythas using a 2 to 1 ratio 
of TFA to TFAA.93 
 
Scheme 2.15: Intramolecular cyclisation to afford indanone analogues92 
Published work from the Caggiano group reported the optimisation of the intramolecular 
cyclisation of 4-(indol-3-yl)butanoic acid 99 to the corresponding indanone analogue 100 was 
achieved using just TFAA at 100 °C for 2 hours, Scheme 2.16.47 
  




Scheme 2.16: Intramolecular cyclisation of 4-(indol-3-yl)butanoic acid 100 
Using these optimised conditions, the group expanded on this methodology with the investigation 
of the intermolecular reactions between piperonylic acid and cyclohexene.77 The resulting 
indanones 102 were then subjected to Schmidt reaction conditions to obtain the pancratistatin 
analogue 103, as shown in Scheme 2.17. 
 
Scheme 2.17: Two-step synthesis of phenanthridinone 103 
Applying these optimised conditions to the synthesis of novel analogues of NSC 314622, N-methyl 
isoquinolinone 83 and piperonylic acid 96 were treated with TFAA at 100 °C in a sealed thick-walled 
pressure tube for 18 hours. The 1H NMR spectrum of analogue 104 clearly shows the addition of a 
tri-substituted aromatic compound with a methylenedioxy substituent. The addition of acid 96 at 
C(4) was confirmed due to the disappearance of the peak at 6.84 ppm. The peak consistent with 
C(3) remains, however it has moved from 6.98 ppm to 7.47 ppm and was confirmed using 
correlation data from NOESY and HMBC spectrum. The dimethoxy and aromatic peaks of the AB-
ring starting material remain intact. Pleasingly, this procedure generated the novel analogues 104 
and 105, both in 46 % yield (Figure 2.08) with 1H and 13C NMR spectroscopic analysis being similar 
for compound 105 to that previously discussed for analogue 104. HRMS for both compounds was 
consistent with the proposed structures. As previously observed in the attempted acetylation 
reaction, benzoylation of the dimethoxyhydroxy isoquinolinone 85 was problematic and afforded 
an inseparable mixture of compounds.  
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The mechanism is presumably the capture of the electrophile by the nucleophilic C(4) position, 
followed by elimination of the acidic proton (path a). It is interesting to note that possible 
cyclisation, resulting from capture of the iminium cation intermediate did not occur (route b), unlike 
that previously observed in the research group and shown in Scheme 2.17 above. The novel 
analogues 104 and 105 are of great interest and will be examined for antiproliferative activity by 
the NCI and the results compared to those obtained for the more rigid NSC 314622 compound. 
 
Figure 2.08: Novel NSC 314622 analogues 104 and 105 
2.6.2. Oxygenation at C(3)/C(4) 
Having explored the nucleophilic C(4) position, we next examined oxidation of the C(4) and/or C(3) 
positions. Oxidation of the olefin would produce biologically interesting small molecules, and could 
also emulate the oxygen rich nature of the C-ring present in the natural products. In addition these 
types of small molecules have also been identified as having wide ranging biological activity.  
Section 1.2.2 described the process of apoptosis which is highly regulated by the caspase cascade, 
a series of proteolytic proteins. The importance of these proteins in the cell death pathway has led 
to their exploitation as drug targets and include isoquinolinone 106, shown in Scheme 2.18, an 
effective Caspase 3 inhibitor.94 This framework has also been identified as crucial in a number of 
other biologically significant compounds.95 4H-Isoquinoline-1,3-dione 107 (R=H) is a potent 
inhibitor of NF-κB inducing kinase (NIK) which, amongst other roles, activates the gene transcription 
factor NF-κB, a protein important in the immune response.96 
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Scheme 2.18: Possible C(4) and/or C(3) oxidation products 
2.6.2.1. Benzylic oxidation of the dihydroisoquinolinone derivatives 
Benzylic oxidation has been reported for a similar compound, shown in Scheme 2.19, and was 
achieved using 2 equivalents of DDQ in a mixture of dioxane and water (95:5).97 Attempts at this 
reaction with dihydroisoquinolinone derivatives 59, 60 and 61 unfortunately did not yield any 
product, and the majority of the mass recovery was unreacted starting material. 
 
Scheme 2.19: Benzylic oxidation using DDQ in dioxane and water97  
A more traditional approach is the use of selenium dioxide (SeO2), as shown in Scheme 2.20 for a 
similar compound.94 Unfortunately, submission of our dihydroisoquinolinones 59, 60 and 61 to 
these reaction conditions again only resulted in the recovery of starting material.  
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Scheme 2.20: Benzylic oxidation using SeO294  
2.6.2.2. Oxygenation of the isoquinolinone derivatives 
The olefin present in the isoquinolinones is weakly nucleophilic. We attempted various 
dihydroxylation reactions using the osmium tetroxide (OsO4) Sharpless protocol and the 
preformulated commercial AD mix. This failed to furnish any hydroxylated product and only 
unreacted starting material was recovered. Ruthenium(VIII) tetroxide (RuO4) is a more powerful 
oxidising agent and is also less toxic than its osmium counterpart.98 Although it is typically used for 
the scission of olefins to carboxylic acids,98 controlled reaction conditions have been reported which 
prevent over oxidation and afford cis-diols or diketone products.98,99 
Bettoni and co-workers described the unusual transformation of N-benzyl-3,4-dihydroisoquinolin-
1(2H)-one 112 to N-benzoyl-homophthalimide 113 using ruthenium (Scheme 2.21).100 This was 
extended by subsequent work published by Yoshifuji et al. (Scheme 2.21) in yields surpassing 88 
%.101 In both cases ruthenium(IV) oxide hydrate (RuO2·×H2O) was oxidised to RuO4 using a 10 % 
aqueous solution of sodium periodate (NaIO4), after which the lactam was added and the reaction 
followed by TLC. The oxidation of RuO2 to RuO4 is identified by a change of colour from a black to a 
yellow solution. 
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Bettoni et al.100 
 
Yoshifuji et al.101 
 
Scheme 2.21: Previously reported syntheses of trione compounds 
A common precursor for the generation of RuO2, and subsequently RuO4, is ruthenium(III) chloride 
hydrate (RuCl3·×H2O) with an oxidising agent such as oxone or NaIO4. Using conditions reported by 
Yang et al., dihydroisolquinolone 59 was stirred with RuCl3·×H2O and oxone in EtOAc:MeCN:H2O.102 
The reaction was followed by TLC analysis, however only starting material persisted which was 
further confirmed by 1H NMR spectroscopic analysis of the crude reaction mixture. Altering the 
solvent system with or without the addition of NaHCO3 buffer, as reported by Yang et al.103 gave 
the same result. The examples in the literature reported the oxidation of the N-alkylated 
lactams,100,101 as shown in Scheme 2.21, however, use of the N-methylated dihydroisolquinolone 
87 still only produced unreacted starting material. 
When the reaction was attempted with the oxidised dimethoxy isoquinolinone derivative 64, as 
shown in Scheme 2.22, the colour changed from black to yellow, suggesting the formation of the 
reactive RuO4 species. The reaction was followed by TLC analysis, and once the starting material 
had been consumed the RuO4 was decomposed by the addition of iPrOH. Column chromatography 
of the crude reaction mixture gave the trione 117 in 14 % yield. Unfortunately, repeating these 
conditions with the methylenedioxy analogue 65 only gave an inseparable mixture of compounds, 
although there was the suggestion of the trione in the 1H NMR spectroscopic analysis of the crude 
reaction mixture. Aromatic protons were present without their corresponding C(3) or C(4) peaks, 
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similar to that seen for analogue 117. Despite this, the isolated trione 117 is of great interest as the 
structurally similar trione 106 has been reported to inhibit Caspase 3, as previously discussed.94  
 
Scheme 2.22: Formation of trione 117 
2.6.3. Functionalisation at C(3) 
We wished to investigate C(3) allyl dihydroisoquinolinones as dihydroxylation would afford 
analogues which possess part of the highly oxygenated 6-membered C-ring present in the natural 
products narciclasine 7 and pancratistatin 8. The similarity between the oxygenated analogue 119 
and narciclasine 7 is highlighted in blue in Scheme 2.23 and would provide an interesting 
comparison of biological activity and provide useful information of the rigid C-ring versus the 
flexible and freely rotating hydroxylated C(3)-sidechain. Sharpless asymmetric dihydroxylation (AD) 
provides an established route to hydroxylated analogues, utilising AD-mix α and AD-mix β to 
introduce the hydroxyl groups with control over stereoselectivity.104 
 
Scheme 2.23: Proposed route and similarity of the C-ring analogues 118 and narciclasine 7 
Scheme 2.24 shows the proposed disconnection to achieve analogue 119, starting with a simple α 
allylation of the dihydrocinnamic acid 121 to furnish the allylated carboxylic acid 120.105,106 
Utilisation of the modified Curtius rearrangement and ring closure, developed by our research 
group and described previously,63 would deliver C(3)-allyl analogues 118. The following 
investigations into allylation at C(3), and subsequent functionalisation, were carried out in 
collaboration with undergraduate Erasmus students in the group. 
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Scheme 2.24: Retrosynthetic approach to the bicyclic analogue with side-chain 
Following a literature procedure a solution of methylenedioxy acid 122 in dry THF was added 
dropwise to an excess of lithium diisopropylamide (LDA) at 0 °C, generating a dianion. After an 
optimised stirring time of 40 minutes, allyl-bromide was added and the reaction allowed to warm 
to room temperature. Stirring was continued for 18 hours and following standard aqueous work-
up the -allylated product 123 (Scheme 2.25) was identified by crude 1H NMR spectroscopic 
analysis, in addition to the starting material. Unfortunately purification was not possible using 
standard procedures. 
 
Scheme 2.25: Allylation of methylenedioxy dihydrocinnamic acid 122 
Following this successful procedure with either the dimethoxy or trimethoxy dihydrocinnamic acids 
resulted in precipitation of the dianion and no reaction. Fortunately, addition of the allyl-bromide 
and heating the dimethoxy-dianion suspension to 65 °C for 18 hours solvated the dianion and 
resulted in reaction. Optimisation of the trimethoxy analogue 125 proved to be more challenging, 
however the addition of LDA dropwise to the cooled solution of the trimethoxy acid 124 in THF 
avoided precipitation of the dianion and the reaction with allyl-bromide proceeded as predicted. 
Following standard aqueous work-up of all three analogues 1H NMR spectroscopic analysis of the 
crude reaction mixtures showed a combination of starting material and allylated product. Due to 
the difficulties in separating the starting material from the product, as they are both carboxylic 
acids, we decided to submit the mixture to the modified Curtius rearrangement and cyclisation and 
then separate the lactams. Consequently the crude mixtures were subjected to the optimised 
cyclisation reaction conditions described previously.63 Both the simplified AB-ring and C(3)-allylated 
AB-ring analogues were isolated by column chromatography, with selective demethylation of the 
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trimethoxy derivative 126 being observed as previously noted for similar substrates. The yields over 
two-steps of the racemic compounds are shown in Table 2.04 below. 
Entry Intermediates 
































Table 2.04: Yields of unsubstituted and C(3)-allylated lactam analogues 
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Isoquinolinones were found to be more biologically active than their dihydroisoquinolinone 
counterparts and, as previously discussed in Section 2.3.2, dehydrogenation of 
dihydroisoquinolinone using Pd/C in solvent free conditions had been achieved with some limited 
success.75-77 The allylated analogues 126, 128 and 129 were therefore subjected to these conditions 
in order to gain the corresponding oxidised derivative for further testing. Unfortunately however 
this failed to furnish the expected products giving instead a mixture of unidentifiable compounds. 
2.6.3.1. Sharpless dihydroxylation  
The C(3)-allylated products were all obtained as racemic mixtures. Following unsuccessful attempts 
at separating the allylated enantiomers by chiral HPLC, the racemic mixtures were submitted to the 
stereoselective asymmetric dihydroxylation reaction as described by Sharpless.107 The possible 
outcomes of this reaction include i) chiral resolution – only one starting material enantiomer reacts 
(matched/mismatched); ii) both enantiomers react, affording diastereomeric mixtures. In both 
cases we would hope to separate the products by conventional methods, such as column 
chromatography. 
Following the established Sharpless protocol, the AD-mix was stirred at room temperature in tBuOH 
and water until the aqueous phase was yellow in colour. The solution was then cooled to 0 °C and 
the C(3)-allylated lactams added and stirring was vigorously continued at 0 °C overnight. Following 
standard aqueous work-up the dimethoxy 130 and 131 and methylenedioxy 132 and 133 
dihydroxylated products were isolated in varying yields shown in Table 2.05. However, although 
the differences of the diastereoisomers could be seen by 1H NMR, no separation could be observed 
by TLC analysis with a wide variety of solvent systems, nor could separation be achieved by normal 
or chiral HPLC. Therefore the compounds were obtained as diastereomeric mixtures and as such, 
they were not subject to antiproliferative screening. 
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Table 2.05: Yields for Sharpless AD reactions 
It is worthy of note that there was no observable reaction when the AD reactions were performed 
with the dimethoxyhydroxy C(3)-allylated lactam 126. As previously described, Judd et al. reported 
the crystal structure for the thermally stable BF2-complex 62, shown in Figure 2.09, resulting from 
treatment with the BF3·OEt2 Lewis acid.63 This clearly shows that the OH at C(8) and the carbonyl 
form a potent bidentate ligand, which is capable of co-ordinating to metal ions. It is therefore likely 
that unproductive coordination of the catalytic osmium in the AD reaction prevents the 
dihydroxylation reaction, resulting in recovered starting material as observed.  
 
Figure 2.09: BF2-complex 62 
Owing to the issues of diastereomeric mixtures, their separation and the inactivity of the most 
interesting dimethoxyhydroxy lactam, this avenue was not pursued further. Instead we focused our 
efforts on the synthesis of tricyclic analogues, which is discussed in Chapter 3. 
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2.7. Biological evaluation 
A selected series of AB-ring analogues was tested by MTS cell proliferation assay against the HT29 
colon cancer cells lines and this preliminary work is described herein. Data shown is an average of 
three individual experiments (N=3) unless otherwise stated. 
Initial testing on the AB-ring analogues, shown in Figure 2.10, reaffirmed preliminary work by the 
group64 and showed that N-methylated compounds were still inactive. Pleasingly, the pattern of 
increased activity for the C(8) phenol was observed with analogues 61 and 86 showing a slightly 
higher IC50 of 386 μM and 497 μM respectively, although the N-methyl appears to render the 
compound less active. It was therefore decided not to biologically evaluate the N-methyl oxidised 
derivatives. In addition, published SAR studies suggest the lactam must remain unchanged as 
described in Section 1.3.3.2.2  
 
Figure 2.10: Biological evaluation of dihydroisoquinolinone derivatives by MTS cell proliferation 
assay using HT29 colon cancer cell line 
Biological evaluation of the oxidised analogues 64 and 65 was also undertaken by MTS cell 
proliferation assay using HT29 colon cancer cells (Figure 2.11) and their IC50 values were 220 μM 
and 289 μM respectively. Although they still show improved activity compared to their 
dihydroisoquinolinone counterparts the activity is less than previously thought (shown in Figure 
2.11).64 We suggest that this is due to the potential for palladium contamination affecting the 
results of the antiproliferative assay. Although purity was previously established by HPLC analysis, 
palladium contamination would not be observed using this method as it would not absorb UV light 
and would therefore not be detected. An alternative strategy to determine purity was Elemental 
(CHN) analysis and was used in this case with the accuracy of each compound being found to be 
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within 0.4 % of the theoretical value. Unfortunately, C(8) phenol analogue 63 could not be tested 
due to a lack of material. 
 
Figure 2.11: Biological activity of oxidised analogues 64 and 65 by MTS cell proliferation assay 
using HT29 colon cancer cell line (a This work. b Previous work by Judd.64) 
Evaluation of the C(4) acetylated analogues 90, 91 and 92 (shown in Figure 2.12) shows an improved 
activity with IC50 of 176 μM, 110 μM and 33 μM respectively. The pattern already established of the 
dimethoxy analogues being more active than the methylenedioxy analogues is replicated here. In 
addition, the N-H analogue has approximately three times the activity observed for the N-methyl 
counterpart. Data for analogues 91 and 92 should be used with caution however as purity data was 
not acquired due to limited access to these compounds. Human breast cancer cells (MDA) were 
also used to assess activity of analogue 90 which was found to have a slightly improved IC50 of 117 
μM against this cell line. 
 
Figure 2.12: Biological activity of C(4) acetylated analogues by MTS cell proliferation assay using 
HT29 colon cancer cell line (a N=1, b N=2) 
Allylation at C(3) also gave some interesting analogues which were also tested and the results are 
shown in Figure 2.13. These compounds were found to be active with free phenol analogue 126 
being the most active, in concordance with the previously reported pattern of activity. 
- 50 - 
 
 
Figure 2.13: Biological activity of C(3) allylated analogues 126, 128 and 129 by MTS cell 
proliferation assay using HT29 colon cancer cell line 
2.8. Conclusions and future work 
The one-pot synthesis of AB-ring analogues, published by the group,63 has been used here to 
develop methods for further functionalisation and biological evaluation of these analogues. The 
inactivity of the dihydroisoquinolinone analogues, in addition to their N-methylated counterparts, 
has been confirmed by MTS cell proliferation assay.  
An efficient procedure to furnish oxidised dimethoxy and methylenedioxy analogues 64 and 65 has 
also been optimised using cinnamic acid starting materials. Formation of the acyl-azide, followed 
by Curtius rearrangement and thermal isomerisation to the Z-isomer of the isocyanate and 
subsequent thermally-induced intramolecular Friedel-Crafts acylation gave the isoquinolinones in 
good yields on both a 10 and 25 mmol scale. In addition, the biological results obtained for these 
compounds show reduced antiproliferative activity compared to previous studies,64 and suggest 
that previous samples may have been contaminated with palladium. Therefore, not only is this 
route more efficient and higher yielding but it also provides cleaner compound, as established by 
CHN analysis. Analogues with the free phenol have persistently been found to be the most 
biologically active. It is therefore unfortunate that this analogue has not been synthesised in 
sufficient quantities for analysis and further functionalisation. The above reaction should be 
examined further as access to the phenol analogue would be of great interest due to its superior 
activity.  
Functionalisation at C(3) or C(4) has been realised with limited success. With a robust procedure to 
the oxidised analogues from the corresponding cinnamic acids in place further functionalisation of 
these analogues could be achieved. For example, further optimisation of the oxidation by 
ruthenium can be investigated in order to gain access to caspase 3 inhibitors in just two-steps. In 
addition, preliminary biological evaluation of the NSC-type analogues found them to be insoluble 
in our in-house MTS assay. However, alternative strategies such as using ethanol in place of DMSO 
are available and should be investigated.  
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Synthesis of allylated analogues was successful, however the dihydroxylation of the analogues is 
worth investigating further. Although separation could not be achieved by traditional methods 
alternatives could be tried. Separation of the ensuing diastereomers may be achieved by formation 
of a cyclic carbonate from the diol, which could then be separated by column chromatography or 
HPLC. Biological evaluation would then provide insight into the need for a tricyclic system. 
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3. Synthesis and evaluation of ABC-ring analogues 
3.1. Introduction and preliminary work by the Caggiano group 
The total synthesis of narciclasine 7 and pancratistatin 8, previously discussed in Section 1.3, is a 
laborious process requiring many synthetic steps and often resulting in low overall yields.2 Reported 
total syntheses often preclude the biological investigations of late stage analogues, something 
which is of interest to this group in order to identify biologically active simplified molecules. An 
efficient synthesis of late stage analogues would allow for functionalisation and further 
examination of the structure-activity relationship (SAR) shown by these molecules. 
Previous work within the group described our preliminary investigations of synthesising advanced 
narciclasine analogues utilising our novel methodology, as outlined in Chapter 2. The synthesis of 
the dimethoxy and trimethoxy analogues were achieved by Judd and employed the Robinson 
annulation, Curtius rearrangement and intramolecular Friedel-Crafts acylation as the key reactions 
(Scheme 3.01).64 This preliminary work was optimised and successfully repeated here, and also 
extended to novel methylenedioxy narciclasine analogues, which are now discussed together with 
the results of the optimisation studies. 
 
Scheme 3.01: Synthetic route to narciclasine analogues 
3.2. Synthesis of 3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one 148 
3.2.1. Claisen condensation in the synthesis of β-ketoester 135 
The initial step towards the simplified tricyclic core is the synthesis of the β-ketoester 135, Scheme 
3.02. Following the procedure reported by Jung et al.,108 starting with the commercially available 
methylenedioxyacetophenone 134, condensation with diethyl carbonate at 80 °C using NaH as base 
furnished the expected β-ketoester 135 as a yellow oil. Although several attempts were made to 
purify the resulting product 135, minor residual starting material 134 persisted after column 
chromatography. The product was therefore used as a mixture of acetophenone 134 to β-ketoester 
135 of 17:83 in the subsequent reactions. 
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Scheme 3.02: Claisen condensation reaction to furnish β-ketoester 135 
3.2.2. The Robinson annulation as a one-pot procedure 
During his research into sterol derivatives, Robert Robinson found that the sodium enolate of 
cyclohexenone 136 and methyl styryl ketone 137 gave the bicyclic analogue 138, shown in Scheme 
3.03.109 Since then it has become ubiquitous in synthetic chemistry, playing a key part in a number 
of synthetic processes. The preliminary step is a Michael addition between an enolate and a Michael 
acceptor, such as methyl styryl ketone or methyl vinyl ketone (MVK). This is followed by an 
intramolecular aldol reaction to give bicyclic analogues in a one-pot transformation. 
 
Scheme 3.03: Robinson annulation109 
Preliminary work on the Robinson annulation within the Caggiano group was achieved by a two-
step process. Given that the Robinson annulation can be achieved in a one-pot transformation, this 
step was investigated further. Previous initial studies also identified that using hydroxide as a base 
caused decarboxylation of any ensuing enone product, see Section 3.2.4,64 and its use was therefore 
avoided and alternative conditions sought. Reaction conditions were reported for a similar 
compound using sodium ethoxide in ethanol at 70 °C for 16 hours, as shown in Scheme 3.04, 
however a mixture of unidentifiable products was recovered.110 An alternative base was reported 
by Chong et al. using potassium tert-butoxide in tert-butanol, but again, a mixture of unidentifiable 
products was recovered in our system.111 
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Scheme 3.04: Attempts at one-pot Robinson annulation 
Unusual reaction conditions were reported by Miyamoto et al., in which ester 140 was ground in a 
pestle and mortar with MVK and sodium methoxide (NaOMe), with or without solvent, and left for 
3 hours (Scheme 3.05).112 This was of interest as these conditions gave the cyclohexenone 141 with 
the ester intact. Using either of these reported conditions with ester 135 unfortunately did not 
furnish the desired product, giving an unidentifiable mixture of compounds.  
 
Scheme 3.05: Solvent and solvent-free Robinson annulation, with intact ester112 
Regrettably, these one-pot methods did not produce the expected Hagemann’s ester 139 and so 
the original two-step process was pursued.  
3.2.3. The Robinson annulation as a two-step procedure 
3.2.3.1. Michael Addition 
Using the conditions reported by Judd for the dimethoxy analogue,64 the potassium enolate of β-
keto ester 135 was made in anhydrous acetonitrile using potassium carbonate (K2CO3) at 0 °C, 
Scheme 3.06. After 10 minutes MVK was added and the reaction warmed to room temperature for 
90 minutes to furnish analogue 142 in 79 % yield over two-steps, following column 
chromatography. Previously, the bis-product had also been reported for the dimethoxy analogue 
158, however this was not observed in this reaction. 
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Scheme 3.06: Michael addition using MVK 
3.2.3.2. Intramolecular aldol cyclisation  
The intramolecular Aldol reaction was previously achieved with catalytic p-toluene sulfonic acid (p-
TsOH) in toluene at reflux under Dean-Stark conditions.64,113,114 This method was employed for the 
synthesis of Hagemann’s ester 139, shown in Scheme 3.07, with varying degrees of success. 
Unfortunately, low yields between 6 and 16 % were achieved together with the recovery of a black 
insoluble mass. Furthermore, this reaction required 100 % conversion of the Michael adduct as this 
starting material co-eluted with the cyclohexenone 139 product. 
The capricious nature of this reaction forced alternative strategies to be sought. Attempts were 
made to circumvent the need for Dean-Stark conditions. A screen of solvents was tested, both at 
room temperature and reflux, in the presence of anhydrous magnesium sulfate to promote 
dehydration. Unfortunately, no observable reaction was detected.  
Keeping with the original conditions but changing the apparatus to Soxhlet equipment with 
molecular sieves proved to be much more successful and reproducible, and was used for all 
subsequent reactions (Scheme 3.07). In order to improve the yield the catalytic amount of p-TsOH 
was also screened, however no improvements of the 53 % yield were observed over 40 mol % of 
the catalyst. 
 
Scheme 3.07: Cyclisation of the Michael adduct 142 
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3.2.4. Reduction of the ketone 
With an optimised and reproducible method to the modified Hagemann’s ester 139 in hand, 
procedures for saponification were considered in order to obtain the carboxylic acid precursor 
required for the Curtius rearrangement. Previous research by the group had identified 
decarboxylated by-products, due to the extended conjugate system of ester 143. Methods for the 
reduction of the carbonyl (Route a) or olefin (Route b) were therefore previously investigated as 
they would prevent the decarboxylation by this route (Scheme 3.08). However, control over the 
newly formed stereogenic centres proved difficult, as did separating the ensuing diastereoisomers, 
therefore these routes were abandoned. Although complete reduction of the carbonyl could be 
considered counterproductive as the natural product has a polyhydroxylated C-ring, it was found 
to provide access to the narciclasine core (Route c). The current work would build on the previous 
results and complete the series of analogues and examine ways of functionalising the ABC-ring 
products further. 
 
Scheme 3.08: Summary of methods employed to remove the conjugated system of ketone 143 
Using reaction conditions reported by Freixa et al., sodium borohydride (NaBH4) was added step-
wise to a stirring solution of trifluoroacetic acid (TFA), acetic acid (AcOH) and acetonitrile (MeCN) 
at 0 °C under inert conditions (Scheme 3.09).115 Cyclohexenone 139 in CH2Cl2 was added dropwise 
and the reaction was allowed to warm to room temperature and followed by TLC analysis. Following 
aqueous work-up and column chromatography, we were delighted to obtain the desired alkene 
144 in 99 % yield. 
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Scheme 3.09: Complete reduction of the carbonyl in analogue 139 
3.2.5. Saponification of the ester 
Standard conditions for hydrolysis were then employed using NaOH(aq) and ethanol at reflux and 
after 6 hours acid 145 was isolated in quantitative yield following recrystallization, shown in Scheme 
3.10. Due to the absence of the enone, decarboxylation was not observed.  
 
Scheme 3.10: Saponification of the ester 144 
3.2.6. Modified Curtius rearrangement and Friedel-Craft acylation 
Using our established novel methodology for the formation of the isoquinolinone, as described in 
Section 2.2 and published by Judd et al. for the AB-ring systems,63 we successfully obtained the 
novel methylenedioxy tricyclic analogue 148. The acid 145 in toluene was treated with DPPA and 
Et3N and heated from room temperature to 90 °C for 90 minutes to initially afford the intermediate 
acyl-azide 146 and subsequent isocyanate 147, as shown in Scheme 3.11. Optimisation of the 
reaction conditions found that removing the toluene to near dryness, prior to the addition of 
BF3·OEt2, improved the yield by keeping the reaction in solution. No advantage was observed in 
performing this step at 0 °C and it was therefore performed at room temperature. The tricyclic 
analogue 148 was isolated in 57 % yield following column chromatography and no other products 
were isolated. This represents a 24 % overall yield over 6 steps of the narciclasine analogue 148.  
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Scheme 3.11: Isocyanate formation and intramolecular acylation to analogue 148 
3.3. Synthesis of 7-hydroxy-8,9-dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-
one 155 
Judd reported the synthesis of dimethoxyhydroxy analogue 155 over 6-steps in 18 % overall yield.64 
Repeated synthesis of this analogue was undertaken in order to obtain compound for further 
functionalisation studies and evaluation of its biological activity, which is now described. 
Diethyl carbonate was treated with NaH base and then 3,4,5-trimethoxyacetophenone 149 to 
afford the -ketoester 150 in 92 % yield (Scheme 3.12). This time the product and starting materials 
did not co-elute and the product could be purified by column chromatography. As previously 
outlined the -ketoester 150 was then treated with K2CO3 base and MVK to afford the 1,4-Michael 
adduct 151 in 93 % yield. 
Scheme 3.12: Synthesis of the Michael adduct 151 
Due to the inconsistency observed using the Dean-Stark apparatus for the cyclisation reaction to 
the Hagemann’s ester 152, which was previously used, the more consistent Soxhlet apparatus was 
instead employed, shown in Scheme 3.13. This gave a slightly poorer yield of 40 % (Judd reported 
53 %)64 however the reaction proceeded in a more reliable manner with the yield being consistently 
around 40 %. 
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Scheme 3.13: Cyclisation using Soxhlet apparatus 
As previously reported for the methylenedioxy analogue 144, described in Section 3.2.4, complete 
reduction of the carbonyl was achieved in 80 % yield (Scheme 3.14). Subsequent hydrolysis of the 
ester 153 to afford the carboxylic acid 154 also proceeded in high yield of 97 %. 
Scheme 3.14: Reduction, then saponification of ester 152 
Pleasingly, cyclisation and concurrent demethylation proceeded smoothly using the previously 
reported conditions to give the narciclasine analogue 155 in 40 % yield as shown in Scheme 3.15. 
This is comparable to the 46 % yield previously reported by Judd.64 Although the overall 6-step yield 
reported here is less than Judd, 11 % compared to 18 % respectively, the reliability of the cyclisation 
to the Hagemann’s ester is improved.  
 
Scheme 3.15: Cyclisation to afford the narciclasine analogue 155 
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3.4. Synthesis of 8,9-dimethoxy-3,4,4a,5-tetrahydrophenanthridin-6(2H)-one 162 
The previous synthesis of dimethoxy analogue 162 described within the group was achieved in a 15 
% overall yield again over 6-steps, with analogue 163 also being isolated in 10 % yield (discussed in 
Section 3.5 and 3.9). Again, the complete synthesis was repeated to gain more compounds for 
further analysis, which is now described.  
The condensation of 3,4-dimethoxyacetophenone 156 with diethyl carbonate furnished the β-keto 
ester 157 in 95 % yield after purification by column chromatography (Scheme 3.16). This was 
followed, as previously described, by a 1,4-Michael addition with methyl vinyl ketone (MVK) to 
afford the Michael adduct 158 in 94 % yield as a yellow oil following column chromatography 
(Scheme 3.16). 
Scheme 3.16: Synthesis of the Michael adduct 158 
Cyclisation of the Michael adduct 158 using the Soxhlet apparatus gave the enone ester 159 in an 
improved 68 % yield (Scheme 3.17), which is similar to the 70 % yield reported by Judd using the 
Dean-Stark apparatus. Reduction of the carbonyl 159 and saponification of the ethyl ester 160 
proceeded smoothly in 85 % and 96 % yield respectively. 
 
Scheme 3.17: Cyclisation, reduction and then saponification of enone 158 
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With the carboxylic acid 161 in hand, treatment with DPPA and Et3N, as previously described, gave 
the desired dimethoxy isoquinolinone analogue 162 in 36 % yield as the only isolated product and 
represents an overall yield of 18 % yield over 6-steps. This is comparable to the yield previously 
obtained by Judd, who obtained a 34 % yield of this product in the final step.64 However, in addition 
to the expected product 162, Judd also isolated the product resulting from double bond migration 
163 in 23 % yield and shown in Scheme 3.18. This rearranged product was however not observed 
in the repeat reactions, and could be the result of slight variations in the reaction or work-up which 
results in its formation. In an attempt to examine this result, the expected product 162 was treated 
with neat BF3·OEt2 and the mixture examined by 1H NMR spectroscopic analysis which showed no 
change.  
Scheme 3.18: Modified Curtius rearrangement and cyclisation (a Reported by Judd. b This work.) 
3.5. Functionalisation of the narciclasine derivatives 
The previous syntheses of the ABC-ring analogues gave the following narciclasine analogues 155, 
162 and 163 (Figure 3.01). Biological evaluation by MTS cell proliferation assay using a HT29 cell 
line demonstrated that these compounds have antiproliferative activities in the micromolar range, 
the values of which are shown in Figure 3.01. These narciclasine analogues lack hydroxyl groups 
which are present in the natural product C-ring, which obviously improve potency. Strategies to 
incorporate oxygenation in the C-ring are discussed shortly, but we wished to investigate the 
corresponding pancratistatin analogues, which are devoid of the olefin. Subjecting analogues 148, 
155 and 162 to conditions for hydrogenation would provide an interesting contrast to the potential 
anticancer activity already observed for C(10b) sp2-hybridisation. The hybridisation of C(10b) of 
pancratistatin is sp3- in contrast to sp2-hybridisation of narciclasine and our late stage 
intermediates. 
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Figure 3.01: Previous preliminary biological assessment undertaken by the Caggiano group by 
MTS cell proliferation assay using HT29 colon cancer cells64 
3.5.1. Hydrogenation with palladium 
Using standard conditions, the narciclasine analogues 148, 155 and 162 were stirred in ethanol with 
Pd/C under an atmosphere of hydrogen. The addition of the hydrogen can occur from the top 
and/or bottom face of the double bond, which would afford cis and/or trans products respectively. 
Furthermore, given that the starting material is a racemic mixture these diastereoisomers will also 
be racemic. 
Treatment of the dimethoxyhydroxy narciclasine analogue 155 with hydrogen and Pd/C under 
standard hydrogenation conditions gave a mixture of products. 1H NMR spectroscopic analysis of 
the crude reaction mixture revealed the presence of three compounds, which were identified as a 
59:41 mixture of cis:trans 164 in addition to the product of double bond migration 165, as shown 
in Scheme 3.19. Attempts to separate the products by column chromatography were only partially 
successful, as the cis/trans mixture proved to be inseparable in a variety of solvents systems. 
However, following purification the fully reduced pancratistatin analogues were obtained in 54 % 
yield and the migration product in 33 % yield. 
Scheme 3.19: Reduction of narciclasine analogue 155 using Pd/C and atmospheric hydrogen 
It is very interesting to note the appearance of the unsaturated B/C-ring junction analogue 165, as 
it demonstrates isomerisation to afford the more thermodynamically stable tetra-substituted olefin 
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is possible, and that presumably the migration product is more resistant to hydrogenation than the 
trisubstituted olefin starting material. The observed cis/trans mixture could be the result of a poorly 
diastereoselective reaction, or that the hydrogenation reaction is highly selective for the trans-
isomer, but hydrogenation of the migration by-product also results in the formation of the cis-
isomer. Given the isolation of the migration product, it seems likely the mixture is a result of low 
diastereoselectivity. 
Analogue 165 has recently been described by our group in a different but related project, and was 
produced via an alternative synthetic pathway to the late stage pancratistatin analogues described 
herein (Scheme 3.20).77 3,4,5-Trimethoxy-1-bromobenzene 167 and α,β-cyclohexene carboxylic 
acid 166 were joined using a Heck cross-coupling reaction. This was followed by the modified 
Curtius rearrangement to furnish tricyclic 165. Preliminary biological testing showed analogue 165 
to have an IC50 of 9 μM against the HT29 cells following MTS cell proliferation assay. This enhanced 
anticancer activity complements observations by Judd et al. following bond migration of the 
dimethoxy 163 shown previously in Figure 3.01. This is in addition to the increase in activity caused 
by the free phenol and is consistent with the pattern observed for the anticancer activity of the 
oxidised AB-ring analogues described in Chapter 2. 
 
Scheme 3.20: Synthesis for the late stage intermediate 165 via a two-step pathway77 
The dimethoxy and methylenedioxy narciclasine analogues 162 and 148 were also subject to 
hydrogenation as previously described, except that the solvent was changed for methanol to 
improve the solubility of the starting materials. As previously observed, a cis/trans mixture of the 
fully reduced dimethoxy analogue 169 was observed by 1H NMR in 58:42 ratio respectively, in 64 % 
yield which again could not be separated by column chromatography (Scheme 3.21). Similarly, the 
product of migration to the tetra-substituted olefin 163 was also identified and could be separated 
and isolated in 23 % yield. 
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Scheme 3.21: Reduction of narciclasine analogue 162 using Pd/C and atmospheric hydrogen 
When the methylenedioxy narciclasine analogue 148 was treated with hydrogen and Pd/C only two 
products were identified by 1H NMR, which were the cis/trans isomers 103 in a 54:46 ratio (Scheme 
3.22). As previously noted for the related analogues, these isomers were inseparable by column 
chromatography and the mixture was obtained in 47 % yield. In this case, the cis-isomer 103 was 
obtained within our research group, via an alternative method, and an X-ray crystal structure 
obtained confirming the cis-assignment. The 1H NMR spectroscopic data for the major isomer 
present in our mixture matched perfected data obtained for the isolated and fully characterised cis-
methylenedioxy analogue described by Tunbridge.77 A second compound was isolated by column 
chromatography which was presumably analogue 170, however it proved to be insoluble in a 
number of different solvents and was consequently not fully characterised. 
Scheme 3.22: Reduction of narciclasine analogue 148 using Pd/C and atmospheric hydrogen 
The stereochemistry of the reduced compounds is worth noting and is highlighted using analogue 
103 in Scheme 3.23.  
In all cases the resulting diastereomers were clearly visible by 1H NMR spectroscopic analysis and 
were assigned by extrapolating the data reported by Tunbridge of the cis-analogue 103cis, as there 
is a high similarity between the 1H and 13C NMR spectra.77 We consistently observed mixtures which 
slightly favoured the cis-isomer.  
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Unfortunately NOESY data did not show correlation between the C(4a)H and the C(10b)H in either 
isomer. However, using the Karplus equation it is highly suggestive that isomer 103cis, J C(4a)H and 
C(10b)H is 3 Hz, corresponds to an equatorial/axial interaction. Isomer 103trans, shown in Scheme 
3.23, corresponds to an axial/axial interaction as this coupling is approximately 12 Hz. This 
correlation is consistent throughout the series. 
 
Scheme 3.23: Coupling constants of the B/C-ring junction and idealised dihedral angle  
Comparing to the natural product, the trans-analogue would be of particular interest due to its 
similarity with pancratistatin 8, shown in Figure 3.02. Preliminary antiproliferative investigations of 
analogue 103cis and 165 were untaken by Tunbridge,77 and 163 by Judd,64 both of which will be 
discussed further in Section 3.9. Unfortunately, due to the difficulties in separating the isomers, 
these mixtures were not investigated for antiproliferative activity.  
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Figure 3.02: Comparison of pancratistatin 8 with the 103trans and 103cis isomers obtained 
3.6. Epoxidation of the Hagemann’s ester 
The natural products narciclasine 7 and pancratistatin 8 are single enantiomers, however our 
current synthesis produces analogues which are racemic and this will have an impact on their 
antiproliferative activity. A possible solution would be to perform enantioselective epoxidation, 
which could generate diastereoisomers which could then be separated to afford analogues which 
are not only enantiomerically pure, but contain oxygenation in the C-ring. 
Our initial efforts focused on straightforward epoxidation strategies to examine the viability of the 
reaction and ease of separation. The hope was that the diastereomers would be separable which 
could then lead to individual testing and is shown in Scheme 3.34 using the methylenedioxy 
analogue 139 as an example. In addition, the extended conjugated system which previously caused 
problems with decarboxylation should no longer be a problem as the enone has been removed 
without having to fully reduce the carbonyl as previously described and outlined in Scheme 3.08. 
Furthermore, asymmetric reduction of the ketone would install a hydroxyl group with controlled 
stereochemistry, analogue 172 (Scheme 3.24). Due to their availability, methylenedioxy analogues 
were initially investigated. 
 
Scheme 3.24: Proposed epoxidation and diastereomeric outcomes of analogue 139 
Hydrogen peroxide (H2O2) is a well-established source of nucleophilic oxygen for the epoxidation of 
enones. Using conditions reported by Cabeza et al.,116 enone 139 was stirred in methanol and 
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NaOH(aq), H2O2 was added at room temperature, and stirring continued for 18 hours. A mixture of 
diastereomers was observed by crude 1H NMR spectroscopic analysis, shown in Scheme 3.25, with 
a single diastereomer being isolated in 46 % yield following column chromatography. 
Unfortunately, it was not possible to determine which isomer was isolated by spectroscopic 
methods, but one would expect the product to be that from the least hindered face, as observed in 
literature examples,117 favouring the desired epoxide 171.  
Scheme 3.25: Epoxidation products of analogue 139 and their proposed stereochemistry 
Although initially these reactions were successful, they were found to be unreliable with starting 
material often being recovered. Alterations in reaction time and/or the concentration of H2O2 or 
NaOH failed to improve the reliability of the reaction. Replacing the solvent with other water 
miscible solvents such as THF or MeCN had no beneficial effect. 
Keeping the reaction at 0 °C for 48 hours as described by Ringold et al.118 failed to furnish the 
epoxide, instead only unreacted enone 139 was recovered. Conversely, heating the reaction to 50 
°C with NaOH (2 eq.) and an excess of H2O2 in ethanol,119 gave a single diastereomer on a 0.16 mmol 
scale. The reaction was repeated and performed on a larger, more viable scale, but regrettably only 
a mixture of unidentifiable materials was recovered. This was presumably caused by the 
degradation of the enone 139 and/or decarboxylation due to saponification previously discussed in 
Section 3.2.4. Changing the base to potassium carbonate as described by Goldenstein et al.,120 also 
failed to furnish the epoxide.  
Similar conditions were reported by Das Sarma et al. using sodium carbonate as the base in a 
biphasic system of methanol and CH2Cl2.121 Unfortunately, only starting material was recovered in 
quantitative yield. The addition of tetrabutylammonium chloride as a phase transfer agent proved 
to be ineffective and changing the base122 also failed to furnish the epoxide. 
An alternative peroxide is t-butyl hydroperoxide (TBHP). Sabol et al. reported the epoxidation of 
the enone ester 174 using TBHP and 1,8-diazobicyclo[4.5.0]undecane (DBU), Scheme 3.26.117 They 
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reported a mixture of diastereoisomers, 175 and 176, which could be separated by column 
chromatography. The major product in this reaction was that obtained from nucleophilic attack 
from the least hindered face, as desired in our system. Similar transformations and conditions were 
reported by Schlessinger et al.123 in THF and Goldenstein et al.120 in CH2Cl2. Tatsuta et al. also 
reported using potassium t-butoxide (tBuOK) as the base in THF.124 Using enone 139 and following 
these reported reaction conditions, analysis by TLC showed the presence of starting material, even 
after 24 hours stirring at room temperature. 
 
Scheme 3.26: Epoxidation of enone 174 using TBHP117 
It is possible that ester hydrolysis to the corresponding water-soluble carboxylate, caused by 
residual water in the H2O2 or TBHP, was responsible for the issues of reproducibility, so alternative 
conditions were investigated. Yadav and Kapoor reported the capricious nature of epoxidising 
lactones and cyclic enones using a screen of oxidising agents, bases and solvent systems, all with 
literature precedent.125 They investigated a more reliable non-aqueous epoxidation of electron 
deficient alkenes using TBHP and DBU. Using conditions reported by Sharpless and Verhoeven for 
the azeotropic drying of TBHP in 1,2-dichloroethane (DCE) a 2.35mmol/mL solution was 
prepared.126 Yadav et al.125 reported that treatment of enone 177 under anhydrous conditions with 
DBU and TBHP at 0 °C gave epoxide 178, as shown in Scheme 3.27. Unfortunately, using these 
reported conditions with our enone 139 always gave an unidentifiable mixture of compounds. 
 
Scheme 3.27: Epoxidation of enone 177 using anhydrous conditions125  
Although an enone is electrophilic there has been some literature precedent for their epoxidation 
by m-chloroperoxybenzoic acid (mCPBA). Pirkle and Hoover show the preparation of a single isomer 
180 in high yield using mCPBA (1.3 eq.) in CH2Cl2 at reflux, shown in Scheme 3.28.127 This is further 
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corroborated by Tamura128 and Cheng129 using mCPBA (1 eq.) in CH2Cl2 at room temperature over a 
longer reaction time. This is an unusual reaction so perhaps unsurprisingly, only starting material 
was recovered when enone 139 was subjected to these reaction conditions.  
 
Scheme 3.28: Epoxidation of an enone using mCPBA127 
3.7. Saponification of epoxide 171 
Preliminary investigations into the saponification of the ester in the presence of the epoxide was 
also investigated. Zhu et al. reported the basic hydrolysis of epoxide 181 using NaOH and methanol 
could be conducted at room temperature to give the acid 182 quantitatively, as shown in Scheme 
3.29.122 Sakagami et al. reported similar conditions gave their product in 92 % yield.130 Despite 
following this literature precedent, an unidentifiable mixture of products was observed by crude 1H 
NMR spectroscopic analysis when the epoxy ester 171 was treated with NaOH, which could not be 
separated. 
 
Scheme 3.29: Saponification of an ester in the presence of an epoxide122 
Due to the issues experienced in synthesising the epoxy ester, and in the subsequent hydrolysis of 
the ester, this synthetic route was not pursued further. The previously described route towards 
deoxy-narciclasine analogues was successful, and the three desired analogues were achieved. 
However, owing to the requirement to remove the enone, this current synthetic route is not 
appropriate for the synthesis of C-ring hydroxylated narciclasine analogues. At present, the exact 
C-ring substitution pattern required for potent biological activity is not yet known, so a much more 
straightforward synthesis of hydroxylated analogues was sought to fully explore C-ring substitution, 
the preliminary results of which are now described. 
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3.8. Narciprimine 183 
A rare compound isolated by Piozzi et al. in 1968 from Narcissus bulbs was identified as a tricyclic 
narciclasine analogue, narciprimine 183 shown in Figure 3.03.29 It is related to narciclasine 7 and 
pancratistatin 8 as it possesses the same substitution patterns on the A-ring, a 6-membered lactam 
B-ring, however the C-ring is aromatic and only mono-hydroxylated. Due to its scarcity, only 
minimal investigations have so far been completed into its biological activity. Despite this lack of 
data, narciprimine 183 is of interest as Sarikaya et al. demonstrated that it interferes with 
topoisomerase I and has an anti-proliferative effect on HeLa cervical cancer, MCF7 breast cancer 
and A431 skin cancer cell lines.131 This is further supported by work by Nair et al. identifying micro-
molar activity across a minipanel of human cancer cell lines.132 This natural product 183 is not as 
potent as narciclasine 7 or pancratistatin 8 however an investigation into the SAR in this analogue 
would establish if this was due to the planar nature of narciprimine 183 or its lack of hydroxyl groups 
on the C-ring. 
 
Figure 3.03: Structure of narciprimine 183 and proposed analogues 184 and 185 
The tricyclic structure of analogue 184 could be accessed in a two-step process, the retrosynthetic 
analysis of which is shown in Scheme 3.30. Initial cross-coupling of two aryl groups, one of which is 
a benzoic acid derivative, would give A/C-biaryl 186. This could then undergo the modified Curtius 
rearrangement and cyclisation previously described in Chapter 2. Using aryl-halides 187 with 
various benzoic acid derivatives such as salicylic acid 188, with different patterns of substitution, 
would provide a series of analogues which could be used to probe the SAR of narciprimine 183. 
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Scheme 3.30: Retrosynthetic approach to the narciprimine analogues 
The traditional approach for forming the aryl-aryl bond involves the coupling of an aryl-halide and 
an organometallic reactant, usually in the presence of a transition metal.133 This is often an 
inefficient and costly approach requiring pre-functionalisation of the aromatic groups. Direct 
arylation via C-H bond activation has received an increasing amount of attention due to its obvious 
advantages over the traditional approach some of which are reviewed by McGlacken and 
Bateman.133 
Mousseau et al. coupled substituted bromobenzene analogues, including benzoic acid 189 shown 
in Scheme 3.31, with unactivated arenes to get analogue 190.134 These reactions are palladium 
catalysed in the presence of silver carbonate or acetate. Although good yields were reported, 
problems of regioselectivity occurred when methoxy substituted arenes were used, as would be 
the case in synthesising A-ring narciprimine analogues. In addition, decarboxylation was often a 
factor in the synthesis of acid derivatives. 
 
Scheme 3.31: Synthesis of biphenyl analogue 190 from bromobenzoic acid134  
An alternative strategy was reported by Chiong et al. in which palladium catalysed coupling was 
achieved by the direct ortho-arylation of free benzoic acids with aryl iodides and silver acetate, an 
example of which is shown in Scheme 3.32.135 Both electron withdrawing and donating groups on 
either aryl were tolerated. In addition, aryl bromide derivatives were also reported to be adequate 
coupling partners.  
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Scheme 3.32: Example of ortho-arylation of free benzoic acids by aryl iodides135 
Using the reported conditions, the inexpensive and commercially available 1-bromo-3,4,5-
trimethoxybenzene 192 was chosen to be coupled with salicylic acid 188 in order to more closely 
replicate the substitution pattern of narciprimine 183. Although specialist equipment was not 
reported by Chiong et al.135 preliminary reactions were carried out using a thick walled pressure 
tube as implied by Mousseau et al.134 in their work on aryl bromide derivatives. Unfortunately 
quantitative recovery of starting material was observed, and none of the expected product, as 
shown in Scheme 3.33 and Entry 1, Table 3.01, was observed.  
 
Scheme 3.33: Attempted coupling of 1-bromo-3,4,5-trimethoxybenzene 192 and salicylic acid 188 
To understand the scope and limitations of this reaction, benzoic acid was used to examine the 
effect of the free phenol. In addition, substituted and unsubstituted aryl bromides and aryl iodides 
were also examined and the results are shown in Table 3.01. The reactions were analysed by 1H 
NMR of the crude reaction mixture and comparison with literature spectroscopic data for known 
compounds enabled positive identification of coupled products.  
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Table 3.01: Optimisation of the reaction conditions to form biaryl analogues (a Salicylic acid. b Aryl 
bromide: b1 1-bromo-3,4,5-trimethoxybenzene; b2 bromobenzene. c Reaction performed in a pressure tube. d Aryl iodide: 
d1 1-iodo-3,4,5-trimethoxybenzene; d2 iodobenzene) 
As can be seen in Table 3.01, there was no observable reaction between 1-bromo-3,4,5-
trimethoxybenzene and salicylic acid (Entry 1) or benzoic acid (Entry 2) under these conditions. The 
reaction was repeated with bromobenzene, which again resulted in no observable reaction by 1H 
NMR spectroscopic analysis of the crude reaction mixture (Entry 3). These results demonstrate the 
difficulties in performing the cross-coupling reaction with aryl bromides, therefore our attention 
focused on using the more reactive aryl iodides.  
Using iodobenzene under the same reaction conditions gave the desired product in 32 % yield by 
1H NMR spectroscopic analysis, with the remaining mass being unreacted starting materials (Table 
3.01, Entry 4). Reducing the reaction time led to a decrease in the conversion (Entries 4-6) and 
although increasing the palladium loading from 5 mol % to 10 mol % did lead to an increase from 
32 % to 40 % (Entries 4 and 7), it was small so was not adopted. Likewise, an increase in the amount 























1 1a 3b1 5  1.3 130c 16 100 0 
2 1 3b1 5 1.3 130 24  100 0 
3 1 3b2 5 1.3 130 24 100 0 
4 1 3d2 5 1.3 130 24 68 32 
5 1 3d2 5 1.3 130 16 87 13 
6 1 3d2 5 1.3 130 4 80 20 
7 1 3d2 10 1.3 130 24 60 40 
8 1 10d2 5 1.3 130 24 75 25 
9 1 3d1 5 1.3 130 24 46 54 
10 1 3d1 5 1.3 130 24 44 55 
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With the success of the iodobenzene couplings, we investigated the reaction with 1-iodo-3,4,5-
trimethoxybenzene using our optimised conditions (shown in Entry 4). We were delighted to 
observe good levels of conversion to the corresponding trimethoxyaryl coupled product, which 
could be repeated (Entries 9 and 10). Unfortunately, despite good conversion the product 194 was 
only isolated in 12 % yield following column chromatography (Scheme 3.34). Due to the small 
quantities of the benzoic acid 194 obtained, the cyclisation step could not be fully investigated, 
although based on our experience in this cyclisation reaction,63 we are very confident this step will 
furnish the desired lactam. These results demonstrate the coupling reaction works with aryl iodides 
and can be further optimised to provide a range of narciprimine analogues readily, via a two-step 
synthesis. 
Scheme 3.34: Successful synthesis of the coupled benzoic acid 194 and proposed cyclised product 
3.9. Biological evaluation 
Preliminary in-house studies of the tricyclic compounds were undertaken by the group using HT29 
colon cancer cells in an MTS cell proliferation assay the results of which are shown in Figure 3.04. 
Initial IC50 values for late stage analogues 155 and 162 were 20 μM and 37 μM respectively and 
these results were subsequently validated following the described synthesis herein and a repeat of 
the MTS assay. The novel methylenedioxy narciclasine analogue 148, lacking the free phenol group, 
has a slightly poorer IC50 of 50 μM, which is consistent with observations previously reported for 
the AB-ring structures, Chapter 2. All three tricyclic compounds show superior activity compared to 
their bicyclic counterparts, suggesting that even without the hydroxylation present on the C-ring of 
the natural products, the tricyclic analogues show improved activity. 
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Figure 3.04: IC50 values following MTS cell proliferation assay using HT29 colon cancer cells              
(a Preliminary biological data generated by Judd et al.64 b Preliminary biological data generated by Tunbridge et al.77)  
The saturated analogues were not examined for antiproliferative activity, as they were mixtures of 
both cis and trans isomers which could not be separated by column chromatography using several 
solvent systems. The cis-methylenedioxy analogue 103cis however was previously isolated within 
the group and examined and found to be inactive (IC50 > 500 μM).77 It is interesting to note that this 
mirrors previous results discussed in Chapter 2 that the saturated AB-ring analogues all displayed 
little or no activity, whilst the oxidised AB-ring analogues showed some activity. Furthermore, it is 
also worthy to note that although cis-methylenedioxy analogue 103cis lacks the free phenol and C-
ring hydroxyl groups present in the natural product, the unsaturated parent compound 148, also 
lacking the same substituents, did show some activity (IC50 50 μM). This clearly demonstrates the 
need for the double bond, however, it may be that this analogue is inactive because it is the cis-
isomer, and that the trans-isomer would be a closer analogue of pancratistatin and therefore more 
active. Future investigations should examine separating these diastereomers by HPLC, which would 
allow for the effect of the cis/trans configuration to be assessed. 
An increase in activity was observed with the oxidised AB-bicyclic analogues, previously discussed 
in Section 2.7. Data shown in Figure 3.04 suggests that an unsaturated B/C-ring junction also 
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increases activity with dimethoxy analogue 163 having an IC50 value of 17 μM. Predictably, having 
a free phenol at C(7), analogue 165, shows the best activity with an IC50 of 9 μM and is consistent 
with the pattern previously observed, Section 2.7. Unfortunately, the corresponding product of 
double bond migration was not isolated using the methylenedioxy analogue 148, so the biological 
activity of this analogue could not be assessed. 
3.10. NCI 60 cell line screening 
The National Cancer Institute (NCI) offers a service screening biologically interesting compounds 
against 60 human cancer cells lines, initially at a single dose of 15 μg/mL. If a fixed threshold of anti-
proliferative activity is observed in a minimum number of cell lines then these compounds are 
carried forward to a five-dose screening programme. The five-dose screen will determine the GI50, 
total growth inhibition (TGI) and LC50 of the compounds selected and will suggest whether in vivo 
testing would be beneficial. 
The five active analogues shown in Figure 3.04 were submitted for evaluation and were accepted 
by the NCI for initial one-dose testing. The growth of the cells is measured relative to the control, 
in which no cells were treated, and the number of cells at time zero. This is then displayed as a 
mean graph of the percentage growth relative to the control. The values for growth inhibition lie 
between 0 and 100, where 100 shows no growth inhibition and therefore a value of 30 mean 70 % 
growth inhibition. Lethality is displayed as a value of less than 0 with -100 meaning all the cells had 
been killed.  
Unfortunately the compounds typically showed growth inhibition of less than 10 %, as shown in the 
Appendices, and were not selected by the NCI for further five-dose testing. The best compound was 
analogue 165 with growth inhibition of 17.30 % (Table 3.02, Entry 2). This observation fits with the 
SAR gathered so far as analogue 165 has a C(7) free phenol and also has the olefin at the B/C-ring 
junction.  
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Entry Compound 







91.27 8.73 47.77 
2 
 
82.70 17.30 63.46 
3 
 
97.49 2.51 59.32 
4 
 
97.82 2.18 64.96 
5 
 
97.15 2.85 55.68 
Table 3.02: NCI data for the mean growth inhibition using single-dose data 
3.11. Conclusions and Future work 
The 6-step synthesis of the late stage ABC-ring narciclasine derivatives developed by the Group has 
successfully been utilised to furnish the dimethoxy and dimethoxyhydroxy analogues 162 and 155 
and has been extended to the novel methylenedioxy analogue 148. Unfortunately, the product of 
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double bond migration 163 was not isolated following these conditions, as previously reported, 
however access to the dimethoxy and dimethoxyhydroxy analogues, 163 and 165, was successful 
using conditions for hydrogenation. Although the methylenedioxy analogue was not isolated it can 
be presumed that this would be the least active compound as shown by the previously discussed 
pattern of antiproliferative activity. 
The late stage analogues were then subjected to an in-house MTS cell proliferation assay and five 
were subsequently sent to the NCI for one-dose testing. The results obtained from these 
investigations highlight the importance for a free phenol group at C(7) in the A-ring and also the 
presence of hydroxyl groups in the C-ring. In addition, it is worth noting that the fused B/C-ring 
junction analogues 163 and 165 are achiral and are our most active analogues in this series. Further 
investigations into the functionalisation of these analogues, providing hydroxylation of the C-ring 
would be beneficial. 
Although our efforts to functionalise the synthesised narciclasine analogues proved challenging the 
successful coupling strategy outlined here in Section 3.8 could gain narciprimine analogues in an 
efficient two-step process. Further investigations using substituted C-ring hydroxylated acids, such 
as salicylic acid or gallic acid, could improve the potency and selectivity of narciprimine as the 
analogues will more closely resemble the more active natural products narciclasine and 
pancratistatin. 
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4. Synthesis and evaluation of N ABC-ring analogues 
4.1. Introduction to quinazolinones 
Narciclasine and pancratistatin are well established as biologically active lead compounds; however 
their poor aqueous solubility has hampered their progression into clinical use. Further 
investigations aiming to improve water solubility, whilst keeping their unique anticancer properties 
intact, are thereby warranted. The incorporation of a basic nitrogen to the skeleton would improve 
solubility, with the tertiary amine providing a hydrogen bond acceptor. There would also be an 
opportunity to make the salt form of any compounds made. The reduction of the lactam to afford 
the corresponding cyclic amine results in loss of antiproliferative activity,136 therefore another 
solution needs to be found. 
Quinazolinones are important structural motifs present in a large number of pharmacologically 
diverse active compounds.137 Of particular interest is 4(3H)-dihydroquinazolinone 195, which has 
obvious structural similarity to the dihydroisoquinolinone motif of the natural products 7 and 8, as 
shown in Figure 4.01. Furthermore, the aniline N would be an effective bioisostere for the sp2-
hybridised C(10b) present in narciclasine, whilst a protonated analogue would generate a sp3-
hybridised tetrahedral arrangement seen in pancratistatin. The inclusion of a quinazolinone core 
would be of great interest, therefore N(10b) analogues were investigated.  
 
Figure 4.01: Similarity in structure of dihydroquinazolinone highlighted in the natural products 
4.2. Synthesis of quinazolinones 
Due to the pharmacological importance of the quinazolinone building block, there are multiple 
procedures for their construction. Traditionally metal-catalysed condensation reactions between 
substituted anthranilamides and an aldehyde or ketone generated the desired bicyclic 
dihydroquinazolinone derivative.138-140 
Recent developments in the field have shown that more facile reaction conditions can be used, 
often resulting in a higher yield, such as that shown in Scheme 4.01 reported by Shaabani et al.141 
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The reaction conditions are mild, using catalytic NH4Cl in EtOH at room temperature to facilitate 
the condensation reaction between anthranilamide 196 and a variety of alkyl, aryl and alicyclic 
aldehydes and ketones, which after intramolecular capture of the intermediate imine by the amide 
nitrogen, affords the dihydroquinazolinone derivative in high yield. 
 
Scheme 4.01: One-pot click synthesis of 2-phenyl-2,3-dihydroquinazolin-4(1H)-one 197141  
We wished to employ a similar strategy to afford a C-ring, generating a fused B/C-ring system in the 
process. Despite no reports of this process in the literature, we postulated that a dialdehyde would 
initially undergo the transformation shown in Scheme 4.01 (condensation reaction, followed by 
intramolecular cyclisation of the amide). Then the remaining aldehyde could undergo another 
condensation reaction with the aniline nitrogen, affording the desired C-ring. A retrosynthetic 
approach is shown in Scheme 4.02 below, which represents a one-step synthesis of a tricyclic 
analogue 198. 
 
Scheme 4.02: Proposed disconnections to achieve a fused cyclic B/C-ring 
Using the reaction conditions specified by Shaabani et al., treatment of anthranilamide 196 with 
one equivalent of the symmetrical dialdehyde, glutaraldehyde 200, gave a mixture of compounds 
observed by crude 1H NMR spectroscopic analysis with very little separation seen by TLC. 
Adjustment of the reaction time and temperature failed to improve the outcome, with a mixture of 
unidentifiable compounds being obtained. We proposed that these mixtures represented the 
various intermediates possible during the reaction mechanism. The proposed reaction between 
anthranilamide and glutaraldehyde to obtain the enamine ABC-ring analogue 198 is a reversible 
process, highlighted in Scheme 4.03. Hydrolysis is continually pushing the reaction towards the 
starting materials. In addition to the formation of hemi-aminals (R=H) from the reaction of water 
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with iminium cations, it is also likely that reaction with the ethanol solvent would afford the 
corresponding hemi-aminal ethers (R=Et), which would further complicate the process. 
Furthermore, diastereomeric mixtures are also possible for these hemi-aminal intermediates. This 
complex equilibrium accounts for the multiple, unidentified products observed in the crude 1H NMR 
spectrum. 
Scheme 4.03: Reversibility of the condensation reaction 
Different optimisation conditions were made varying temperature and time which only afforded 
mixtures of compounds. These were combined and purified by column chromatography from which 
the expected enamine was isolated, suggesting that reaction fundamentally works and that further 
modifications should be investigated (Scheme 4.04). Trace amounts of a second compound was 
also isolated, with an indicative 1H NMR peak at approximately 6 ppm. This was proposed, and later 
identified, as being the hemi-aminal ether 202 which will be discussed further in Section 4.4. 
 
Scheme 4.04: Isolated products from a combination of reactions 
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4.3. Optimisation of the reaction conditions 
Optimisation of the reaction was required to avoid the numerous products and obtain the enamine 
198 in good yield for further development. The ability of protic solvents to interact with the iminium 
cation could be avoided by using tetrahydrofuran (THF), a polar aprotic solvent. Magnesium sulfate 
(MgSO4) was also added in order to remove the water generated in the condensation reaction, 
thereby driving the reaction towards the enamine 198. A standard aqueous work-up was 
maintained in order to remove any unreacted starting material (Scheme 4.05).   
 
Scheme 4.05: Synthesis of enamine 198 and proposed structure of compound 203 
Analysis of the crude reaction mixture showed the major product to be enamine 198. Hemi-aminal 
203 was also thought to be observed, presumably formed during the aqueous workup. Although 
the hemi-aminal 203 was never isolated, 1H NMR spectroscopic analysis of the crude reaction 
mixture suggested C(1)H at approximately 6 ppm. This is consistent with that reported for similar 
hemi-aminals reported in the literature.142,143 
Since we still obtained the hemi-aminal, we performed the reaction without the aqueous work-up. 
Instead, once the reaction was deemed complete by TLC, the MgSO4 was simply removed by 
filtration and after removing the solvent the only product observed was the enamine product 198 
in quantitative yield without the need for further purification (Scheme 4.06). This is an important 
result as it represents a one-step synthesis of the tricyclic core of the interesting N(10b) analogues 
in quantitative yield and furthermore provides a functionalised C-ring for further manipulation. 
 
Scheme 4.06: One-pot procedure the synthesis of enamine 198 
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The proposed reaction mechanism is outlined in Scheme 4.07. Initial condensation of the aniline 
196 with the carbonyl furnishes an iminium cation with the loss of water. The ensuing iminium 
cation 204 is captured by the amide group generating the B-ring. Further condensation between 
the remaining aldehyde and the basic nitrogen affords the C-ring and the initial iminium cation 201 
rearranges to afford the observed enamine 198. 
 
Scheme 4.07: Proposed reaction mechanism for the tricyclic ring 
4.4. Ethanol adduct and pro-drug type analogues 
Formation of the hemi-aminal ether 202 (Scheme 4.04), mentioned briefly in Section 4.2, is an 
interesting and possibly advantageous observation and could be used to create pro-drugs. Pro-
drugs, which have been described in Section 1.3.4, are a well-established method of delivering a 
drug like molecule into the target cell. The addition of an alcohol would provide the lipophilicity 
required to pass over the cell membrane followed by subsequent hydrolysis of the group leaving 
the active molecule to accumulate in the cytosol. 
A method for improving the pharmacokinetic and pharmacodynamic profiles of therapeutic 
proteins is PEGylation and is reviewed by Harris and Chess.144 PEGylation is the process of adding 
polyethylene glycol to a candidate molecule reducing renal clearance, improving stability and 
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masking the potential toxicity of the parent compound, preventing the body from mounting an 
immune response. Although typically used in the delivery of peptides, PEGylated organic small 
molecules have also been developed.145 An opioid antagonist, Naloxegol, reduces the side effects 
of opioid treatment without interfering with pain relief.146 A PEGylated version of irinotecan, a 
topoisomerase I inhibitor anticancer agent is also in development.147 There is the potential for 
further improving the drug-likeness of the tricyclic series described here by PEGylation. 
Identification of the hemi-aminal ether 202 was possible by 1H NMR spectroscopic analysis with a 
peak at approximately 6 ppm consistent with C(1)H joined to both O and N (Table 4.01, Entry 1). 
This in accordance with literature data for similar compounds.143 A large multiplet, integrating for 
2H, at 3.56 ppm (Table 4.01, Entry 11) and a triplet, integrating for 3H, at 1.18 ppm (Table 4.01, 
Entry 12) suggest OCH2CH3 respectively. This is similar to that seen for ethanol.  
Entry Carbon 
1H Chemical Shift 
(ppm) 
Integration J (Hz) 
1 1 6.01 1H t, J 3.0 
2 2 and 3 2.02-1.88 2H m 
3 3 and 2 1.69-1.61 2H m 
4 4 1.87-1.76 2H m 
5 4a 5.10 1H ddd, J 9.5, 4.0 and 1.0 
6 5(N) 4.09 1H brs 
7 7 7.87 1H dd, J 7.5 and 1.5 
8 8 6.77 1H ddd, J 8.0, 7.5 and 1.0 
9 9 7.24 1H ddd, J 8.0, 7.0 and 1.5 
10 10 6.53 1H dd, J 8.0 and 1.0 
11 1’ 3.56 2H m 
12 2’ 1.18 3H t, J 7.0 
Table 4.01: 1H NMR assignment for ethanol adduct 202 
It is of interest that the hemi-aminal ether 202 was isolated (in 6 % yield, see Section 4.9) as a single 
diastereoisomer and fully characterised. Owing to the planar nature of the iminium cation 201, 
ethanol could add from the Re or Si face (Scheme 4.08).  
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Scheme 4.08: Suggested structure of analogue 202 
Attack from the Si face would afford a substituted cyclohexane derivative which would not expect 
to show a NOESY correlation of the Ha and Hb protons in either conformation (Scheme 4.08). Attack 
from the Re face would generate a 1,3-diaxial or 1,3-diequitorial cyclohexane derivative, which 
would mostly exist as the diequatorial species as it is lower in energy. This species would expect to 
give a strong NOESY correlation between the Ha and Hb protons. However, no correlation was 
observed by NOESY NMR spectroscopic analysis between C(1)Ha and C(4a)Hb, suggesting that the 
ethanol adds to the least hindered Si face, affording the hemi-aminal ether 202 with high 
diastereoselectivity as the other epimer was never observed. 
We proposed that using the conditions reported by Shaabani et al. (Scheme 4.01) and altering the 
protic solvent we could furnish the corresponding adduct analogue.141 Although the indicative peak 
at 6 ppm was observed using ethanol or methanol isolation of the products was not achieved and 
attempts at optimising the reaction conditions to favour adduct formation was found to be 
unpredictable. In addition, owing to the reversibility of the reaction, identified previously in Scheme 
4.03, attempts to promote the formation of the iminium ion from the enamine with the addition of 
an acid resulted in decomposition. However, it was found that simply heating the enamine 198 at 
60 °C in the corresponding alcohol overnight gave the best results, which are shown in Table 4.02 
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as the ratio of starting material to hemi-aminal ether as determined by crude 1H NMR spectroscopic 
analysis. Unfortunately these compounds were unstable and decomposed upon purification and 
could not be isolated for further analysis.  
   
Ratio by crude 1H NMR 
spectroscopic analysis  
Entry Solvent Solvent pKa Enamine 198 
Hemi-aminal 
ether 
1 MeOH ≈15 25 75 
2 EtOH ≈16 75 25 
3 iPrOH ≈16.5 100 0 
Table 4.02: 1H NMR ratio after the enamine 198 is stirred in protic solvent 
Despite the decomposition observed during purification, the hemi-aminal methyl ether 205 was 
isolated (Scheme 4.09), albeit in trace amounts, which allowed for 13C and 1H NMR characterisation. 
The compound again had an indicative 1H NMR peak at approximately 6 ppm, with a methyl group 
also being identified at 3.36 ppm, shown in Table 4.03, Entry 1 and 14. The instability of this 
analogue is perhaps unsurprising as the pKa of methanol, Table 4.02, Entry 1, suggests that this 
adduct would be the least stable as it would be a better leaving group than either the ethanol or 
propanol (pKa 16 and 16.5 respectively, Table 4.02, Entry 2 and 3). However, it is the most abundant 
analogue by 1H NMR spectroscopic analysis. 1H NMR NOESY experiments again did not show a 
correlation between the Ha and Hb protons, suggesting the same diastereoisomer was obtained as 
that previously described.  
 
Scheme 4.09: Obtaining the methoxy analogue 205 
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Entry Carbon 
13C Chemical Shift 
(ppm) 
1H Chemical Shift 
(ppm) 
Integration J (Hz) 
1 1 80.2 5.91 1H t, J 3.0 
2 2 16.9 1.64-1.68 2H m 
3 3 28.7 1.91-1.96 2H m 
4 4 33.4 1.79-1.87 2H m 
5 4a 63.9 5.08 1H ddd, J 9.5, 4.0 and 1.0 
6 5(N) na 4.02 1H brs 
7 6 163.8 na na na 
8 6a 114.9 na na na 
9 7 129.0 7.89 1H dd, J 8.0 and 1.5 
10 8 118.7 6.79 1H td, J 8.0 and 1.0 
11 9 133.8 7.26 1H td, J 8.0 and 1.5 
12 10 113.6 6.54 1H dt, J 8.0 and 0.5 
13 10a 145.8 na na na 
14 1’ 55.8 3.36 3H s 
Table 4.03: 1H and 13C NMR assignment for methoxy analogue 205 
The instability of the hemi-aminal ethers prevented further investigations in this area and other 
avenues were pursued.  
4.5. Attempted synthesis of vinyl dihydroquinazolinone analogues 
We previously described the synthesis and biological activity of the allylated AB-ring analogues 126, 
128 and 129. Following the success of the glutaraldehyde reaction, we believed that the 
corresponding allylated dihydroquinazolinone analogue 206 could be accessed using the reaction 
conditions previously described. This would provide an interesting comparison with the previously 
reported analogues, and would offer a substrate for further functionalisation (i.e. dihydroxylation) 
as previously described in Section 2.6.3 and shown below in Figure 4.02.   
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Figure 4.02: C-ring analogues for the dihydroquinazolinone compounds 
Initial investigations were undertaken using the commercially available acrolein in order to obtain 
a vinyl analogue. Using the original conditions as reported by Shaabani et al. for benzaldehyde,141 
analogue 196 was treated with acrolein in ethanol in the presence of NH4Cl. However, the reaction 
failed to give the expected product 207 and only generated an unidentified precipitate which was 
insoluble in a range of different solvents. Even using the optimised conditions, which gave the 
enamine in quantitative yield, failed to furnish the desired product and gave a mixture of 
unidentified compounds, including the insoluble precipitate (Scheme 4.10). 
 
Scheme 4.10: Attempted cyclisation using acrolein 
Presumably the enone present in acrolein is too reactive, leading to the formation of many by-
products and polymers. In addition, there are competing reaction pathways to the desired 
condensation reaction, such as 1,4-conjugate addition. Due to these issues, and the success in 
obtaining the enamine 198 from glutaraldehyde, we investigated the scope and limitations of this 
reaction. We examined i) functionalisation of the enamine 198; ii) other anthranilamide derivatives 
and iii) other aldehyde substrates, the results of which are now described.  
4.6. Attempted functionalisation of the Enamine 
With ready access to the enamine 198 in a single step, we investigated the further functionalisation 
of the C-ring which could provide novel narciclasine analogues and allow us to explore the effects 
of C-ring substitutions on biological activity. A number of procedures are described below. 
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The formation of an epoxide is a well-established method of adding an oxygen atom to an olefin. 
The peracid meta-chloroperoxybenzoic acid (mCPBA) is a commonly used reagent, providing an 
electrophilic source of oxygen to react with the nucleophilic olefin. Using standard procedures the 
enamine was stirred in CH2Cl2 at 0 °C under argon, after which mCPBA was added step-wise and the 
reaction warmed to room temperature. The reaction was followed by TLC until the enamine 198 
was consumed. Crude 1H NMR spectroscopic analysis showed only a complicated mixture of 
compounds which could not subsequently be separated and identified. Possible degradation of the 
compounds was thought to be occurring due to the benzoic acid generated in situ. A buffer was 
therefore added to the system, following the procedure reported for the carvone analogue 208 in 
Scheme 4.11.148 In a model system using carvone the reaction was successful. Unfortunately using 
enamine 198 resulted in unidentified materials, so alternative methods for the addition of oxygen 
were sought.  
 
Scheme 4.11: Epoxidation of the nucleophilic alkene of carvone analogue 208148 
A procedure described by Botman et al., shown in Scheme 4.12, shows the oxidation of enamine 
210 using oxone, introducing α-methoxy and β-hydroxy substituents in one-step.149 The reaction 
proceeds via an unstable epoxide intermediate which is opened immediately by the methanol to 
give analogue 211.150 Subsequent removal of the α-methoxy moiety by acid hydrolysis gave 
compound 212 in high yields. Following the reported procedure with our substrate 198, crude 1H 
NMR spectroscopic analysis suggests the possibility of the methanol adduct, with a peak at 
approximately 6 ppm described previously (Section 4.4). Unfortunately, purification of the products 
caused degradation, leaving only a mixture of unidentified compounds. 
 
Scheme 4.12: Reported functionalisation of an enamine 210 using oxone149 
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Acetylation of oxidised isoquinolinones was achieved using acetic anhydride and sulfuric acid,89 as 
described in Section 2.6.1 and shown in Scheme 4.13. Likewise, the enamine 198 provides a 
nucleophilic olefin which could react in a similar fashion, providing an acetylated analogue. 
Although initial investigations were positive, attempts at optimisation of this reaction and 
subsequent isolation of compounds were not achieved, giving only a mixture of unidentifiable 
compounds. 
 
Scheme 4.13: Acetylation of lactam 83, described in Section 2.6.1 
The use of ruthenium chloride has previously been described in Section 2.6.2.2 for oxidation of a 
double bond. Following on from this success, we wished to examine the dihydroxylation of the 
enamine using this methodology. Indeed, this method had been used to achieve cis-dihydroxylation 
in the total synthesis of narciclasine 7 reported by Hudlicky et al. in 2002 and shown in Scheme 
4.14.151  
 
Scheme 4.14: Cis-dihydroxylation using catalytic RuO4151  
Owing to the previous success in isolation of the dione 117 (Section 2.6.2.2), the enamine 198 was 
treated with an aqueous solution of RuCl3·×H2O (0.4 mol %) and NaIO4(aq) (5 eq.) in EtOAc at room 
temperature. The reaction was followed by TLC until the starting material had been consumed. As 
previously reported, iPrOH was added and the reaction stirred for a further 3 hours in order to 
neutralise the active RuO4 generated in situ. Crude 1H NMR spectroscopic analysis suggested one 
major product, although mass recovery was very poor, and was initially assigned as trione 215, 
Scheme 4.15. This initial assignment could not be confirmed by 13C NMR spectroscopic analysis due 
to low yield so further investigations were undertaken.  
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Scheme 4.15: Initial assignment of product 215 based on 1H NMR spectroscopic analysis  
Oxidation reactions involving RuO4 are known to be difficult to control and it was hoped that 
limiting the amount of oxidant available would prevent over-oxidation. Repeating the reaction 
using 1 eq. NaIO4(aq), rather than 5 eq., allowed for new compounds to be observed. Very little 
separation was observed by TLC and isolation was not achieved, however mass spectrometry of the 
crude products suggested the presence of the compounds shown in Figure 4.03 amongst others.  
 
Figure 4.03: Suggested compounds extracted from the oxidation reaction with RuO4 
The mixture of products was stirred with the mild oxidising agent manganese dioxide (MnO2) in 
order to further understand what compounds had been synthesised. Following purification by 
column chromatography, the bislactam 216 shown below in Scheme 4.16 was the sole product 
isolated in 54 % yield over the two-steps. The bislactam 216 was fully assigned and was the actual 
compound obtained in Scheme 4.15 as the 13C NMR clearly shows 11 carbons, highlighting the loss 
of one carbon from the enamine 198. This then suggests the loss of CO2 during the reaction 
mechanism and a plausible pathway is shown in Scheme 4.16 below. Oxidative cleavage of the 
double bond reveals a carbamate, which can undergo decarboxylation leaving an aniline which 
undergoes lactamisation. This is supported by research undertaken by Lu et al. for a similar 
compound. Omitting MnO2 led to a mixture of compounds from which the bislactam was isolated 
in a reduced 26 % yield. 
- 92 - 
 
 
Scheme 4.16: Oxidation, decarboxylation and cyclisation towards product 216  
Sodium borohydride (NaBH4) is a ubiquitous reducing agent typically used for the reduction of 
aldehydes and ketones to their corresponding alcohols. A more aggressive agent is lithium 
aluminium hydride which will also reduce amides and lactams. Preliminary investigations were 
carried out in order to reduce the tertiary amide present in bislactam 216 over the secondary amide 
using NaBH4, as reported in the literature.152,153 Based on these reported conditions, the tricyclic 
analogue 216 was treated with NaBH4 in methanol under nitrogen (Scheme 4.17, the numbering for 
the product has been kept consistent with analogue 216). The reaction was followed by TLC analysis 
until the starting material had been consumed.  
 
Scheme 4.17: Reduction of C(3a) using NaBH4 
Crude 1H NMR spectroscopic analysis showed a single compound which was isolated in quantitative 
yield. Characteristic carbon peaks are outlined in Table 4.04. It is suggested that the compound is 
the fused [6, 9] bicyclic ring 217, shown in Scheme 4.17 as it is missing the C(3a) peak at 6.31 ppm. 
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Instead, there are two triplets, both integrating for 2H, at 2.70 and 3.53 ppm suggesting C(2) 
(CH2C=O) and C(4) (NCH2) respectively due to their respective chemical shifts and the strong COSY 
between C(4) and the N(5)H, (Table 4.04, Entry 2 and 4). The 2H multiplet at 1.90-1.97 ppm equates 
to C(3) (Entry 3) and has a strong COSY with both C(2) and C(4). Unfortunately a lack of material 
meant that 13C NMR could not be obtained, however the structure is consistent with HRMS analysis. 
The reaction was performed on larger scale, but regrettably starting material persisted. Isolation 
was therefore not possible due to co-eluting of the starting material with the product. 
Entry Carbon 
1H Chemical Shift 
(ppm) 
Integration J (Hz) 
1 1 na na na 
2 2 2.70 2H t, J 7.5 
3 3 1.90-1.97 2H m 
4 4 3.53 2H t, J 6.5 
6 6 na na na 
7 6a na na na 
8 7 8.13 1H ddd, J 8.0, 1.5 and 0.5 
9 8 7.51 1H ddd, J 8.0, 7.0 and 1.0 
10 9 7.82 1H ddd, J 8.0, 7.0 and 1.5 
11 10 7.64 1H d, J 7.5 
Table 4.04: 1H NMR assignment for [6, 9] fused bicyclic ring 217 
This result can be explained by appreciating that the C(3a) carbon  
(highlighted in Scheme 4.17) is at the +2 oxidation level (c.f. aldehydes and ketones) and is therefore 
susceptible to reduction by NaBH4. This removes B/C-ring junction leaving an expanded 9-
membered ring.  
In order to ascertain what types of reagent might be used to successfully functionalise the enamine 
198 without causing decomposition, stability tests were performed. Enamine 198 was stirred in a 
1:1 mixture of THF and either water, NaOH(aq) or HCl(aq) at room temperature. TLC analysis was done 
over a 24 hour period and in each case decomposition of the enamine occurred which was 
confirmed by crude 1H NMR spectroscopic analysis. This study then explains some of the problems 
encountered in the reactions described above, since the enamine is not compatible with aqueous 
systems. Future efforts to functionalise the enamine will therefore use non-aqueous reaction 
conditions.  
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4.7. Synthesis of A-ring analogues 
As described in Section 1.3.3.1, the presence of a free hydroxyl group at C(7) on the A-ring is 
paramount in ensuring the anticancer activity of the narciclasine analogues. Thus far a series of 
unsubstituted A-ring compounds have been examined, containing the additional nitrogen at the 
B/C-ring junction. Using substituted anthranilamides as starting materials will furnish the 
corresponding A-ring analogues.  
We previously investigated dimethoxy and trimethoxy analogues and we wished to examine the 
corresponding substituted quinazolinones 218 and 220, shown in Scheme 4.18. The benzamide 
starting materials 219 and 221 for each target compound is not commercially available, however, 
the corresponding carboxylic acid and ester of the dimethoxy derivatives are and due to the 
ubiquitous nature of the amide group in medicinal products, as well as biological processes, there 
are a range of conditions and strategies towards making this important bond. 
 
Scheme 4.18: Proposed disconnection to achieving hydroxylated A-ring analogues 
4.7.1. Attempted synthesis of 2-amino-4,5-dimethoxybenzamide from 2-amino-4,5-
dimethoxybenzoate  
Published procedures describe the direct conversion of the readily available and inexpensive 2-
amino-4,5-dimethoxybenzoate 222 to the 2-amino-4,5-dimethoxybenzamide 219, shown in 
Scheme 4.19. Typical reported conditions describe the ester reacting with ammonia water in a 
protic solvent over a number of days or at elevated temperatures under pressure.154,155 
Unfortunately attempts at reproducing the results obtained were unsuccessful, with starting 
material being recovered in quantitative yield.  
 
Scheme 4.19: Proposed conversion of the dimethoxy ester 222 to an amide 219 
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Other literature reports describe a two-step process initially using hydroxylamine or hydrazine to 
access the corresponding benzamide 219,156-158 as these are more nucleophilic owing to the α-
effect, shown in Scheme 4.20. A second step is then required to cleave the N-N or N-O bond to 
reveal the desired amide. 
 
Scheme 4.20: Proposed synthetic route to benzamide 219 
From the literature,159 aminobenzoate 223 was treated with NaOH(aq) and NH2OH·HCl, MeOH was 
added dropwise until all of the constituents were in solution and the reaction was left to stir for 5 
days to afford the hydroxylamine product 224 in 80 % yield (Scheme 4.21). However, when this 
method was applied to the dimethoxy derivative 222, only starting material was recovered. A 
similar method and transformation was published using KOH,160 however when the base was 
changed to KOH and the reaction even heated to reflux, only recovered starting material was 
obtained. 
 
Scheme 4.21: Reported reaction with hydroxylamine159  
A procedure was reported for a similar transformation of benzoate 225 using hydrazine in ethanol 
at reflux by Kuemmerle et al., shown in Scheme 4.22161 Again, when dimethoxy ester 222 was 
subjected to these conditions only unreacted starting material was obtained with good mass 
recovery. 
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Scheme 4.22: Reaction with hydrazine reported by Kuemmerle et al.161  
It was then concluded that the ortho-amino group might be causing interference, preventing the 
reaction from occurring. Protection of the aniline was therefore examined to observe if this had 
any effect. Using a well-established procedure, the aniline was acetylated with acetyl chloride and 
Na2CO3 in chloroform (Scheme 4.23).162 The acetylated product 227 was isolated in 99 % yield and 
spectroscopic data was consistent with that previously reported for this compound. 
 
Scheme 4.23: Protecting the amine with acetyl chloride 
The protected aniline 227 was subjected to the reaction conditions described previously with 
moderate success. Crude 1H NMR spectroscopic analysis of the reaction with NH2OH showed a 
mixture of compounds, including unreacted starting material, the acid and the product (Figure 
4.04). These results demonstrated that the unprotected ortho-amino group did prevent the desired 
reaction, so instead of examining a protecting group strategy and optimising these reaction 
conditions, we investigated an alternative synthetic route of the desired amides from the 
corresponding carboxylic acids.  
 
Figure 4.04: Percentage ratio ascertained by crude 1H NMR spectroscopic analysis 
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4.7.2. Synthesis of 2-amino-4,5-dimethoxybenzamide from 2-amino-4,5-
dimethoxybenzoic acid 
Carboxylic acids, rather than esters, are primarily used in the standard approaches to amides, many 
of which are reviewed by Montalbetti et al.163 Since conversion of the ester to the corresponding 
amide was problematic, we investigated the transformation of the 2-amino-4,5-dimethoxybenzoic 
acid instead, which is also commercially available.  
Upon mixing an acid with an amine the stable salt is first to form meaning the coupling of these 
functional groups has to overcome adverse thermodynamics, the equilibrium of which is depicted 
in Scheme 4.24.164 The barriers to this reaction can be overcome at elevated temperature; however 
this risks denaturing of the rest of the molecule involved.  
 
Scheme 4.24: Equilibrium of amide formation 
Activation of the acid can be achieved by a variety of methods. 1,1’-Carbonyldiimidazole 231 (CDI) 
was chosen as the reaction is a well-documented one-pot procedure, giving only imidazole and 
carbon dioxide as by-products.163 The initial reaction between the carboxylic acid 230 and CDI 231 
forms the activated ester 232 which is susceptible to nucleophilic attack by the ammonia generating 
the amide 196 with the release of imidazole (Scheme 4.25). 
Scheme 4.25: Summary mechanism of the CDI reaction 
Substituted 2-amino benzoic acids were treated with CDI and NH3(aq) and gave the desired 
benzamide products with isolated yields shown in Figure 4.05. It is worthy of note that the crude 
reaction mixtures were simply washed with base to remove any unreacted starting material and 
then washed with iron(II)sulfate (FeSO4) solution, which complexes the imidazole and removes it. 
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The products were therefore obtained analytically pure after aqueous washes without the need for 
further purification.  
 
Figure 4.05: Benzamide analogues obtained using CDI followed by aqueous washes 
4.7.3. Proposed synthesis of 6-amino-2,3,4-trimethoxybenzamide 
As previously described, narciclasine 7 and pancratistatin 8 analogues with a C(7)OH group have 
consistently been shown to have superior anticancer activity. We envisioned obtaining the 
corresponding free phenol 236 from the trimethoxy derivative 220, Scheme 4.26. Based on our 
previous observations, BF3·OEt3 mediated intramolecular Friedel-Crafts acylation with trimethoxy 
derivatives led to concurrent selective demethylation at the C(7) position. We therefore expected 
that treatment of the trimethoxy-quinazolinone derivative 220 with BF3·OEt3 would result in 
selective demethylation and afford the desired analogue 236. The construction of 6-amino-2,3,4-
trimethoxybenzamide 221 from commercially available 3,4,5-trimethoxyaniline 237 is suggested in 
Scheme 4.26.   
 
Scheme 4.26: Proposed disconnection in the synthesis of trimethoxybenzamide 236 
One potential synthetic route would involve installing a bromine group at the 2 position, followed 
by treatment with butyl lithium and dry ice to afford the benzoic acid. Finally the amide could be 
synthesised as previously described. However, this is a multi-step procedure using harsh reaction 
conditions. 
There is growing interest in accessing benzoic acids via an istatin intermediate. A successful strategy 
reported by Zhang et al. for a similar compound describes ortho carboxylation of the 3,5-
dimethoxyaniline salt 238, shown in Scheme 4.27.165 This transformation has also been reported by 
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Newman et al. with the suggestion that the reaction proceeds via the oxamyl chloride intermediate 
239.166 The subsequent intramolecular acylation occurs ortho to the amino group without the need 
for a Lewis acid. This is thought to be due to the ortho and para activating properties of the methoxy 
groups, directing the electrophilic attack. Ring opening then occurs with hydrogen peroxide and 
concentrated sodium hydroxide to get analogue 241. 
Scheme 4.27: Synthesis of 3,5-dimethoxyanthranilic acid 241165,166 
Although the procedure required heating compound 238 in oxalyl chloride to 165 °C initial attempts 
were carried out at reflux, 65 °C, as no specialist equipment was mentioned in the experimental 
procedure.165 In addition, no advantage was apparent for using the salt form of the aniline therefore 
the free base 237 was used.  
Following the literature, oxalyl chloride (4 eq.) was added to trimethoxyaniline 237 at room 
temperature under argon forming an insoluble mass of black material which persisted upon 
heating. Excess oxalyl chloride was therefore required in order to achieve solvation. Upon 
quenching with methanol, product 242 was observed by crude 1H NMR spectroscopic analysis, 
suggesting that cyclisation had not occurred (Scheme 4.28). This was further confirmed by mass 
spectrometry, with no istatin being observed. Isolation was not attempted due to co-eluting with 
other compounds in the crude reaction mixture. 
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Scheme 4.28: Suggested structure of compound 242 
Although the published experimental for 3,5-dimethoxyaniline 238 suggested the reaction might 
proceed without the need for a Lewis acid, other reports suggest a Lewis acid is required. Conditions 
reported by Browne et al. showed the successful formation of istatin 244 using aluminium chloride 
(AlCl3), shown in Scheme 4.29.167 They describe the aniline 243 treated with oxalyl chloride in CH2Cl2 
at reflux. After 1 hour, the removal of residual oxalyl chloride and treatment with AlCl3 facilitated 
the intramolecular cyclisation and gave the product 244 in 70 % yield. Similar conditions were 
reported by Shindikar who also described the isolation of the ensuing oxamyl analogue 246 prior to 
Lewis acid mediated acylation.168 Unfortunately, only a black, insoluble mass was recovered using 
these procedures with trimethoxyaniline 237, which could not be separated. 
Brown et al.167 
 
Shindikar et al.168 
Scheme 4.29: Model reactions facilitated by AlCl3 
A procedure reported for a similar compound, shown in Scheme 4.30, reported by Kaila et al. 
described the dropwise addition of oxalyl chloride to a solution of 3-methoxyaniline 248 in benzene. 
Following heating to reflux, the reaction was then cooled to 0 °C, AlCl3 was added and the reaction 
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warmed to room temperature for a further 3 hours.169 However, when these reaction conditions 
were applied to trimethoxyaniline they were again unsuccessful, with a black mass of unidentifiable 
materials being recovered. 
Scheme 4.30: Procedure demonstrated by Kaila et al.169 
The initial methodology was revisited, given the problems with using the Lewis acid mediated 
reactions. A procedure reported by Kallander et al. for the same compound describes the successful 
conversion of trimethoxyaniline 237, shown in scheme 4.31, to the benzoic acid.170 The HCl salt 251 
was obtained by treating a solution of trimethoxyaniline 237 in diethyl ether with HCl(aq). The 
product 251 was confirmed by an increased melting point, from 109-110 °C171 for the starting 
material 237 to 256-260 °C172 for the HCl salt, which was isolated as a grey solid without further 
purification. Using a 0.26 mmol scale, the aniline salt was then stirred in oxalyl chloride at 170 °C in 
a sealed thick-walled pressure tube for 50 minutes. After cooling to room temperature the reaction 
was quenched with methanol and refluxed for 10 minutes. Following column chromatography the 
desired product 252 was finally isolated in 62 % yield.  
Scheme 4.31: Formation of the trimethoxyistatin analogue 252 
This small amount was subjected to the reported conditions for ring opening, shown in Scheme 
4.27.165,166,170 Although this appeared a robust procedure, only a mixture of unidentifiable 
compounds were unfortunately recovered. In an effort to synthesise a viable amount of the 
trimethoxyistatin compound 252 for further investigations, the reaction was repeated on a 10 
mmol scale. Although the formation of the hydrochloride salt was more successful (90 % yield 
without further purification) reaction with oxalyl chloride on a 5 mmol scale did not give the 
expected istatin 252 as previously obtained. Upon purification, 1H NMR and HRMS data was 
consistent with structure 253 shown in Figure 4.06. Attempts at optimising the reaction proved to 
- 102 - 
 
be unsuccessful and we summarised that this reaction was capricious. We therefore investigated 
the reaction of substituted 2-amino benzamides already obtained with glutaraldehyde. 
 
Figure 4.06: Structure of compound 253 
4.8. Tricyclic substituted A-ring analogues 
With the methyl substituted anthranilamide analogues in hand and using the optimised conditions 
previously described in Section 4.3, cyclisation was investigated with glutaraldehyde. 
Unfortunately, the reaction to form the enamine with these substituted derivatives did not proceed 
as efficiently as previously described. Crude 1H NMR spectroscopic analysis showed predominantly 
the expected products, however there were also unidentifiable contaminants within the reaction 
mixture. These contaminants could not be removed by column chromatography, as the enamine 
simply decomposed. Efforts to optimise these reaction conditions failed to eliminate the by-
products, so the enamine intermediates were therefore used as crude for subsequent reactions. 
It is worthy of note that when dimethoxy anthranilamide 219 was subjected to the reaction shown 
in Scheme 4.06, only a complex mixture of products was obtained, with no enamine identified. 
Given the comparative success of the methyl derivatives, this is presumably due to the electron 
donating properties of the dimethoxy groups affecting the condensation-cyclisation cascade 
reaction described in Scheme 4.07. 
4.9. Reduction of the enamine by Pd/C 
Due to the instability of the enamine analogues, reduction of the double bond was considered in 
order to obtain the stable cyclic amine analogues and evaluate the potential benefit of the 
additional nitrogen in comparison to similar late stage intermediates already synthesised. 
Using standard procedures for hydrogenation, mentioned in Section 3.5.1, the intermediate 
enamine 198 and Pd/C (10 % wt.) were stirred vigorously in EtOH and exposed to an atmosphere 
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of H2 for 16 hours. Upon filtering and purification compound 254 was isolated in 39 % yield (Scheme 
4.32). 
 
Scheme 4.32: Hydrogenation using Pd/C and atmospheric H2 gas 
Interestingly, the hemi-aminal ethyl ether 202 was also isolated in 6 % yield suggesting that the 
solvent reacted with the enamine, via the iminium ion, as previously described in Section 4.4 
(Scheme 4.08). 
An interesting observation was made of the crude 1H NMR spectrum. In addition to the main cyclic 
amine product 254 and hemi-aminal ethyl ether 202, another by-product was observed, 
approximately 4 % by crude 1H NMR spectroscopic analysis. This revealed triplets at 3 and 4 ppm 
and it was postulated that this was the [6-10] fused bicyclic analogue 255, shown in Scheme 4.33, 
formed by the reduction of the C(4a) carbon as previously observed in Scheme 4.17. Data reported 
for a similar [6-10] fused bicyclic compound are consistent, with reported triplets at 4.44 ppm and 
2.86 ppm.173 Unfortunately this by-product could not be isolated due to the small mass and 
attempts at optimising the reaction to favour its formation failed. 
 
Scheme 4.33: Potential reaction mechanism 
Performing the condensation-cyclisation reaction of the 3, 4 and 5-methyl 2-amino-benzamides 
with glutaraldehyde, and subsequent hydrogenation of the enamine intermediate, was largely 
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successful. With 4-methyl 2-amino-benzamide, in addition to the desired product 257 in 61 % yield, 
the ethanol adduct 256 was also isolated in 24 % yield, (Scheme 4.34), with 1H NMR spectroscopic 
data being consistent with that reported previously for compound 202 discussed in Section 4.4. 
Unfortunately decomposition of this unstable hemi-aminal ethyl ether occurred before full 
characterisation could be achieved.  
 
Scheme 4.34: Product 257 isolated following the hydrogenation of the corresponding enamine 
With 5-methyl 2-amino-benzamide, only the corresponding saturated tricyclic analogue 258 was 
obtained in 31 % yield over the two-steps without the ethanol adduct being observed (Scheme 
4.35). 
 
Scheme 4.35: Product 258 isolated following the hydrogenation of the corresponding enamine 
Interestingly, when the reaction was performed with 3-methyl 2-amino-benzamide, multiple 
products were observed, shown in Scheme 4.36. Purification by column chromatography and NMR 
spectroscopic analysis of the isolated products allowed us to identify that the major component 
was in fact the imine-amide 260, which was isolated in 40 % yield.  
Scheme 4.36: Two-step reaction for the formation of 261 (not isolated) 
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Palladium is a well-known hydrogen transfer agent and, as previously described in Section 2.3.2, 
the dehydrogenation of isoquinolinones using Pd/C has been reported, usually at elevated 
temperatures under an inert atmosphere.75 The attempted reduction occurs at room temperature, 
however the presence of imine-amide 260 suggests that dehydrogenation at C(4a)/N (to generate 
the imine) occurs prior to hydrogenation at C(1)/C(2) (the enamine). If the enamine reduced first, 
we would have expected to obtain some of the expected analogue 261, which we do not observe. 
This is perhaps due to steric interference from the methyl group causing hydrogenation of the 
enamine to occur slowly over time, with competing dehydrogenation occurring preferentially. 
Leaving the reaction longer, for 24 hours, did not afford any of the expected lactam product 261 
and instead led to an increased yield of the imine-amide 260 to 62 %. This is an interesting 
observation, and together with previous results, demonstrates the sensitivity of the reaction to 
both steric and electronic factors. 
The formation of an enamine, which is then reduced, can be achieved in a single step using sodium 
cyanoborohydride (NaBH3CN), which was also investigated and is now described. 
4.10. Reduction by NaBH3CN 
Sodium cyanoborohydride is a mild reducing agent used in the reduction of imines. The electron 
withdrawing properties of the cyano group lessen the nucleophilicity of the remaining hydride. This 
reagent will reduce an iminium cation, preventing the formation of the enamine. Grigg et al. 
demonstrates the cyclisation of 262 and subsequent reduction of the ensuing iminium cation 263 
to form bicyclic product 264 in 89 % yield using NaBH3CN, Scheme 4.37.174 
Scheme 4.37: Cyclisation and subsequent iminium reduction by NaBH3CN174 
Using modifications of these reported conditions, optimisation of the reaction conditions was 
undertaken on anthranilamide 196. Anthranilamide 196 and glutaraldehyde 200 were stirred in 
methanol with NH4Cl. NaBH3CN was added step-wise at room temperature and the reaction stirred 
for 6 hours. Trace amounts of the reduced product 254 were recovered, however analogue 265 was 
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isolated in 5 % yield, shown in Scheme 4.38, with the rest of the mass being a mixture of 
unidentifiable products.  
 
Scheme 4.38: Using NaBH3CN for the synthesis of tricyclic analogue 254 
The isolation of the piperidine 265 suggested that the reaction initially proceeded as previously 
discussed (Section 4.3) however following the initial condensation reaction, the ensuing imine is 
reduced by the NaBH3CN before intramolecular cyclisation can occur with the amide (Scheme 4.39). 
A second condensation and subsequent reduction then affords the observed analogue 265. 
Allowing for enamine formation prior to the addition of NaBH3CN should allow for the synthesis of 
tricyclic analogue 254.  
 
Scheme 4.39: Reduction of the iminium cation by NaBH3CN 
This is supported by conditions reported by Nacro et al. which show a similar step-wise 
transformation, outlined in Scheme 4.40.175 Condensation of acetaldehyde with aniline occurs first, 
followed by the reduction of the ensuing imine by NaBH3CN to afford compound 267.  
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Scheme 4.40: Conditions reported by Nacro et al.175  
The general procedure for the synthesis of enamine 198 was followed, omitting the addition of 
MgSO4, and the reaction was monitored by TLC analysis until the starting material was consumed. 
Methanol was added to the reaction mixture and the temperature reduced to 0 °C. NaBH3CN was 
added step-wise, followed by acetic acid until the pH was less than 7 (Scheme 4.41). After stirring 
at room temperature for 4 hours the reaction was quenched with hydrogen peroxide and ferrous 
sulfate. Pleasingly, crude 1H NMR spectroscopic analysis showed mostly the desired product 254 
which was isolated in 55 % yield following column chromatography.    
 
Scheme 4.41: Reduction of the tricyclic analogue by NaBH3CN 
Using these optimised one-step conditions, 3-methyl 2-amino-benzamide 233 was investigated. As 
previously noted, this substrate failed to furnish the desired compound with Pd/C presumably due 
to steric clashes, which was replicated here as no product was obtained.  
4.11. Functionalisation of the enamine by ruthenium 
As previously described, treatment of the unsubstituted enamine with RuCl3·×H2O and NaIO4 
followed by MnO2 led to oxidative cleavage, decarboxylation and lactamisation, and gave the 
corresponding bislactam 216 in 54% yield (Scheme 4.16). Conducting the reaction without MnO2 
led to a reduced yield of 26 %. It is pleasing to note that using either 3, or 4-methyl 2-amino 
benzamide, 233 and 234, as starting materials, even without MnO2, gave the corresponding 
bislactams 268 and 269 in 33 % and 26 % respectively (Scheme 4.42). 
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Scheme 4.42: Synthesis of bislactams 268 and 269 
4.12. Functionalisation of the C-ring using sugars 
Using the novel synthetic approach to quinazolinone analogues of narciclasine and pancratistatin 
described for the first time here, retrosynthetic analysis of the natural products shows that sugars 
are a prime candidate to provide hydroxyl groups for the C-ring. This is a major breakthrough, as 
not only do sugars provide the alcohol groups, they are provided as single enantiomers which are 
known. Furthermore, a large number of sugars are available to enable a comprehensive structure-
activity relationship to be built. This would open up a new avenue for investigation and biological 
evaluation and has the potential to provide narciclasine 7 and pancratistatin 8 analogues complete 
with hydroxylated C-ring as single enantiomers in one- or two-steps, Scheme 4.43.  
 
Scheme 4.43: Retrosynthetic analysis of C-ring analogues using sugars 
Initially condensation of the anthranilamide analogue 272 with the aldehyde of the sugar will give 
intermediate 271, subsequent oxidation or activation of the primary alcohol will allow for a second 
cyclisation and C-ring formation, analogue 270. D- and L-lyxose were initially chosen as they exhibit 
the same and reversed stereochemistry of the three hydroxyl groups present in the C-ring of 
narciclasine 7, shown in Scheme 4.44. This would provide an interesting comparison with the 
anticancer activity of the natural product. Preliminary investigations were undertaken with the 
economical D-lyxose, as L-lyxose is more expensive. 
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Scheme 4.44: Stereochemistry of D- and L-lyxose and possible analogues 
Using the initial reaction conditions reported by Shaabani et al. (described in Section 4.2),141 
anthranilamide and D-lyxose were stirred in ethanol at room temperature open to the atmosphere. 
NH4Cl (50 mol %) was added and the reaction initially stirred at room temperature. Upon 
monitoring by TLC analysis for a number of hours no reaction was observed therefore the reaction 
was heated to 60 °C overnight. A precipitate ensued, which upon filtering was found to be pure 
quinazolinone 273 in 33 % yield, which did not require further purification (Scheme 4.45). 1H NMR 
spectroscopic analysis of the crude filtrate showed a mixture of compounds but was not analysed 
further as no product 273 was observed. 
 
Scheme 4.45: Reaction of anthranilamide with D-lyxose 
An interesting intermediate was isolated during attempts at optimising the reaction conditions, as 
shown in Scheme 4.46. Following the same method, but without the addition of NH4Cl, gave a 
precipitate which once filtered and analysed was found to be analogue 274 in 26 % yield. Heating 
the reaction at reflux increased the yield to 89 %. Adding less than 100 mol % of NH4Cl gave solely 
product 274. 
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Scheme 4.46: Formation of the sugar derivative 274 
In addition, using the conditions specified in Scheme 4.45 without the addition of an air condenser 
again gave exclusively product 274. It was postulated that cyclised analogue 274 was an 
intermediate to straight chained analogue 273 and that analogue 274 was slightly less soluble and 
therefore precipitated first, preventing formation of the fused AB-ring. Decreasing the 
concentration of the reaction by increasing the proportion of solvent failed to furnish consistent 
results and was found to be highly dependent on the evaporation of ethanol. Conducting the 
reaction at lower temperatures in order to prevent evaporation again failed to give analogue 273 
as did increasing the amount of NH4Cl to 150 mol % or increasing the temperature.  
As previously mentioned it was suggested that analogue 274 was an intermediate to the fused 
bicyclic analogue 273. Indeed, stirring cyclised 274 in ethanol with NH4Cl at 60 °C for a further 20 
hours (Scheme 4.47) produced a mixture of analogue 273 and analogue 274 of 37 to 63 respectively 
by 1H NMR spectroscopic analysis. Solubility was an issue so methanol was added until solvation 
was achieved. 
Scheme 4.47: Investigation that sugar 274 in an intermediate of analogue 273 
The reaction was therefore found to be highly dependent on solvent. Better solubility was achieved 
using methanol (rather than ethanol) and analogue 273 was successfully, and consistently, isolated 
in 40 % yield.  
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This improved methodology was repeated with L-lyxose and gave similar results using methanol to 
gain the AB-ring analogue 275 in 39 % yield, shown in Figure 4.07. Conducting the same reaction 
using ethanol as the solvent without NH4Cl instead gave the intermediate analogue 276 in 40 % 
yield, shown in Figure 4.07. These results were not optimised due to the limited availability of the 
sugar.  
 
Figure 4.07: Optimised yields of analogues 275 and 276 
The stereochemistry of the newly formed stereogenic center of these sugar derivatives was not 
assigned. Our next step was to investigate formation of the C-ring, which would afford a rigid 
structure from which it was hoped the stereochemistry could be assigned based on the coupling 
with the known adjacent stereocenter. 
Other sugars were subjected to these optimised conditions, with different patterns of 
stereochemistry, such as galactose, glucose and ribose. Regrettably these sugars made a resinous 
substance which was difficult to manipulate and a crude 1H NMR spectroscopic analysis was not 
possible on all but the ribose analogue. This suggested that the ribose straight chain analogue had 
been synthesised, although it was contaminated with other compounds. Efforts to gain pure 
compound were not attempted due to time constraints on the project.  
4.13. Cyclisation of the sugar side-chain 
Preliminary investigations were undertaken into the cyclisation of the sugar side-chain with two 
proposed routes, shown in Scheme 4.48. Route a outlines the oxidation of the primary alcohol to 
the aldehyde, allowing for cyclisation to occur as previously described, to gain pancratistatin 
analogue 277. Route b shows the activation of the primary alcohol using tosyl chloride and 
subsequent cyclisation that would give narciclasine analogue 278. Preliminary investigations into 
these proposed routes will be described further here. 
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Scheme 4.48: Proposed synthetic routes to the cyclised C-ring 
4.13.1. Oxidation of the primary alcohol 
A strategy to cyclise the side-chain is to oxidise the primary alcohol to the aldehyde which would 
then allow for a condensation reaction to occur as previously mentioned. With a robust procedure 
in place for the synthesis of analogue 273 and 275 efforts were made to oxidise the primary alcohol, 
in preference to the secondary alcohols.  
A reported procedure by Einhorn et al. demonstrated the oxidation of a aliphatic and benzylic 
primary alcohols using TEMPO and N-chlorosuccinamide (NCS) (Scheme 4.49).176 This was in 
preference to secondary alcohols with intermolecular (primary and secondary alcohols on different 
molecules) and intramolecular (primary and secondary alcohols on the same molecule) competition 
demonstrating high chemoselectivity towards the primary alcohol, consequently forming the 
aldehyde. 
 
Scheme 4.49: Oxidation of a primary alcohol in preference to a secondary alcohol176 
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Following the reported procedure and using the model substrate benzyl alcohol, for which Einhorn 
et al. report a 99 % yield, test reactions were carried out. Benzyl alcohol 281 was stirred with TEMPO 
and tertbutylammonium chloride (TBACl) in dichloromethane at room temperature (Scheme 4.50). 
NaHCO3(aq) (0.5 M) and K2CO3(aq) (0.05 M) was added and the reaction vigorously stirred after which 
NCS was added and the reaction followed by TLC. After 3 hours crude 1H NMR spectroscopic analysis 
showed a ratio of starting material to product of 84:16. As reported, improvements in yield were 
achieved by using recrystallised NCS and also increasing the amount of TBACl in the reaction 
mixture. However, an optimised ratio of alcohol 281 to aldehyde 282 of 50:50 by crude 1H NMR 
spectroscopic analysis was the best result. 
 
Scheme 4.50: Synthesis of benzaldehyde 282 
These optimised conditions were implemented on the straight chain analogue 273. Solubility was 
initially an issue, however the starting material dissolved into the reaction mixture over time. The 
reaction was followed by TLC and crude 1H NMR spectroscopic analysis was done after the starting 
material had been consumed. This showed one product, however hydroxyl groups were not 
observed suggesting that over oxidation had occurred. Time constraints prevented further 
investigations however this methodology may be promising and so more examination of these 
conditions is warranted. 
4.13.2. Activation of the primary alcohol 
An alternative strategy is to activate the primary alcohol to a good leaving group, such as p-
toluenesulfonyl chloride (pTsCl), in order to promote intramolecular cyclisation. This is a strategy 
employed by multiple researchers in order to tosylate the primary alcohol in a sugar, in preference 
to secondary ones.177-180 Methodology is consistent throughout, an example of which is work 
reported by Ulgar et al. shown in Scheme 4.51.178 A solution of sugar analogue 283 and anhydrous 
pyridine at -15 °C was added dropwise to a stirring solution of pTsCl in anhydrous pyridine under 
inert conditions. The reaction was stirred at 0 °C for 2 hours to furnish tosylated analogue 284 in 77 
% yield. 
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Scheme 4.51: Selective tosylation of the primary alcohol178 
The standard method was employed using our substrate 273 and two new spots were observed by 
TLC analysis, although the starting material persisted. Unfortunately, crude 1H NMR spectroscopic 
analysis showed mostly the pyridine salts. Altering the work-up in order to remove the salt with an 
aqueous wash and EtOAc extraction only resulted in the recovery of starting materials.  
Crude 1H NMR spectroscopic analysis suggested that the tosylate was formed due to a new methyl 
peak at 2.33 ppm, integrating proportionally for 3 hydrogens when compared to the aromatic 
protons of the AB-ring sugar analogue. Branchaud et al. reported using the tosylated product as 
crude,177 and this was repeated in our system, subjecting the compound to heat in order to promote 
cyclisation. Unfortunately a mixture of unidentifiable compounds was recovered. Although the 
tosylated or cyclised product was not isolated analysis of the crude data suggests that this might be 
a successful avenue for investigation and should be examined further.  
4.14. Conclusions and future work 
The work in this chapter describes the one-pot procedure to novel quinazolinone analogues of 
narciclasine and pancratistatin. Although further functionalisation of the enamine was attempted 
it was found to be unstable in aqueous conditions and reduction of the olefin was required in order 
to furnish compounds which could be biologically evaluated. It is hoped that these compounds, 
along with their bislactam counterparts, will be accepted for evaluation by the NCI. 
Further analysis of the A-ring methoxy derivatives is warranted. Although initial investigations of 
the dimethoxy derivative 219 failed to furnish the desired tricyclic enamine access to the reduced 
analogue might be achieved in a two-step process. Unfortunately, availability of the benzamide was 
restrictive, however a robust procedure for aminolysis from the corresponding benzoate has been 
established here and could be used to gain good yields of starting material for future investigations. 
In addition, there are alternative strategies to gaining the trimethoxybenzamide 221 such as 
installing a bromine group at the C(2) position. This may be followed by treatment with butyl lithium 
and dry ice to afford the benzoic acid which could then be functionalised to the benzamide with 
the optimised conditions described in this chapter. 
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Novel sugar analogues have also been developed using D- and L-lyxose to install hydroxyls with 
defined stereochemistry mimicking the C-ring of the natural products. Preliminary biological 
testing, shown in Figure 4.08, suggest that these analogues are inactive following MTS cell 
proliferation assay against the HT29 colon cancer cells lines. This is presumably due to hydrolysis in 
the biological media, however, cyclisation has yet to be achieved and should be investigated further 
as the narciclasine/pancratistatin analogues outlined in Scheme 4.48 would be of great interest. 
These preliminary investigations into the synthesis of novel quinazolinone analogues of narciclasine 
and pancratistatin show great promise. The results so far demonstrate the reaction of substituted 
anthranilamides and sugars are possible to afford exciting analogues in an efficient and 
stereoselective route, which requires further investigations. 
Figure 4.08: Biological activity of sugar analogues 
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5. Conclusions and future work 
The principal objective of this project was to use short synthetic sequences in order to synthesise 
simplified narciclasine 7 and pancratistatin 8 analogues. This was carried out with a view to 
exploring their biological activity, thereby providing new insight into the SAR of these natural 
products.  
Conditions for Curtius rearrangement and intramolecular Friedel-craft acylation previously 
published by the group for the synthesis of the dihydroisoquinolinone framework was successfully 
employed in gaining AB-ring systems in comparable yield. Previous studies by Judd et al. had 
suggested that oxidation of the dihydroisoquinolinone framework to their isoquinolinone 
counterparts improved their biological activity as observed by MTS cell proliferation assay against 
the HT29 colon cancer cells. Methods employed by Judd for oxidation to the olefin proved to be 
unsuccessful when repeated and a variety of other methodologies were investigated all of which 
were capricious and failed to furnish sufficient clean isoquinolinones for further investigations. 6,7-
dimethoxyisoquinolin-1(2H)-one 64 and 1,3-methylenedioxyisoquinolin-1(2H)-one 65 were 
successfully and reproducibly synthesised from their cinnamic acid counterparts in 46 and 47 % 
yields respectively. Regrettably, the 3,4,5-trimethoxycinnamic acid failed to furnish the desired AB-
ring system presumably due to the additional activation caused by the third methoxy group. 
Functionalisation of the olefin at both C(3) and C(4) provided some interesting molecules for 
biological evaluation. In particular the NSC analogues which will be sent for consideration by the 
NCI. 
Judd had completed the 6-step synthesis of the dimethoxy- and dimethoxyhydroxy late stage 
narciclasine analogues 163 and 155 respectively. This synthetic route was successfully optimised 
and repeated in addition to being employed in the synthesis of the novel methylenedioxy analogue 
148. Interestingly, bond migration was observed for the dimethoxy and dimethoxyhydroxy 
analogues 163 and 165 using conditions for hydrogenation. These had been isolated previously, 
albeit via alternative synthetic procedures, and were found to have good biological activity with 
GI50 of 17 μM and 9 μM respectively. Further biological evaluation of these compounds would be 
interesting, especially using non-cancerous cells to see if they still elicit an antiproliferative 
response.  
The ABC-ring analogues underwent initial screening by the NCI, but were not selected for further 
analysis owing to a lack of potency. This is due to the absence of C-ring hydroxyl groups, which as 
described in the Introduction are required for potency. Functionalisation of these late stage 
analogues proved to be challenging however further investigations may be beneficial, such as 
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hydroxylation of the C-ring. Some success was realised in the synthesis of narciprimine analogues 
using a proposed two-step process. Synthesis of the A/C-ring system was eventually successful, with 
intact hydroxyls on the C-ring. Although cyclisation of the B-ring was not achieved it deserves more 
work as we have confidence and expertise in performing the Curtius rearrangement/Friedel-Crafts 
acylation reactions with similar substrates. 
Novel tricyclic quinazolinone analogues of narciclasine and pancratistatin were successfully 
synthesised in a one-pot procedure in order to incorporate a basic nitrogen into the ABC-ring and 
evaluate if this improved biological activity. Biological investigations and further functionalisation 
of the enamine proved to be unsuccessful due to the instability of the compounds in aqueous 
conditions, however, the more stable hydrogenated and bislactam derivatives will hopefully be 
accepted by the NCI for further evaluation. In addition, novel sugar analogues were also achieved 
using D- and L-lyxose which installed hydroxyls with defined stereochemistry mimicking the C-ring. 
Although preliminary biological testing found these analogues to be inactive this is not surprising 
as cyclisation of the C-ring is yet to be achieved. 
Novel analogues have been synthesised and have been found to have anticancer activity so further 
investigations into some areas of the project are warranted and have been highlighted above. 
Current chemotherapeutic agents work by eliciting catastrophic damage to the DNA replicating 
process, such as alkylating agents or topoisomerase inhibitors, or by preventing mitosis as with the 
mitotic spindle poisons. However, these methods of targeting cancer will also target any highly 
replicating cell and therefore cause undesirable side effects. Growing resistance to a number of 
currents agents is also becoming a problem in treating patients.  
The unique anticancer mode of action of the natural products narciclasine and pancratistatin, and 
potentially our novel compounds, justifies more research in this area. In particular, their effect on 
the intrinsic apoptotic pathway is intriguing. Recently, the mitochondrion has been identified as an 
interesting anticancer target which often bypasses the resistance to apoptosis caused by genetic 
defects common in many human cancers, such as a defective tumour suppressor protein p53. 
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6. Experimental 
6.1. General Experimental 
Chemicals, solvents and reagents used were commercially available and were used without further 
purification. Glassware for anhydrous or air sensitive reactions were dried in an oven and allowed 
to cool to r.t. under a stream of N2 or Ar gas. Petroleum ether (PE) refers to the fraction boiling in 
the range 40 - 60 °C.  
TLC was performed on Merck Aluminium-backed TLC plates Silica Gel 60 F254. They were observed 
using UV light of wavelength 254 nm and then stained with iodine, potassium permanganate 
(KMnO4) or 2,4-dinitrophenylhydrazine (DNP).  
Merck Silica Gel (0.040-0.063 mm) was used for column chromatography. Compounds were loaded 
as an oil, CHCl3 or CH2Cl2 solution or dry loaded by adsorption onto silica gel.  
Analytical RP-HPLC was performed on a Gilson HPLC system equipped with an Agilent Eclipse XDB 
5 µm C18 (150 x 4.6 mm) column with a flow rate of 1.0 mL/min. with detection at 274 nm and 254 
nm. The gradient was T = 0-3 min., 20 % MeCN 80 % H20, T = 3-13 min., 80 % MeCN 20% H2O, T = 
13-22 min., 80 % MeCN 20% H2O, 22-25 min., 20% MeCN 80% H2O. 
Melting points (Mp) were obtained using a Reichert-Jung heated-stage microscope and are 
uncorrected. Solvent for recrystallization is defined in brackets. 
Infrared spectra (IR) were recorded on a Perkin-Elmer Spectrum RX I FT-IR system using KBr disk or 
thin film and all values are recorded in cm−1. 
NMR spectra were obtained on a Bruker Avance III (400 MHz) spectrometer or Bruker Avance III 
(500 MHz) spectrometers. The chemical shifts are recorded in parts per million (ppm) with 
reference to tetramethylsilane and recorded at 298 K. The coupling constants J are quoted to the 
nearest 0.5 Hz and are not corrected. The multiplicities are assigned as a broad singlet (brs), singlet 
(s), doublet (d), triplet (t), doublet of doublets (dd), quartet (q) and multiplet (m). The symbols + 
and – after the carbon NMR chemical shifts indicate odd (CH and CH3) and even (C and CH2) numbers 
of attached protons. HMBC and HMQC NMR spectrum was used to assign Cq where data was 
available. 
Mass spectra and high resolution mass spectra were obtained on a micrOTOFTM from Bruker 
Daltonics (Bremen, Germany) coupled with an electrospray source (ESI-TOF) using an autosampler 
in an Agilent 1100 LC system. Data was processed using external calibration with the Bruker 
Daltonics software, DataAnalysisTM as part of the overall hardware control software, Compass 1.1TM. 
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6.2. MTS cell proliferation assay protocol 
The assay uses a 96-well plate format, with 100 μL per well final volume, to determine cell viability 
using a single reagent (MTS) and is based on the Promega Cell Titer 96 Aqueous One Solution Cell 
Proliferation Assay. As this assay is dependent upon the development of a coloured metabolite 
from viable cells it does not distinguish between cytostatic and cytotoxic compounds. However, this 
assay provides an interesting and convenient approach to initial anticancer screening. 
Human cancer cell lines HT29 colon cancer cell lines were supplied by Cancer Research UK. They 
were maintained in DMEM with high glucose (4.5 g/L) and L-glutamine, supplemented with 
penicillin 100 U/mL, streptomycin 100 μg/mL and foetal bovine serum at 10 %. Cells were 
maintained in 75 cm2 tissue culture flasks (Nunc) with a weekly 1 in 10 split. 
General Procedure: 
Seed densities of 500 cells per well in 50 μL culture medium were used for the HT29 cell line, the 
seed densities having previously been determined to give an acceptable optical density value after 
a three day incubation.181,182 Plates were incubated at 37 °C, in humidified 5% CO2 in air for between 
2 and 4 hours. Test compounds were added to the appropriate wells, to give a final volume of 100 
μL. These were prepared at 100 times the final concentration in DMSO (Sigma), diluted 1 in 50 in 
culture medium to give final drug concentrations of 500 µM, 200 µM, 100 µM, 50 µM, 20 µM, 10 
µM, 5 µM, 2 µM, 1 µM and 500 nM in 1% DMSO. Quadruplicate samples were run as follows: 
1. Culture medium only (background) 
2. Cells only 
3. Cells + 1% DMSO 
4. Cells + test compound in 1% DMSO 
The cells plus test compounds were then incubated at 37 °C, 5 % CO2 in humidified air for 3 days. 
This exposure time appears to be adequate to demonstrate anti-proliferative activity, and is 
routinely used.182 The MTS reagent was added, 20 μL per well and the plates were returned to the 
incubator at 37 °C, in humidified 5% CO2 in air, for colour development. 
Optical density readings at 490 nm were taken at 1 to 4 hours on a BMG Labtech FLUOstar Omega 
plate reader. As the culture medium gives a high OD490nm this value was subtracted from all other 
OD490nm readings. Therefore, means and standard deviations were calculated from background 
corrected OD490nm values. IC50 curves and values were generated using the pharmacology function 
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in SigmaPlot 8 software. Each assay was repeated on three separate occasions and an average value 
calculated unless otherwise stated. 
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6.3. Synthesis of AB-ring analogues 
General Procedure 1: 
Diphenylphosphoryl azide (DPPA) (2.24 mL, 10 mmol) was added dropwise to a rapidly stirred 
solution of dihydrocinnamic acid (10 mmol) and anhydrous triethylamine (Et3N) (1.39 mL, 10 mmol) 
in anhydrous toluene (30 mL) at room temperature (r.t.) under Ar. The reaction was heated at 90 
°C for 90 min then allowed to cool to r.t., concentrated under reduced pressure and the crude oil 
was placed back under Ar and boron trifluoride diethyl etherate (BF3∙OEt2) (5 mL) was added at r.t.. 
After 18 h stirring at r.t. the reaction was quenched with 2M NaOH(aq) to pH 10, diluted with EtOAc 
(30 mL) and left stirring for a further 90 min at 50 °C. After cooling to r.t. the organic layer was 
separated and the aqueous fraction washed with EtOAc (3 x 20 mL). The combined organic fractions 
were washed with sat. brine (40 mL), dried over Na2SO4, filtered and the solvent removed under 
reduced pressure. After column chromatography [silica, PE: EtOAc: MeOH gradient column] the 
purified product was isolated. 
  




Following the general procedure 1, 3-(3,4-dimethoxyphenyl)propanoic acid 56 (5.25 g, 25 mmol), 
DPPA (5.38 mL, 25 mmol) and Et3N (3.47 mL, 25 mmol) in toluene (75 mL) followed by BF3∙OEt2 
(12.5 mL) at 50 °C, gave lactam 59 (3.89 g, 75 %) as a white solid.  
1H NMR δH(400 MHz, CDCl3) 7.56 (1H, s, C(8)H), 6.66 (1H, s, C(5)H), 6.33 (1H, brs, NH), 3.91 (3H, s, 
OCH3), 3.91 (3H, s, OCH3), 3.54 (2H, td, J 6.5 and 3.0 Hz, C(3)H2) and 2.91 (2H, t, J 6.5 Hz, C(4)H2); 
13C NMR δC(100 MHz, CDCl3) 166.4– (C(1)q), 152.1– (C(7)q), 148.0– (C(6)q), 134.5– (C(8a)q), 122.8– 
(C(4a)q), 110.1+ (C(8)H), 109.5+ (C(5)H), 56.0+ (OCH3), 56.0+ (OCH3), 40.4– (C(3)H2) and 28.0– 
(C(4)H2); 
Elemental analysis Found C 63.65 %, H 6.39 % and N 6.86 % requires C 63.76 %, H 6.32 % and N 
6.76 %. 
Spectroscopic data is consistent with that reported by Judd et al.63 
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3-(3,4-Methylenedioxyphenyl)propionic acid (122) 
 
Following the procedure previously reported,65 a flask containing a vigorously stirred suspension of 
3,4-methylenedioxycinnamic acid 80 (5 g, 26 mmol) and Pd/C (10 % wt.) (250 mg) in EtOH (125 mL) 
at r.t. was purged with N2. The flask was degassed and H2 introduced at atmospheric pressure and 
stirred vigorously for 180 min. The reaction was filtered through filter paper and a plug of cotton 
wool. After passing through a plug of silica the product 122 was isolated (4.69 g, 92 %) as a white 
crystalline solid. 
1H NMR δH(400 MHz, CDCl3) 10.87 (1H, brs, OH), 6.73 (1H, d, J 8.0 Hz, C(5)H), 6.69 (1H, d, J 1.0 Hz, 
C(2)H), 6.66 (1H, dd, J 8.0 and 1.0 Hz, C(6)H), 5.92 (2H, s, OCH2O), 2.87 (2H, t, J 8.0 Hz, C(2’)H2COOH) 
and 2.63 (2H, t, J 8.0 Hz, C(3’)H2); 
13C NMR δC(100 MHz, CDCl3) 177.8– (C(1’)q), 147.6– (C(3 or 4)q), 146.0– (C(4 or 3)q), 133.9– (C(1)q), 
121.1+ (C(6)H), 108.7+ (C(2 or 5)H), 108.3+ (C(5 or 2)H), 100.8– (OCH2O), 35.7– (C(2’)H2COOH) and 
30.3– (C(3’)H2). 
Spectroscopic data is consistent with that reported by Haga et al.66  
  




Following the general procedure 1, 3-(3,4-methylenedioxyphenyl)propionic acid 122 (1.94 g, 10 
mmol), DPPA (2.24 mL, 10 mmol) and Et3N (1.39 mL, 10 mmol) in toluene (30 mL) followed by 
BF3∙OEt2 (5 mL), gave lactam 60 (1.4 g, 73 %) as a white solid.  
1H NMR δH(400 MHz, CDCl3) 7.51 (1H, s, C(8)H), 6.64 (1H, s, C(5)H), 5.99 (2H, s, OCH2O), 5.84 (1H, 
brs, NH), 3.51 (2H, td, J 6.5 and 2.5 Hz, C(3)H2) and 2.90 (2H, t, J 6.5 Hz, C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 166.2– (C(1)q), 150.7– (C(7)q), 146.8– (C(6)q), 134.5– (C(8a)q), 122.8– 
(C(4a)q), 107.8+ (C(8)H), 107.2+ (C(5)H), 101.4– (OCH2O), 40.1– (C(3)H2) and 28.4– (C(4)H2). 
Spectroscopic data is consistent with that reported by Judd et al.63 
  




Following the general procedure 1, 3-(3,4,5-trimethoxyphenyl)propanoic acid 124 (2.4 g, 10 mmol), 
DPPA (2.24 mL, 10 mmol) and Et3N (1.39 mL, 10 mmol) in toluene (30 mL) followed by BF3∙OEt2 (5 
mL) gave lactam 61 (1.2 g, 54 %) as a white solid.  
1H NMR δH(400 MHz, CDCl3) 12.35 (1H, s, OH), 6.25 (1H, s, C(5)H), 5.90 (1H, brs, NH), 3.89 (3H, s, 
OCH3), 3.88 (3H, s, OCH3), 3.54 (2H, td, J 7.0 and 2.5 Hz, C(3)H2) and 2.92 (2H, t, J 7.0 Hz, C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 170.4– (C(1)q), 156.9– (C(6 or 7)q), 155.9– (C(8)q), 135.9– (C(7 or 6)q), 
135.2– (C(8a)q), 105.8– (C(4a)q), 101.8+ (C(5)H), 60.7+ (OCH3), 56.0+ (OCH3), 40.3– (C(3)H2) and 
28.1– (C(4)H2);  
Elemental analysis Found C 59.26 %, H 5.80 % and N 6.33 % requires C 59.19 %, H 5.87 % and N 
6.27 %. 
Spectroscopic data is consistent with that reported by Judd et al.63 
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General Procedure 2: 
Method A: Following the previously reported procedure for a similar compound,76 lactam (1.0 
mmol) and Pd/C (10 % wt.) (100 mg) were ground together to a fine powder using a pestle and 
mortar. The dry solid was transferred to a flask, flushed with N2 and heated to 200 °C for 60 min in 
solvent free conditions. After cooling to r.t. the solid reaction mixture was flushed through a pad of 
celite using hot methanol until the crude mass was constant. The solvent was removed under 
reduced pressure and the product was purified by column chromatography [silica, PE: EtOAc: MeOH 
gradient column].  
Method B: Following the previously reported procedure for a similar compound,74 acetic acid (5 
mL) was added dropwise to a stirred mixture of lactam (1.0 mmol) and 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ) (454 mg, 2.0 mmol) at r.t. under Ar. After 16 h stirring at 80 °C the hot 
reaction was poured onto water (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were washed with 10 % NaOH(aq) (10 mL), water (10 mL), sat. brine (10 mL), dried 
over Na2SO4, filtered and the solvent removed under reduced pressure. The purified product was 
isolated by column chromatography [silica, PE: EtOAc: MeOH gradient column].  
  




Following general procedure 2A, 8-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 61 
(114 mg, 0.51 mmol), using Pd/C (10 % wt.) (115 mg), gave the product 63 (7 mg, 6 %) as a white 
crystalline solid.  
Following general procedure 2B, 8-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 61 
(223 mg, 1.0 mmol), using DDQ (250 mg, 1.1 mmol) and acetic acid (5 mL) at 0 °C after which the 
reaction was allowed to warm to r.t. and stirred for 18 h, gave the product 63 (64 mg, 29 %) as a 
white crystalline solid. 
Rf [EtOAc] 0.2;  
Mp [MeOH] > 230 °C;  
IR max (KBr disc) 3329 (OH and NH), 1648 (C=O), 1618 (C=C) and 1235 (C-O);  
1H NMR δH(400 MHz, DMSO) 13.26 (1H, s, OH), 11.53 (1H, s, NH), 7.11 (1H, d, J 7.0 Hz, C(3)H), 
6.73 (1H, s, C(5)H), 6.56 (1H, d, J 7.5 Hz, C(4)H), 3.87 (3H, s, OCH3) and 3.72 (3H, s, OCH3); 
13C NMR δC(100 MHz, DMSO) 165.7– (C(1)q), 157.8– (C(7)q), 153.7– (C(8)q), 135.1– (C(8a)q), 
132.8– (C(6)q), 127.8+ (C(3)H), 106.9– (C(4a)q), 106.7+ (C(4)H), 97.9+ (C(5)H), 59.8+ (OCH3) and 
55.8+ (OCH3); 
MS (+ESI) m/z 222 (100 %, [M+H]+) and 244 (56 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 244.0619, C11H11NNaO4, requires [M+Na]+ 244.0586; 
Elemental analysis Found C 59.83 %, H 5.07 % and N 6.43 % requires C 59.73 %, H 5.01 % and N 
6.33 %. 
  




Following general procedure 2B, 6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 59 (201 mg, 0.97 
mmol), using DDQ (495 mg, 2.18 mmol) and acetic acid (5 mL), gave the product 64 (108 mg, 55 %) 
as a white crystalline solid. 
Rf [EtOAc] 0.2;  
Mp [MeOH] > 230 °C [Lit.,183 244-245 °C];  
IR max (KBr disc) 1639 (C=O), 1607 (C=C) and 1273 (C-O);  
1H NMR δH(400 MHz, CDCl3) 10.84 (1H, brs, NH), 7.78 (1H, s, C(8)H), 7.08 (1H, d, J 7.0 Hz, C(3)H), 
6.91 (1H, s, C(5)H), 6.48 (1H, d, J 7.0 Hz, C(4)H), 4.02 (3H, s, OCH3) and 3.99 (3H, s, OCH3); 
13C NMR δC(100 MHz, CDCl3) 163.4– (C(1)q), 153.8– (C(7)q), 149.4– (C(6)q), 133.8– (C(8a)q), 126.3+ 
(C(3)H), 120.1– (C(4a)q), 107.2+ (C(8)H), 106.3+ (C(5)H), 106.2+ (C(4)H), 56.2+ (OCH3) and 56.1+ 
(OCH3);  
MS (+ESI) m/z 433 (100 %, [2M+Na]+) and 228 (45 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 228.0677 C11H11NNaO3 requires 228.0637 [M+Na]+. Found 
[2M+Na]+ 433.1483 (C11H11NO3)2Na requires 433.1376 [2M+Na]+; 
Elemental analysis Found C 64.49 %, H 5.46 % and N 6.91 % requires C 64.38 %, H 5.40 % and N 
6.83 %. 
Spectroscopic data is consistent with that reported by Awuah et al.75 
  




Following general procedure 2B 6-methyl-7,8-dihydro[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 74 
(236 mg, 1.15 mmol), using DDQ (784 mg, 3.45 mmol) and acetic acid (5.75 mL) and heating at 120 
°C for 22 h, gave the methylated lactam 75 (109 mg, 47 %) as a white solid. 
Rf [MeOH:CH2Cl2, 4:96] 0.41;  
Mp [MeOH] 167-172 °C;  
IR max (Thin film) 3007 (CH), 1646 (C=O) and 1611 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.78 (1H, s, C(8)H), 6.98 (1H, d, J 7.0 Hz, C(3)H), 6.84 (1H, s, C(5)H), 6.36 
(1H, d, J 7.0 Hz, C(4)H), 6.06 (2H, s, OCH2O) and 3.58 (3H, s, NCH3); 
13C NMR δC(100 MHz, CDCl3) 161.8– (C(1)q), 151.8– (C(6)q), 147.8– (C(7)q), 134.4– (C(4a)q), 131.2+ 
(C(3)H), 121.8– (C(8a)q), 105.8+ (C(4)H), 105.5+ (C(8)H), 103.6+ (C(5)H), 101.6– (OCH2O) and 37.0+ 
(NCH3); 
MS (+ESI) m/z 204 (100 %, [M+H]+), 226 (93 %, [M+Na]+) and 429 (45 %, [2M+Na]+);  
Found [M+Na]+ 226.0479, C11H9NNaO3, requires [M+Na]+ 226.0480. 
Spectroscopic data is consistent with that reported by Jangir et al.184 
  




DPPA (5.38 mL, 25 mmol) was added dropwise to a vigorously stirred suspension of 3,4-
dimethoxycinnamic acid 79 (5.21 g, 25 mmol) and Et3N (6.96 mL, 50 mmol) in toluene (25 mL) at 
r.t. open to the atmosphere. After 120 min stirring, the reaction was filtered through a plug of silica 
and washed with toluene leaving only one spot by TLC, Rf [EtOAc] 0.83. The solvent was removed 
under reduced pressure and the crude solid was dissolved in diphenyl ether (42 mL). The reaction 
was heated to 250 °C under a flow of N2 during which time violent effervescence was observed at 
90 °C which then subsided. Heating was continued at 250 °C for 180 min after which the reaction 
was cooled slowly to r.t. and left to stir for 18 h forming a precipitate. The reaction was then filtered 
and the precipitate washed with diethyl ether to leave the product 64 as a yellow solid (2.36 g, 46 
%) without the need for further purification. 
1H NMR δH(400 MHz, CDCl3) 10.84 (1H, brs, NH), 7.78 (1H, s, C(8)H), 7.08 (1H, d, J 7.0 Hz, C(3)H), 
6.91 (1H, s, C(5)H), 6.48 (1H, d, J 7.0 Hz, C(4)H), 4.02 (3H, s, OCH3) and 3.99 (3H, s, OCH3); 
13C NMR δC(100 MHz, CDCl3) 163.4– (C(1)q), 153.8– (C(7)q), 149.4– (C(6)q), 133.8– (C(8a)q), 126.3+ 
(C(3)H), 120.1– (C(4a)q), 107.2+ (C(8)H), 106.3+ (C(5)H), 106.2+ (C(4)H), 56.2+ (OCH3) and 56.1+ 
(OCH3);  
Elemental analysis Found C 64.27 %, H 5.48 % and N 6.91 % requires C 64.38 %, H 5.40 % and N 
6.83 %. 
Spectroscopic data is consistent with that reported by Awuah et al.75 
  




DPPA (2.2 mL, 10 mmol) was added dropwise to a vigorously stirred suspension of 3,4-
(methylenedioxy)cinnamic acid 80 (1.92 g, 10 mmol) and Et3N (2.78 mL, 20 mmol) in toluene (10 
mL) at r.t. open to the atmosphere. After 120 min stirring, the reaction was filtered through a plug 
of silica and washed with toluene leaving only one spot by TLC, Rf [EtOAc] 0.81. The solvent was 
removed under reduced pressure and the crude solid was dissolved in diphenyl ether (17 mL). The 
reaction was heated to 250 °C under a flow of N2 during which time violent effervescence was 
observed at 90 °C which then subsided. Heating was continued at 250 °C for 180 min after which 
the reaction was cooled slowly to r.t. and left to stir for 18 h forming a precipitate. The reaction was 
then filtered and the precipitate washed with diethyl ether to leave the product 65 as a yellow solid 
(887 mg, 47 %) without the need for further purification. 
Rf [EtOAc] 0.22;  
Mp [EtOAc] > 230 °C;  
IR max (KBr disc) 2907 (NH) and 1654 (C=O);  
1H NMR δH(400 MHz, DMSO) 11.14 (1H, brs, NH), 7.49 (1H, s, C(8)H), 7.14 (1H, s, C(5)H), 7.05 (1H, 
dd, J 7.0 and 5.5 Hz, C(3)H), 6.44 (1H, d, J 7.0 Hz, C(4)H) and 6.15 (2H, s, OCH2O); 
13C NMR δC(100 MHz, DMSO) 161.1– (C(1)q), 151.4– (C(7)q), 147.1– (C(6)q), 135.1– (C(4a)q), 127.5+ 
(C(3)H), 121.3– (C(8a)q), 104.7+ (C(4)H), 104.0+ (C(8)H), 103.9+ (C(5)H) and 101.8– (CH2); 
MS (+ESI) m/z 401 (100 %, [2M+Na]+) and 212 (85 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 212.0316, C10H7NNaO3, requires [M+Na]+ 212.0324; 
Elemental analysis Found C 63.53 %, H 3.81 % and N 7.32 % requires C 63.49 %, H 3.73 % and N 
7.40 %. 
Spectroscopic data is consistent with that reported by Xie et al.185 
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General Procedure 3: 
Method A: Sodium hydride (NaH) (60 % dispersion in mineral oil) (120 mg, 3 mmol) was added 
portion-wise to a stirred solution of lactam (1 mmol) in anhydrous THF (6 mL) at 0 °C under Ar. After 
30 min stirring at 0 °C iodomethane (MeI) (0.2 mL, 3 mmol) was added dropwise and the reaction 
warmed to r.t. for 4 hours. The reaction was quenched with the addition of NH4Cl(aq) (15 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organic fractions were washed with sat. brine (50 
mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure. After column 
chromatography [silica, PE: EtOAc: gradient column] the product was isolated. 
Method B: Using modified conditions,87 potassium hydroxide (KOH) (500 mg, 8.9 mmol) was added 
to a rapidly stirred solution of lactam (3 mmol) in acetone (30 mL) at 0 °C. MeI (448 µL, 7.2 mmol) 
and THF (10 mL) was added and the reaction warmed to r.t. and stirred 18 h. MeI was quenched 
with MeOH (5 mL) and after 5 min stirring the solvent was removed under reduced pressure. EtOAc 
(20 mL) and HCl(aq) (1 M, 10 mL) were added to the reaction and the organic layer separated. After 
further extraction with EtOAc (3 x 20 mL) the combined organic fractions were washed with sat. 
brine (20 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure. The 
purified product was isolated by column chromatography [silica, PE: EtOAc: gradient column].  
  
- 133 - 
 
6,7-Dimethoxy-2-methylisoquinolin-1(2H)-one (83) and 5-(3,4-dimethoxyphenyl)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione (84) 
 
Following general procedure 3A, 6,7-dimethoxyisoquinolin-1(2H)-one 64 (126 mg, 0.6 mmol), using 
NaH (72 mg, 1.8 mmol) in THF (3 mL) and leaving the reaction for 16 h after the addition of MeI 
(0.11 mL, 1.8 mmol), gave the product 83 (125 mg, 95 %) as a white solid.  
Following general procedure 3B, 6,7-dimethoxyisoquinolin-1(2H)-one 64 (615 mg, 3 mmol), using 
KOH (500 mg, 8.9 mmol) in acetone (30 mL) followed by MeI (0.45 mL, 7.2 mmol) and THF (10 mL), 
gave product 83 (430 mg, 65 %) and product 84 (96 mg, 23 %) as white solids. 
Lactam (83) 
Rf [EtOAc] 0.56;  
Mp [EtOAc:Cyclohexane] 125-127 °C;  
IR max (Thin film) 2908 (CH), 1655 (C=O), 1608 (C=C) and 1145 (C-O);  
1H NMR δH(400 MHz, CDCl3) 7.79 (1H, s, C(8)H), 6.98 (1H, d, J 7.0 Hz, C(3)H), 6.84 (1H, s, C(5)H), 6.38 
(1H, d, J 7.0 Hz, C(4)H), 3.99 (3H, s, OCH3), 3.96 (3H, s, OCH3) and 3.58 (3H, s, NCH3);  
13C NMR δC(125 MHz, CDCl3) 161.8– (C(1)q), 153.1– (C(6)q), 149.1– (C(7)q), 132.5– (C(4a)q), 131.0+ 
(C(3)H), 120.0– (C(8a)q), 107.4+ (C(8)H), 105.8+ (C(5)H), 105.4+ (C(4)H), 56.1+ (OCH3), 55.9+ (OCH3) 
and 37.0+ (NCH3). 
Spectroscopic data is consistent with that reported by Lapa et al.186 
Pyrimidine (84) 
Rf [EtOAc] 0.47;  
Mp [CH2Cl2] 150-155 °C;  
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IR max (Thin film) 3007 (CH), 1653 (C=O) and 1028 (C-O);  
1H NMR δH(500 MHz, CDCl3) 7.27 (1H, s, C(6’)H), 7.13 (1H, d, J 2.0 Hz, C(2)H), 7.00 (1H, dd, J 8.0 and 
2.0 Hz, C(6)H), 6.88 (1H, d, J 8.5 Hz, C(5)H), 3.91 (3H, s, C(3)OCH3), 3.90 (3H, s, C(4)OCH3), 3.48 (3H, 
s, N(5’)CH3) and 3.43 (3H, s, N(3’)CH3);  
13C NMR δC(125 MHz, CDCl3) 162.5– (C(2’)q), 151.4– (C(4’)q), 148.8– (C(3)q), 148.7– (C(4)q), 139.8+ 
(C(6’)H), 125.6– (C(1’)q), 120.4+ (C(6)H), 114.2– (C(1)q), 111.8+ (C(2)H), 111.0+ (C(5)H), 55.9+ (OCH3), 
55.9+ (OCH3), 37.1+ (N(5’)CH3) and 28.3+ (N(3’)CH3);  
MS (+ESI) m/z 575 (100 %, [2M+Na]+), 299 (56 %, [M+Na]+) and 277 (46 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 277.1198, C14H17N2O4, requires 277.1188 [M+H]+. Found [M+Na]+ 
299.1028, C14H16N2NaO4, requires 299.1008 [M+Na]+. 
Spectroscopic data is consistent with that reported by Seki et al.88 
  




Following general procedure 3A, 8-hydroxy-6,7-dimethoxyisoquinolin-1(2H)-one 63 (53 mg, 0.24 
mmol), using NaH (57 mg, 1.4 mmol) and THF (2 mL) followed by MeI (15 µL, 0.24 mmol), gave the 
methylated product 85 (56 mg, 99 %). 
Rf [EtOAc] 0.58;  
Mp [EtOAc] 133-137 °C;  
IR max (Thin film) 2939 (OH), 1657 (C=O) and 1597 (C=C);  
1H NMR δH(400 MHz, CDCl3) 12.98 (1H, s, C(8)OH), 6.91 (1H, d, J 7.5 Hz, C(3)H), 6.42 (1H, s, C(5)H), 
6.41 (1H, d, J 7.5 Hz C(4)H), 3.93 (3H, s, OCH3), 3.92 (3H, s, OCH3) and 3.54 (3H, s, N(2)CH3); 
13C NMR δC(100 MHz, CDCl3) 165.2– (C(1)q), 157.9– (Cq), 154.2– (Cq), 134.6– (Cq), 134.3– (Cq), 131.1+ 
(C(3)H), 107.7– (Cq), 107.4+ (C(4)H), 97.2+ (C(5)H), 60.6+ (OCH3), 55.9+ (OCH3) and 36.0+ (NCH3); 
MS (+ESI) m/z 258 (100 %, [M+Na]+), 493 (57 %, [2M+Na]+) and 236 (47 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 236.0926, C12H14NO4, requires [M+H]+ 236.0923. Found [M+Na]+ 
258.0747, C12H13NNaO4, requires [M+Na]+ 258.0742. 
  




Following general procedure 3A [1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 65 (47 mg, 0.25 mmol), 
using NaH (30 mg, 0.75 mmol) and THF (2 mL) followed by MeI (50 µL, 0.75 mmol), gave the 
methylated lactam 75 (48 mg, 94 %). 
1H NMR δH(400 MHz, CDCl3) 7.77 (1H, s, C(8)H), 6.98 (1H, d, J 7.0 Hz, C(3)H), 6.84 (1H, s, C(5)H), 6.36 
(1H, d, J 7.0 Hz, C(4)H), 6.06 (2H, s, CH2) and 3.58 (3H, s, NCH3); 
13C NMR δC(100 MHz, CDCl3) 161.8– (C(1)q), 151.8– (C(6)q), 147.8– (C(7)q), 134.4– (C(4a)q), 131.2+ 
(C(3)H), 121.8– (C(8a)q), 105.8+ (C(4)H), 105.5+ (C(8)H), 103.6+ (C(5)H), 101.6– (CH2) and 37.0+ 
(NCH3). 
Spectroscopic data is consistent with that reported by Jangir et al.184 
  




Following general procedure 3A, 8-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 61 
(223 mg, 1 mmol), using NaH (240 mg, 6 mmol) and THF (6 mL) followed by MeI (60 µL, 1 mmol), 
gave the methylated lactam 86 (170 mg, 72 %) as a white solid. 
Rf [EtOAc] 0.56;  
Mp [EtOAc:Cyclohexane] 142 °C;  
IR max (Thin film) 3034 (CH), 2943 (OH), 1638 (C=O) and 1615 (C=C);  
1H NMR δH(400 MHz, CDCl3) 12.80 (1H, s, C(8)OH), 6.19 (1H, s, C(5)H), 3.87 (3H, s, OCH3), 3.86 (3H, 
s, OCH3), 3.51 (2H, t, J 7.0 Hz, C(3)H2), 3.09 (3H, s, N(2)CH3) and 3.01 (2H, dt, J 7.0 and 0.5 Hz, C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 168.7– (C(1)q), 156.4– (Cq), 155.7– (Cq), 135.3– (Cq), 134.0– (Cq), 106.3– 
(Cq), 101.2+ (C(5)H), 60.6+ (OCH3), 55.9+ (OCH3), 48.1– (C(3)H2), 34.3+ (N(2)CH3) and 27.7– (C(4)H2);  
MS (+ESI) m/z 238 (100 %, [M+H]+), 497 (92 %, [2M+Na]+) and 260 (80 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 238.1183, C12H16NO4, requires [M+H]+ 238.1079. Found [M+Na]+ 
260.0994, C12H15NNaO4, requires [M+Na]+ 260.0899;  
Elemental analysis Found C 60.68 %, H 6.42 % and N 6.00 % requires C 60.75 %, H 6.37 % and N 
5.90 %.  




Following general procedure 3A, 6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 59 (207 mg, 1 
mmol), using NaH (120 mg, 3 mmol) and THF (6 mL) followed by MeI (200 µL, 3 mmol), gave the 
methylated lactam 87 (202 mg, 91 %) as a white solid.  
Rf [EtOAc] 0.41;  
Mp [EtOAc:Cyclohexane] Sublimes 112 °C, melts 133 °C [Lit.,187 125-126 °C];  
Mp [MeOH] Sublimes 175-180 °C, melts > 230 °C 
IR max (KBr disc) 3004 (CH), 1639 (C=O) and 1603 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.60 (1H, s, C(8)H), 6.62 (1H, s, C(5)H), 3.91 (3H, s, C(6)OCH3), 3.90 (3H, 
s, C(7)OCH3), 3.53 (2H, t, J 7.0 Hz, C(3)H2), 3.12 (3H, s, NCH3) and 2.92 (2H, t, J 7.0 Hz, C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 164.8– (C(1)q), 151.6– (C(6)q), 147.9– (C(7)q), 131.5– (C(4a)q), 122.0– 
(C(8a)q), 110.5+ (C(8)H), 109.2+ (C(5)H), 56.0+ (OCH3), 55.9+ (OCH3), 48.3– (C(3)H2), 35.1+ (NCH3) 
and 27.5– (C(4)H2); 
MS (+ESI) m/z 465 (100 %, [2M+Na]+) and 244 (49 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 244.1063, C12H15NNaO3, requires [M+Na]+ 244.0950; 
Elemental analysis Found C 65.23 %, H 6.80 % and N 6.41 % requires C 65.14 %, H 6.83 % and N 
6.33 %. 
Spectroscopic data is consistent with that reported by Ying et al.188 
  




Following general procedure 3A, 7,8-dihydro[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 60 (382 mg, 
2 mmol), using NaH (240 mg, 6 mmol) and THF (12 mL) followed by MeI (400 µL, 6 mmol), gave the 
methylated lactam 74 (389 mg, 95 %) as a white solid. 
Rf [EtOAc] 0.51;  
Mp [EtOAc:Cyclohexane] 97 °C [Lit.,184 95-97 °C];  
IR max (Thin film) 3007 (CH), 1643 (C=O) and 1610 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.48 (1H, s, C(8)H), 6.55 (1H, s, C(5)H), 5.93 (2H, s, OCH2O), 3.46 (2H, 
dd, J 6.5 and 7.0 Hz, C(3)H2), 3.07 (3H, s, NCH3) and 2.85 (2H, dd, J 6.5 and 7.0 Hz, C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 164.4– (C(1)q), 150.1– (Cq), 146.7– (Cq), 133.3– (Cq), 123.4– (Cq), 108.0+ 
(C(8)H), 106.7+ (C(5)H), 101.3– (OCH2O), 48.1– (C(3)H2), 35.0+ (NCH3) and 27.9– (C(4)H2);  
MS (+ESI) m/z 206 (100 %, [M+H]+), 228 (44 %, [M+Na]+) and 433 (49 %, [2M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 206.0941, C11H12NO3, requires [M+H]+ 206.0817. Found [M+Na]+ 
228.0718, C11H11NNaO3, requires [M+Na]+ 228.0637; 
Elemental analysis Found C 64.33 %, H 5.35 % and N 6.92 %, requires C 64.38 %, H 5.40 % and N 
6.83 %. 
Spectroscopic data is consistent with that reported by Jangir et al.184 
  




Following a procedure previously reported,89 concentrated sulfuric acid (4 drops) was added to a 
stirred solution of 6-methyl[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 75 (49 mg, 0.24 mmol) in 
acetic anhydride (3.4 mL) and raised to 119 °C for 1 h. Ice-water was poured onto the reaction 
slowly and it was stirred for a further 30 min without heat. Upon extraction with CH2Cl2 the 
combined organic fractions were washed with sat. brine (50 mL), dried over Na2SO4, filtered and 
the solvent removed under pressure. Column chromatography [silica, PE: EtOAc gradient column] 
afforded the product 90 as a white solid (12 mg, 21 %). 
Rf [MeOH:CH2Cl2, 6:94] 0.39;  
Mp [from EtOAc:Cyclohexane] 195-203 °C;  
IR max (Thin film) 3030 (CH), 1655 (C=O) and 1474 (C=C);  
1H NMR δH(500 MHz, CDCl3) 8.46 (1H, s, C(5)H), 7.88 (1H, s, C(3)H), 7.78 (1H, s, C(8)H), 6.10 (2H, s, 
OCH2O), 3.68 (3H, s, NCH3) and 2.55 (3H, s, CH3);  
13C NMR δC(125 MHz, CDCl3) 195.6– (C(=O)q), 161.6– (C(1)q), 152.8– (C(6 or 7)q), 148.0– (C(7 or 6)q), 
140.1+ (C(3)H), 131.4– (C(4a)q), 121.2– (C(8a)q), 115.0– (C(4)q), 105.5+ (C(8)H), 104.6+ (C(5)H), 
101.9– (OCH2O), 37.9+ (NCH3) and 27.7+ (CH3);  
MS (+ESI) m/z 513 (100 %, [2M+Na]+) and 268 (48 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 268.0598, C13H11NNaO4, requires [M+Na]+ 268.0586; 
Elemental analysis Found C 63.62 %, H 4.58 % and N 5.70 %, required C 63.67 %, H 4.52 % and N 
5.71 %. 
  




Following a procedure previously reported,89 concentrated sulfuric acid (8 drops) was added to a 
stirred solution of 6,7-dimethoxy-2-methylisoquinolin-1(2H)-one 83 (111 mg, 0.51 mmol) in acetic 
anhydride (8.67 mL) and raised to reflux for 2 h. Ice-water was poured onto the reaction slowly and 
it was stirred for a further 30 min without heat. Upon extraction with CH2Cl2 the combined organic 
fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered and the solvent removed 
under pressure. Column chromatography [silica, PE: EtOAc then EtOAc: MeOH gradient column] 
afforded the product 91 as a white solid (70 mg, 53 %). 
Rf [MeOH:CH2Cl2, 6:94] 0.45;  
Mp [MeOH] 203-205 °C;  
IR max (Thin film) 1634 (C=O), 1652 (C=O) and 1508 (C=C);  
1H NMR δH(400 MHz, CDCl3) 8.54 (1H, s, C(5)H), 7.89 (1H, s, C(3)H), 7.76 (1H, s, C(8)H), 4.01 (3H, s, 
C(7)OCH3), 3.98 (3H, s, C(6)OCH3), 3.67 (3H, s, NCH3) and 2.54 (3H, s, CH3); 
13C NMR δC(100 MHz, CDCl3) 195.8– (C(=O)q), 161.7– (C(1)q), 153.8– (C(6)q), 149.3– (C(7)q), 140.3+ 
(C(3)H), 129.6– (C(4a)q), 119.5– (C(8a)q), 114.4– (C(4)q), 107.3+ (C(8)H), 106.7+ (C(5)H), 56.1+ 
(OCH3), 56.0+ (OCH3), 37.9+ (NCH3) and 27.6+ (CH3); 
MS (+ESI) m/z 262 (100 %, [M+H]+), 545 (89 %, [2M+Na]+) and 284 (53 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 262.1068, C14H16NO4, requires [M+H]+ 262.1079. Found [M+Na]+ 
284.0888, C14H15NNaO4, requires [M+Na]+ 284.0899. 
  




Following a procedure previously reported,89 concentrated sulfuric acid (6 drops) was added to a 
stirred solution of 6,7-dimethoxyisoquinolin-1(2H)-one 64 (68 mg, 0.33 mmol) in acetic anhydride 
(5.6 mL) at r.t. under Ar and heated to reflux for 18 h. Ice-water was poured onto the reaction slowly 
and it was stirred for a further 30 min without heat. Upon extraction with CH2Cl2 the combined 
organic fractions were washed with sat. brine (50 mL), dried over Na2SO4, filtered and the solvent 
removed under pressure. Column chromatography [silica, PE: EtOAc then EtOAc: MeOH gradient 
column] afforded the product 92 as a yellow solid (31 mg, 38 %).  
Rf [MeOH:CH2Cl2, 6:94] 0.32;  
Mp [MeOH] > 230 °C;  
IR max (Thin film) 3675 (NH), 1652 (C=O), 1634 (C=O) and 1506 (C=C);  
1H NMR δH(400 MHz, CDCl3) 9.74 (1H, brs, NH), 8.64 (1H, s, C(5)H), 7.93 (1H, d, J 6.0 Hz, C(3)H), 7.79 
(1H, s, C(8)H), 4.05 (3H, s, OCH3), 4.02 (3H, s, OCH3) and 2.57 (3H, s, CH3);  
13C NMR δC(125 MHz, CDCl3) 196.1– (C(=O)q), 162.4– (C(1)q), 154.1– (C(6)q), 149.6– (C(7)q), 135.2+ 
(C(3)H), 130.5– (C(5a)q), 119.6– (C(8a)q), 115.3– (C(4)q), 107.2+ (C(5 or 8)H), 107.1+ (C(8 or 5)H), 
56.2+ (OCH3), 56.1+ (OCH3) and 27.7+ (CH3); 
MS (+ESI) m/z 517 (100 %, [2M+Na]+), 248 (99 %, [M+H]+) and 270 (65 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 248.0905, C13H14NO4, requires [M+H]+ 248.0923. Found [M+Na]+ 
270.0719, C13H13NNaO4, requires [M+Na]+ 270.0742. 
  




6,7-Dimethoxy-2-methylisoquinolin-1(2H)-one 83 (36 mg, 0.16 mmol) and piperonylic acid (25 mg, 
0.15 mmol) was stirred in TFAA (70 µL, 0.53 mmol) at 100 °C in a thick-walled pressure tube for 18 
h. Upon cooling to r.t. the solution was transferred to a round bottom flask with CH2Cl2 and the 
solvent removed under pressure. The reaction was then stirred for a further 24 h in EtOAc: H2O (1: 
1, 10 mL) then the organic layer was isolated and the water layer extracted with EtOAc (3 x 5 mL). 
The combined organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered 
and the solvent removed under pressure. Column chromatography [silica, PE: EtOAc gradient 
column] afforded the product 104 as a white crystalline solid (27 mg, 46 %). 
Rf [EtOAc] 0.59;  
Mp [MeOH] > 230 °C;  
IR max (Thin film) 3014 (CH), 1639 (C=O), 1598 (C=C) and 1045 (C-O);  
1H NMR δH(500 MHz, CDCl3) 7.84 (1H, s, C(5 or 8)H), 7.81 (1H, s, C(8 or 5)H), 7.47 (1H, s C(3)H), 7.36 
(1H, dd, J 8.0 and 1.5 Hz, C(6’)H), 7.34 (1H, d, J 1.5 Hz, C(2’)H), 6.89 (1H, d, J 8.0 Hz, C(5’)H), 6.09 
(2H, s, OCH2O), 4.03 (3H, s, OCH3), 3.96 (3H, s, OCH3) and 3.63 (3H, s, NCH3);  
13C NMR δC(125 MHz, CDCl3) 192.6– (C(=O)q), 161.6– (C(1)q), 153.7– (Cq), 151.6– (Cq), 149.6– (Cq), 
148.2– (Cq), 139.3+ (C(3)H), 133.4– (Cq), 130.2– (Cq), 126.1+ (C(6’)H), 119.8– (Cq), 115.2– (Cq), 109.6+ 
(C(2’)H), 107.9+ (C(5’)H), 107.6+ (CH), 105.8+ (CH), 102.0– (OCH2O), 56.2+ (OCH3), 56.1+ (OCH3), 
37.7+ (NCH3);  
MS (+ESI) m/z 368 (100 %, [M+H]+) and 390 (69 %, [M+Na]+); 
HRMS (+ESI) m/z Found [M+H]+ 368.1117 C20H18NO6, requires [M+H]+ 368.1134. Found [M+Na]+ 
390.0954 C20H17NNaO6, requires [M+Na]+ 390.0954;  
Elemental analysis Found C 65.29 %, H 4.64 % and N 3.87 % requires C 65.39 %, H 4.66 % and N 
3.81 %. 




6-Methyl[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 75 (93 mg, 0.46 mmol) and piperonylic acid (70 
mg, 0.42 mmol) was stirred in TFAA (204 µL, 1.47 mmol) at 100 °C in a thick-walled pressure tube 
for 18 h. Upon cooling to r.t. the solution was transferred to a round bottom flask with CH2Cl2 and 
the solvent removed under pressure. The reaction was then stirred for a further 24 h in EtOAc: H2O 
(1: 1, 25 mL) then the organic layer was isolated and the water layer extracted with EtOAc (3 x 20 
mL). The combined organic fractions were washed with sat. brine (40 mL), dried over Na2SO4, 
filtered and the solvent removed under pressure. Column chromatography [silica, PE: EtOAc 
gradient column] afforded the product 105 as a white crystalline solid (73 mg, 46 %). 
Rf [EtOAc] 0.84;  
Mp [EtOAc] > 230 °C;  
IR max (Thin film) 2927 (CH), 1660 (C=O), 1623 (C=C) and 1040 (C-O);  
1H NMR δH(400 MHz, CDCl3) 8.40 (1H, s, C(5)H), 8.07 (1H, s, C(3)H), 7.79 (1H, s, C(8)H), 7.75 (1H, dd, 
J 8.5 and 1.5 Hz, C(6’)H), 7.53 (1H, d, J 1.5 Hz, C(2’)H), 6.89 (1H, d, J 8.0 Hz, C(5’)H), 6.13 (2H, s, 
C(6)OCH2), 6.09 (2H, s, C(3’)OCH2O) and 3.72 (3H, s, CH3);  
13C NMR δC(100 MHz, CDCl3) 177.1– (C(=O)q), 161.0– (C(1)q), 153.4– (C(6)q), 153.0– (C(4’)q), 148.2– 
(C(7)q), 148.1– (C(3’)q), 144+ (C(3)H), 130.8– (C(4a)q), 127.0+ (C(6’)H), 122.7– (C(1’)q), 120.0– 
(C(8a)q), 110.0+ (C(2’)H), 108.3+ (C(5’)H), 107.6– (C(2)q), 105.9+ (C(8)H), 103.9+ (C(5)H), 102.2– (2 × 
CH2) and 38.5+ (CH3);  
MS (+ESI) m/z 204 (100 %, [M+H]+–ArCO), 226 (75 %, [M+Na]+–ArCO) and 352 (7 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 352.0812, C19H14NO6, requires [M+H]+ 352.0821. Found [M+Na]+ 
374.0643, C19H13NNaO6, requires [M+Na]+ 374.0641. 
  




Sodium periodate(aq) (NaIO4) (2.2 mL, 10 %) was added to Ruthenium(III) chloride hydrate 
(RuCl3·×H2O) (2.2 mg, 5 mol %) and this solution was added dropwise to a stirred solution of 6,7-
dimethoxyisoquinolin-1(2H)-one 64 (45 mg, 0.22 mmol) in EtOAc (4.4 mL) at r.t.. After 40 min 
stirring, the layers were separated and the aqueous layer washed with EtOAc (3 x 5 mL). The 
combined organic fractions were stirred with iPrOH (10 mL) until a black precipitate was formed 
after which the reaction was filtered and the solvent removed under reduced pressure. Column 
chromatography [silica, PE: EtOAc gradient column] afforded the product 117 as a yellow solid (18 
mg, 14 %). 
Rf [EtOAc] 0.63;  
Mp [MeOH] Sublimes 175-180 °C, melts > 230 °C [Lit.,189 sublimes 165-175 °C, melts 275 °C];  
IR max (Thin film) 3354 (NH), 1747 (C=O), 1701 (C=O) and 1516 (C=C);  
1H NMR δH(400 MHz, DMSO) 11.94 (1H, s, NH), 7.58 (1H, s, C(8)H), 7.51 (1H, s, C(5)H), 4.02 (3H, s, 
CH3) and 3.99 (3H, s, CH3); 
13C NMR δC(100 MHz, DMSO) 174.4– (C(4)q), 162.8– (C(1)q), 157.6– (C(3)q), 154.3– (C(7)q), 153.0– 
(C(6)q), 126.2– (C(4a)q), 124.3– (C(8a)q), 109.4+ (C(8)H), 108.0+ (C(5)H), 56.3+ (CH3) and 56.2+ (CH3);  
MS (+ESI) m/z 258 (100 %, [M+Na]+), 493 (35 %, [2M+Na]+) and 236 (15 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 236.0789, C11H10NO5 requires [M+H]+ 236.0559. Found [M+Na]+ 
258.0368, C11H9NNaO5 requires 258.0378 [M+Na]+. 
  




LDA (6.11 mL, 11 mmol) was added dropwise to a stirred solution of 3-(3,4,5-
trimethoxyphenyl)propanoic acid 124 (1.20 g, 5 mmol) in THF (5 mL) at 0 °C under N2. After stirring 
for 40 min at 0 °C the reaction was allowed to warm to room temperature, allyl-bromide (490 µL, 
5.5 mmol) was added and the reaction was left stirring for a further 18 h. The reaction was 
quenched with 6M HCl(aq) to pH 2 and extracted with EtOAc (3 x 10 mL). The combined organic 
fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure to afford the crude.  
DPPA (1.05 mL, 5 mmol) was added dropwise to a stirred solution of crude (2-(3,4,5-
trimethoxybenzyl)pent-4-enoic acid and anhydrous Et3N (700 µL, 5 mmol) in anhydrous toluene (15 
mL) under Ar. The reaction was heated at 90 °C for 90 min after which the reaction was 
concentrated under reduced pressure. Upon being put back under Ar, BF3∙OEt2 (4 mL, 30 mmol) 
was added and the reaction left to stir for 16 h at room temperature. The reaction was quenched 
with 2M NaOH to pH 10, diluted with EtOAc (15 mL) and left stirring for 3 h. After cooling to room 
temperature the organic layer was removed and the aqueous fraction washed with EtOAc (3 x 15 
mL). The combined organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, 
filtered and the solvent removed under pressure. Column chromatography [silica, PE: EtOAc 
gradient column] afforded the product 126 (460 mg, 35 %) as a white solid. 
Rf [EtOAc] 0.68;  
Mp [EtOAc] 104-107 °C;  
IR max (KBr disc) 3685 (OH), 3583 (NH) and 1646 (C=O);  
1H NMR δH(500 MHz, CDCl3) 12.33 (1H, s, OH), 6.23 (1H, s, C(5)H), 5.81-5.71 (2H, m, NH and C(2’)H), 
5.24-5.18 (2H, m, C(3’)H2), 3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.73-3.68 (1H, m, C(3)H), 2.89-2.73 
(2H, m, C(4)H2), 2.46-2.40 (1H, m, C(1’)H2) and 2.37-2.24 (1H, m, C(1’)H2);  
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13C NMR δC(125 MHz, CDCl3) 170.2– (C(1)q), 157.0– (Cq), 155.8– (Cq), 135.2– (Cq), 134.0– (Cq), 132.8+ 
(C(2’)H), 119.7– (C(3’)H2), 105.5– (Cq), 101.9+ (C(5)H), 60.6+ (OCH3), 56.0+ (OCH3), 50.3+ (C(3)H), 
39.6– (C(1’)H2) and 34.1– (C(4)H2);  
MS (+ESI) m/z 549 (100 %, [2M+Na]+), 286 (89 %, [M+Na]+) and 264 (38 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 264.1319, C14H18NO4, requires [M+H]+ 264.1236. Found [M+Na]+ 
286.1166, C14H17NNaO4, requires [M+Na]+ 286.1055;  
Elemental Analysis Found C 63.78 %, H 6.50 % and N 5.37 %, requires C 63.87 %, H 6.51 % and N 
5.32 %. 
  




3-(3,4-Dimethoxyphenyl)propanoic acid 56 (1.05 g, 5 mmol) in THF (5 mL) was added dropwise to 
a stirred solution of LDA (6.11 mL, 11 mmol) at 0 °C under N2. After stirring for 40 min at 0 °C the 
reaction was allowed to warm to room temperature, allyl-bromide (490 µL, 5.5 mmol) was added 
and the reaction was left stirring for a further 18 h at 65 °C. The reaction was quenched with 6M 
HCl(aq) to pH 2 and extracted with EtOAc (3 x 10 mL). The combined organic fractions were washed 
with sat. brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to 
afford the product as a crude.  
DPPA (1.05 mL, 5 mmol) was added dropwise to a stirred solution of crude (2-(3,4-
dimethoxybenzyl)pent-4-enoic acid and anhydrous Et3N (700 µL, 5 mmol) in anhydrous toluene (15 
mL) under Ar. The reaction was heated at 90 °C for 90 min after which the reaction was 
concentrated under reduced pressure. Upon being put back under Ar, BF3∙OEt2 (4 mL, 30 mmol) 
was added and the reaction left to stir for 16 h at 50 °C. The reaction was quenched with 2M NaOH 
to pH 10, diluted with EtOAc (15 mL) and left stirring for 1 h. After cooling to room temperature the 
organic layer was removed and the aqueous fraction washed with EtOAc (3 x 15 mL). The combined 
organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered and the solvent 
removed under pressure. Column chromatography [silica, PE: EtOAc gradient column] afforded the 
product 128 (450 mg, 36 %) as a yellow solid. 
Rf [EtOAc] 0.50;  
Mp [EtOAc] 194-196 °C;  
IR max (KBr disc) 3583 (NH) and 1658 (C=O);  
1H NMR δH(500 MHz, CDCl3) 7.56 (1H, s, C(8)H), 6.65 (1H, s, C(5)H), 5.82-5.71 (1H, m, C(2’)H), 5.67 
(1H, brs, NH), 5.23 (1H, s, C(3’)H), 5.20-5.19 (1H, m, C(3’)H), 3.92 (3H, s, OCH3), 3.92 (3H, s, OCH3), 
3.77-3.70 (1H, m, C(3)H), 2.89-2.76 (2H, m, C(4)H2), 2.46-2.40 (1H, m, C(1’)H2) and 2.33-2.25 (1H, m, 
C(1’)H2);  
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13C NMR δC(125 MHz, CDCl3) 166.0– (C(1)q), 152.3– (C(7)q), 148.1– (C(6)q), 133.1+ (C(2’)H), 131.6– 
(C(8a)q), 121.1– (C(4a)q), 119.4– (C(3’)H2), 110.2+ (C(8)H), 109.7+ (C(5)H), 56.1+ (OCH3), 56.0+ 
(OCH3), 50.6+ (C(3)H), 39.9– (C(1’)H2) and 34.0– (C(4)H2);  
MS (+ESI) m/z 517 (100 %, [2M+Na]+), 270 (38 %, [M+Na]+) and 248 (27 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 248.1300, C14H18NO3, requires [M+H]+ 248.1287. Found [M+Na]+ 
270.1145, C14H17NNaO3, requires [M+Na]+ 270.1106;  
Elemental Analysis Found C 67.93 %, H 6.84 % and N 5.64 %, requires C 68.00 %, H 6.93 % and N 
5.66 %.  




3-(Benzo[d][1,3]dioxol-5-yl)propanoic acid 122 (0.97 g, 5 mmol) in THF (5 mL) was added dropwise 
to a stirred solution of LDA (6.11 mL, 11 mmol) at 0 °C under N2. After stirring for 40 min at 0 °C the 
reaction was allowed to warm to room temperature, allyl-bromide (490 µL, 5.5 mmol) was added 
and the reaction was left stirring for a further 18 h. The reaction was quenched with 6M HCl(aq) to 
pH 2 and extracted with EtOAc (3 x 10 mL). The combined organic fractions were washed with sat. 
brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford the 
crude.  
DPPA (1.05 mL, 5 mmol) was added dropwise to a stirred solution of crude (2-(benzo[d][1,3]dioxol-
5-ylmethyl)pent-4-enoic acid and anhydrous Et3N (700 µL, 5 mmol) in anhydrous toluene (15 mL) 
under Ar. The reaction was heated at 90 °C for 90 min after which the reaction was concentrated 
under reduced pressure. Upon being put back under Ar, BF3∙OEt2 (4 mL, 30 mmol) was added and 
the reaction left to stir for 16 h at room temperature. The reaction was quenched with 2M NaOH 
to pH 10, diluted with EtOAc (15 mL) and left stirring for 1 h. After cooling to room temperature the 
organic layer was removed and the aqueous fraction washed with EtOAc (3 x 15 mL). The combined 
organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered and the solvent 
removed under pressure. Column chromatography [silica, PE: EtOAc gradient column] afforded the 
product 129 (590 mg, 51 %) as a white solid. 
Rf [EtOAc] 0.69;  
Mp [EtOAc] 118-121 °C;  
IR max (KBr disc) 3583 (NH) and 1659 (C=O);  
1H NMR δH(500 MHz, CDCl3) 7.49 (1H, s, C(8)H), 6.61 (1H, s, C(5)H), 5.99 (2H, dd, J 1.0 and 3.0, 
OCH2O), 5.81-5.70 (2H, m, NH and C(2’)H), 5.17 (1H, s, C(3’)H), 5.14-5.13 (1H, m, C(3’)H), 3.74-3.66 
(1H, m, C(3)H), 2.86-2.73 (2H, m, C(4)H2), 2.45-2.37 (1H, m, C(1’)H2) and 2.31-2.23 (1H, m, C(1’)H2);  
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13C NMR δC(125 MHz, CDCl3) 165.8– (C(1)q), 150.8– (Cq), 145.8– (Cq), 133.5– (Cq), 133.2+ (C(2’)H), 
122.6– (Cq), 119.1– (C(3’)H2), 107.7+ (C(8)H), 107.3+ (C(5)H), 101.4– (OCH2O), 50.4+ (C(3)H), 39.6– 
(C(1’)H2) and 34.1– (C(4)H2);  
MS (+ESI) m/z 485 (100 %, [2M+Na]+), 254 (29 %, [M+Na]+) and 232 (21 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 232.0992, C13H14NO3, requires [M+H]+ 232.0974. Found [M+Na]+ 
254.0839, C13H13NNaO3, requires [M+Na]+ 254.0793;  
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6.4. Synthesis of ABC-ring analogues 
Ethyl 2-(1,3-benzodioxol-5-ylcarbonyl)-5-oxohexanoate (142) 
 
NaH (60 % dispersed in mineral oil) (1.20 g, 30 mmol) was added portion wise to a rapidly stirred 
solution of 3',4'-(methylenedioxy)acetophenone 134 (3.28 g, 20 mmol) in diethyl carbonate (40 mL) 
at 0 °C under N2. The reaction was heated to 80 °C for 90 min. Upon cooling to r.t. the reaction was 
quenched with sat. NH4Cl(aq) (25 mL), diluted with water (100 mL) and extracted with EtOAc (3 × 50 
mL). The combined organic fractions were washed with sat. brine (50 mL), dried over Na2SO4 and 
filtered. The solvent was removed under reduced pressure and the crude product 135 was isolated 
as a yellow oil without further purification  
K2CO3 (3.06 g, 22.2 mmol) was added to a rapidly stirred solution of ethyl 3-(1,3-benzodioxol-5-yl)-
3-oxopropanoate 135 (4.72 g, 20 mmol) in anhydrous MeCN (90 mL) at 0 °C under Ar. After 10 min 
vigorous stirring MVK (1.8 mL, 22.2 mmol) was added drop wise and the reaction mixture was 
allowed to warm to r.t.. After 90 min the reaction was quenched with saturated sat. NH4Cl(aq) (15 
mL) and extracted with EtOAc (3 × 50 mL). The combined organic fractions were washed with sat. 
brine (50 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure. After 
column chromatography [silica, PE: EtOAc gradient column] the product 142 (4.8 g, 79 %) was 
isolated as a yellow oil. 
Rf [PE:EtOAc, 50:50] 0.53;  
IR νmax (thin film) 2983 (CH), 1736 (C=O), 1715 (C=O), 1676 (C=O) and 1605 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.64 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 7.48 (1H, d, J 2.0 Hz, C(2’)H), 6.85 
(1H, d, J 8.0 Hz, C(5’)H), 6.04 (2H, s, OCH2O), 4.33 (1H, d, J 6.0 Hz, C(2)H), 4.14 (2H, ddd, J 3.0, 7.0 
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and 14.0 Hz, OCH2CH3), 2.63-2.48 (2H, m, C(4)H2), 2.27-2.17 (2H, m, C(3)H2), 2.11 (3H, s, C(6)H3) and 
1.18 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 207.8– (C(=O)q), 193.1– (C(=O)q), 169.8– (C(=O)q), 152.2– (Cq), 148.3– 
(Cq), 130.8– (C(1’)q), 125.2+ (C(6’)H), 108.3+ (C(5’)H), 107.9+ (C(2’)H), 101.9– (OCH2O), 61.3– 
(OCH2CH3), 52.4+ (C(2)H), 40.5– (C(4)H2), 29.9+ (C(6)H3), 22.9– (C(3)H2) and 13.9+ (OCH2CH3);  
MS (+ESI) m/z 329 (100 %, [M+Na]+), 635 (55 %, [2M+Na]+) and 307 (28 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 307.1269, C16H19O6, requires [M+H]+ 307.1182. Found [M+Na]+ 
329.1117, C16H18NaO6, requires [M+Na]+ 329.1001. 
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Ethyl 2-(1’,3’-benzodioxol-5-yl)-4-oxocyclohex-2-ene-1-carboxylate (139) 
 
pTsOH.H2O (494 mg, 2.6 mmol) in toluene (75 mL) was stirred under Ar for 90 min with the oil bath 
at 143 °C and the azeotropic removal of water using Soxhlet equipment. Ethyl 2-(1’,3’-
benzodioxol-5-ylcarbonyl)-5-oxohexanoate 142 (1.99 g, 6.5 mmol) in toluene (10 mL) was added 
and the reaction heated for a further 24 h. After cooling the toluene was removed under reduced 
pressure to near dryness and loaded onto a column. After column chromatography [silica, PE: EtOAc 
gradient column] the purified product 139 (993 mg, 53 %) was isolated as a light yellow amorphous 
solid. 
Rf [PE:EtOAc, 50:50] 0.35;  
MP [EtOAc] 107-110 °C;  
1H NMR δH(400 MHz, CDCl3) 7.02 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 6.99 (1H, d, J 2.0 Hz, C(2’)H), 6.82 
(1H, d, J 8.0 Hz, C(5’)H), 6.38 (1H, s, C(3)H), 6.00 (2H, s, OCH2O), 4.12 (2H, q, J 7.0 Hz, OCH2CH3), 3.88 
(1H, m, C(1)H), 2.66-2.56 (1H, m, C(4)H2), 2.50-2.41 (2H, m, C(6)H2 and C(5)H2), 2.40-2.31 (1H, m, 
C(6)H2) and 1.18 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 198.4+ (C(=O)q), 171.5+ (C(=O)q), 154.7+ (Cq), 149.4+ (Cq), 148.3+ (Cq), 
131.8+ (Cq), 126.0– (C(3)H), 120.9– (C(6’)H), 108.4– (C(5’)H), 106.5– (C(2’)H), 101.6+ (OCH2O), 61.4+ 
(OCH2CH3), 43.6– (C(1)H), 33.9+ (C(5)H2), 26.5+ (C(6)H2) and 14.0– (OCH2CH3);  
MS (+ESI) m/z 289 (100 %, [M+H]+), 599 (72 %, [2M+Na]+) and 311 (43 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 289.1180, C16H17O5, requires [M+H]+ 289.1076. Found [M+Na]+ 
311.0993, C16H16NaO5, requires [M+Na]+ 311.0895. 
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Ethyl 2-(1’,3’-benzodioxol-5-yl)cyclohex-2-ene-1-carboxylate (144) 
 
NaBH4 (378 mg, 10 mmol) was added portion wise over 3 min to a rapidly stirred solution of TFA 
(2.4 mL), AcOH (2.4 mL) and anhydrous MeCN (2.4 mL) at 0 °C under Ar and effervescent was 
observed. Ethyl 2-(1’,3’-benzodioxol-5-yl)-4-oxocyclohex-2-ene-1-carboxylate 139 (576 mg, 2.0 
mmol) in CH2Cl2 (12 mL) was added at 0 °C and the reaction was allowed to warm to r.t. over 4 h. 
The reaction was quenched with 1M NaOH(aq) to pH 6 and extracted with EtOAc (3 × 20 mL). The 
combined organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, filtered and 
the solvent removed under reduced pressure. After column chromatography [silica, PE: EtOAc 
gradient column] the product 144 (541 mg, 99 %) was isolated as a pale yellow oil. 
Rf [PE:EtOAc, 60:40] 0.57;  
IR νmax (thin film) 2936 (OH), 1731 (C=O) and 1505 (C=C);  
1H NMR δH(400 MHz, CDCl3), 6.83 (1H, d, J 2.0 Hz, C(2’)H), 6.76 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 
6.72 (1H, d, J 8.0 Hz, C(5’)H), 6.08 (1H, dt, J 4.0 and 1.0 Hz, C(3)H), 5.91 (2H, s, OCH2O), 4.05-3.99 
(2H, m, OCH2CH3), 3.61-3.58 (1H, m, C(1)H), 2.31-2.13 (2H, m, C(4)H2), 2.07-1.93 (2H, m, C(6)H2), 
1.81-1.71 (1H, m, C(5)H2), 1.69-1.60 (1H, m, C(5)H2) and 1.10 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 174.6+ (C(=O)q), 147.5+ (Cq), 146.4+ (Cq), 136.2+ (Cq), 134.3+ (Cq), 
127.4– (C(3)H), 118.8– (C(2’)H), 107.9– (C(5’)H), 106.4– (C(6’)H), 100.8+ (OCH2O), 60.3+ (OCH2CH3), 
43.7– (C(1)H), 27.0+ (C(6)H2), 25.5+ (C(4)H2), 19.3+ (C(5)H2) and 14.0– (OCH2CH3);  
MS (+ESI) m/z 297 (100 %, [M+Na]+), 571 (38 %, [2M+Na]+) and 275 (30 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 275.1298, C16H19O4, requires [M+H]+ 275.1283. Found [M+Na]+ 
297.1181, C16H18NaO4, requires [M+Na]+ 297.1103. 
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2-(1’,3’-Benzodioxol-5-yl)cyclohex-2-ene-1-carboxylic acid (145) 
 
A rapidly stirred solution of ethyl 2-(1’,3’-benzodioxol-5-yl)cyclohex-2-ene-1-carboxylate 144 (263 
mg, 0.96 mmol) in 1M NaOH(aq): EtOH (1: 1, 6 mL) was heated at reflux for 6 h. The solution was 
then cooled to 0 °C, acidified to pH 2 using 6M HCl(aq) and extracted with EtOAc (3 × 15 mL). The 
combined organic fractions were washed with sat. brine (10 mL), dried over Na2SO4, filtered and 
the solvent removed under reduced pressure to give the product 145 (237 mg, 100 %) as a white 
solid without further purification. 
MP [EtOAc] 122-126 °C;  
IR νmax (KBr disc) 2935 (OH), 1703 (C=O) and 1516 (C=C);  
1H NMR δH(400 MHz, CDCl3) 6.83 (1H, d, J 2.0 Hz, C(2’)H), 6.78 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 6.73 
(1H, d, J 8.0 Hz, C(5’)H), 6.12 (1H, t, J 4.0 Hz C(3)H), 5.93 (2H, s, OCH2O), 3.64 (1H, s, C(1)H), 2.25-
2.20 (2H, m, C(4)H2), 2.18-2.09 (1H, m, C(5)H2), 2.02-1.94 (1H, m, C(5)H2) and 1.83-1.64 (2H, m, 
C(6)H2);  
13C NMR δC(100 MHz, CDCl3) 179.0+ (C(=O)q), 147.7+ (Cq), 146.5+ (Cq), 135.8+ (Cq), 133.5+ (Cq), 
127.9– (C(3)H), 118.7– (C(5’)H), 108.0– (C(6’)H), 106.3– (C(2’)H), 100.9+ (OCH2O), 42.9– (C(1)H), 
26.9+ (C(5)H2), 25.4+ (C(4)H2) and 18.9+ (C(6)H2);  
MS (+ESI) m/z 269 (100 %, [M+Na]+), 247 (53 %, [M+H]+) and 515 (30 %, [2M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 247.0973, C14H15O4, requires [M+H]+ 247.0970. Found [M+Na]+ 
269.0818, C14H14NaO4, requires [M+Na]+ 269.0790. 
 
  




DPPA (192 μL, 0.89 mmol) was added dropwise to a rapidly stirred solution of 2-(1’,3’-benzodioxol-
5-yl)cyclohex-2-ene-1-carboxylic acid 145 (199 mg, 0.81 mmol) and anhydrous Et3N (124 μL, 0.89 
mmol) in anhydrous toluene (3 mL) at r.t. under Ar. The reaction was heated at 90 °C for 90 min 
after which the reaction was allowed to cool and was concentrated under reduced pressure. The 
oil was placed back under Ar and BF3∙OEt2 (1 mL) was added. After stirring at r.t. for 16 h the reaction 
was quenched with 2M NaOH(aq) to pH 10, diluted with EtOAc (10 mL) and left stirring at 50 °C for 
60 min. After cooling to r.t. the organic layer was separated and the aqueous fraction washed with 
EtOAc (3 × 5 mL). The combined organic fractions were washed with sat. brine (20 mL), dried over 
Na2SO4, filtered and the solvent removed under pressure. After column chromatography [silica, PE: 
EtOAc: MeOH gradient column] the product 148 (113 g, 57 %) was isolated as a white crystalline 
solid. 
Rf [EtOAc] 0.30;  
MP [EtOAc] 126-129 °C;  
IR νmax (KBr disc) 3176 (NH), 3055 (CH), 1674 (C=O) and 1615 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.51 (1H, s, C(7)H), 6.89 (1H, s, C(10)H), 6.11 (1H, brt, J 2.0 Hz, C(1)H), 
6.00 (2H, dd, J 7.5 and 1.5 Hz, OCH2O), 5.58 (1H, brs, NH), 4.33 (1H, brs, C(4a)H), 2.39-2.22 (2H, m, 
C(2)H2), 2.11-2.06 (1H, m, C(3)H2), 1.91-1.87 (1H, m, C(4)H2) and 1.73-1.64 (2H, m, C(3)H2 and 
C(4)H2);  
13C NMR δC(100 MHz, CDCl3) 164.6+ (C(6)q), 151.3+ (Cq), 147.6+ (Cq), 133.3+ (Cq), 130.9+ (Cq), 124.7– 
(C(1)H), 121.5+ (Cq), 107.4– (C(7 or 10)H), 102.7– (C(10 or 7)H), 101.5+ (OCH2O), 50.7– (C(4a)H), 
29.9+ (C(3)H2), 25.7+ (C(2)H2) and 20.1+ (C(4)H2);  
MS (+ESI) m/z 509 (100 %, [2M+Na]+) and 244 (24 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 244.1010, C14H14NO3, requires [M+H]+ 244.0974. Found [M+Na]+ 
266.0789, C14H13NNaO3, requires [M+Na]+ 266.0793. 
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Ethyl 3-oxo-3-(3’,4’,5’-trimethoxyphenyl)propanoate (150) 
 
NaH (60 % dispersed in mineral oil) (1.5 g, 37.5 mmol) was added portion wise to a rapidly stirred 
solution of 3,4,5-trimethoxyacetophenone 149 (5.25 g, 25 mmol) in diethyl carbonate (50 mL) at 0 
°C under N2. The reaction was heated to 80 °C for 90 min. Upon cooling to r.t. the reaction was 
quenched with sat. NH4Cl(aq) (25 mL), diluted with water (100 mL) and extracted with EtOAc (3 × 50 
mL). The combined organic fractions were washed with sat. brine (50 mL), dried over Na2SO4 and 
filtered. The solvent was removed under reduced pressure which was purified by column 
chromatography [silica, PE: EtOAc gradient column] giving the β-ketoester 150 (6.46 g, 92 %) as a 
pale yellow solid. 
Rf [PE:EtOAc, 50:50] 0.42;  
Mp [EtOAc] 84-88 °C;  
1H NMR δH(400 MHz, CDCl3) 7.20 (2H, s, C(2’)H and C(6’)H), 4.20 (2H, q, J 7.0 Hz, OCH2CH3), 3.95 
(2H, s, C(2)H2), 3.91 (3H, s, OCH3), 3.90 (6H, s, OCH3) and 1.25 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 191.2– (C(3)q), 167.5– (C(1)q), 153.1– (Cq), 143.1– (Cq), 131.1– (C(1’)q) 
106.1+ (C(2’)H and C(6’)H) 61.5– (C(2)H2), 61.0+ (OCH3), 56.3+ (OCH3), 46.1– (OCH2CH3) and 14.1+ 
(OCH2CH3). 
Spectroscopic data is consistent with that reported by Lawrence et al.190  
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Ethyl 5-oxo-2-(3’,4’,5’-trimethoxybenzoyl)hexanoate (151) 
 
K2CO3 (1.16 g, 8.4 mmol) was added to a rapidly stirred solution of ethyl 3-oxo-3-(3’,4’,5’-
trimethoxyphenyl)propanoate 150 (2.16 g, 7.66 mmol) in anhydrous MeCN (40 mL) at 0 °C under 
Ar. After 10 min vigorous rapidly stirred methyl vinyl ketone (MVK) (680 μL, 8.4 mmol) was added 
dropwise and the reaction mixture was allowed to warm to r.t.. After 90 min the reaction was 
quenched with saturated sat. NH4Cl(aq) (15 mL) and extracted with EtOAc (3 × 30 mL). The combined 
organic fractions were washed with sat. brine (50 mL), dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. After column chromatography [silica, PE: EtOAc gradient 
column] the purified product 151 (2.50 g, 93 %) was isolated as a yellow oil. 
Rf [PE:EtOAc, 50:50] 0.52;  
IR max (Thin film) 2979 (CH), 1731 (C=O), 1722 (C=O), 1681 (C=O), 1234 (C-O);  
1H NMR δH(400 MHz, CDCl3) 7.36 (2H, s, C(2’)H and C(6’)H), 4.42 (1H, dd, J 8.5 and 6.0 Hz, C(2)H), 
4.19-4.12 (2H, m, OCH2CH3), 3.93 (6H, s, OCH3), 3.91 (3H, s, OCH3), 2.68-2.52 (2H, m, C(4)H2), 2.29-
2.15 (2H, m, C(3)H2), 2.13 (3H, s, C(6)H3) and 1.20 (3H, t, J 7.5 Hz, OCH2CH3); 
13C NMR δC(100 MHz, CDCl3) 208.0– (Cq), 194.2– (Cq), 170.0– (Cq), 153.1– (Cq), 143.0– (Cq), 130.8– 
(C(1’)q), 106.2+ (C(2’)H and C(6’)H), 61.4– (OCH2CH3), 60.9+ (OCH3), 56.3+ (OCH3), 52.6+ (C(2)H), 
40.5– (C(4)H2), 30.0+ (C(6)H3), 23.0– (C(3)H2) and 14.0+ (OCH2CH3); 
MS (+ESI) m/z 353 (100 %, [M+H]+) and 375 (69 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 353.1601, C18H25O7, requires [M+H]+ 353.1600. 
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Ethyl 4-oxo-2-(3’,4’,5’-trimethoxyphenyl)cyclohex-2-ene-1-carboxylate (152) 
 
pTsOH.H2O (380 mg, 2.0 mmol) in toluene (70 mL) was stirred under Ar for 90 min with the oil bath 
at 143 °C with the azeotropic removal of water using Soxhlet equipment. Ethyl 5-oxo-2-(3’,4’,5’-
trimethoxybenzoyl)hexanoate 151 (1.76 g, 5.0 mmol) in toluene (10 mL) was added and the 
reaction heated for a further 24 h. After cooling the toluene was removed under reduced pressure 
to near dryness and loaded onto a column. After column chromatography [silica, PE: EtOAc gradient 
column] the purified product 152 (668 mg, 40 %) was isolated as a light yellow amorphous solid. 
Rf [PE:EtOAc, 50:50] 0.53;  
IR max (Thin film) 2938 (CH), 1728 (C=O), 1661 (C=O), 1518 (C=C) and 1252 (C-O); 
1H NMR δH(400 MHz, CDCl3) 6.73 (2H, s, C(2’)H and C(6’)H), 6.44 (1H, s, C(3)H), 4.15-4.08 (2H, m, 
OCH2CH3), 3.94-3.92 (1H, m, C(1)H), 3.87 (9H, s, 3 × OCH3), 2.68-2.61 (1H, m, C(5)H2), 2.51-2.38 (3H, 
m, C(5)H2 and C(6)H2) and 1.14 (3H, t, J 7.5 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 198.5– (C(=O)q), 171.7– (C(=O)q), 155.3– (C(1’)q), 153.3– (C(3’)q), 139.9– 
(C(4’)q), 133.2– (C(1)q), 126.7+ (C(3)H), 103.8+ (C(2’)H) 61.5– (OCH2CH3) 60.9+ (OCH3) 56.2+ (OCH3) 
43.7+ (OCH3) 34.0– (C(5)H2), 26.6– (C(6)H2), 14.1+ (OCH2CH3);  
MS (+ESI) m/z 335 (100 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 335.1495, C18H23O6, requires [M+H]+ 335.1495. 
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Ethyl 2-(3’,4’,5’-trimethoxyphenyl)cyclohex-2-ene-1-carboxylate (153) 
 
NaBH4 (378 mg, 10 mmol) was added portion wise over 3 min to a rapidly stirred solution of TFA 
(2.4 mL), AcOH (2.4 mL) and anhydrous MeCN (2.4 mL) at 0 °C under Ar and effervescent was 
observed. The ethyl 4-oxo-2-(3’,4’,5’-trimethoxyphenyl)cyclohex-2-ene-1-carboxylate 152 (668 mg, 
2 mmol) in CH2Cl2 (15 mL) was added at 0 °C and the reaction was allowed to warm to r.t. and was 
stirred for 4 h. The reaction was quenched with 1M NaOH(aq) to pH 6 and extracted with EtOAc (3 × 
15 mL). The combined organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, 
filtered and the solvent removed under reduced pressure. After column chromatography [silica, PE: 
EtOAc gradient column] the product 153 (514 mg, 80 %) was isolated as a pale yellow solid. 
Rf [PE:EtOAc, 50:50] 0.50;  
Mp [EtOAc] 75-80 °C;  
IR max (Thin film) 2937 (CH), 1731 (C=O) and 1243 (C-O);  
1H NMR δH(400 MHz, CDCl3) 6.53 (2H, s, C(2’)H and C(6’)H), 6.16 (1H, t, J 4.0 Hz, C(3)H), 4.09-3.95 
(2H, m, OCH2CH3), 3.84 (6H, s, 2 × OCH3), 3.81, (3H, s, OCH3), 3.65-3.63 (1H, m, C(1)H), 2.32-2.18 
(2H, m, C(4)H2), 2.06-1.97 (2H, m, C(6)H2), 1.84-1.74 (1H, m, C(5)H2), 1.70-1.61 (1H, m, C(5)H2) and 
1.08 (3H, td, J 7.0 and 0.5 Hz, CH2CH3);  
13C NMR δC(100 MHz, CDCl3) 174.6– (C(=O)q), 152.9– (C(3’)q and C(5’)q), 137.5– (C(1’ or 4’)q), 137.0– 
(C(4’ or 1’)q), 134.8– (C(2)q), 128.0+ (C(3)H), 102.8+ (C(2’)H and C(6’)H), 60.8+ (OCH3), 60.4– 
(OCH2CH3), 56.0+ (2 × OCH3), 43.8+ (C(1)H), 27.0– (C(6)H2), 25.4– (C(4)H2), 19.4– (C(5)H2) and 14.0+ 
(OCH2CH3);  
MS (+ESI) m/z 321 (100 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 321.1684, C18H25O5, requires [M+H]+ 321.1702. 
 
- 162 - 
 
2-(3’,4’,5’-Trimethoxyphenyl)cyclohex-2-ene-1-carboxylic acid (154) 
 
A rapidly stirred solution of ethyl 2-(3’,4’,5’-trimethoxyphenyl)cyclohex-2-ene-1-carboxylate 153 
(512 mg, 1.6 mmol) in 1M NaOH(aq) : EtOH (1: 1, 10 mL) was heated at reflux for 6 h. The solution 
was then cooled to 0 °C, acidified to pH 2 using 6M HCl(aq) and extracted with EtOAc (3 × 15 mL). 
The combined organic fractions were washed with sat. brine (10 mL), dried over Na2SO4, filtered 
and the solvent removed under reduced pressure to give the product 154 (454 mg, 97 %) as a white 
solid without further purification. 
Mp [CHCl3] 143-147 °C;  
IR max (Thin film) 3161 (OH), 2937 (CH) and 1073 (C=O);  
1H NMR δH(400 MHz, CDCl3) 6.54 (2H, s, C(2’)H and C(6’)H), 6.20 (1H, td, J 4.0 and 1.0 Hz, C(3)H), 
3.83 (6H, s, C(3’)OCH3 and C(5’)OCH3), 3.82 (3H, s, C(4’)OCH3), 3.68 (1H, brt, J 4.5 Hz, C(1)H), 2.32-
2.20 (2H, m, C(4)H2), 2.13-2.08 (1H, m, C(6)H2), 2.05-1.97 (1H, m, C(6)H2) and 1.82-1.64 (2H, m, 
C(5)H2);  
13C NMR δC(100 MHz, CDCl3) 180.1– (C(=O)q), 153.0– (C(3’)q and C(5’)q), 137.2– (C(1’)q), 137.1– 
(C(4’)q), 133.9– (C(2)q), 128.6+ (C(3)H), 102.7+ (C(2’)H and C(6’)H), 60.8+ (C(4’)OCH3), 56.0+ 
(C(3’)OCH3 and C(5’)OCH3), 42.9+ (C(1)H), 26.9– (C(6)H2), 25.4– (C(4)H2) and 19.0– (C(5)H2);  
MS (+ESI) m/z 293 (100 %, [M+H]+) and 315 (20 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 315.1196, C16H20NaO5, requires [M+Na]+ 315.1208. 
  




Diphenylphosphoryl azide (DPPA) (106 μL, 0.49 mmol) was added dropwise to a rapidly stirred 
solution of 2-(3’,4’,5’-trimethoxyphenyl)cyclohex-2-ene-1-carboxylic acid 154 (131 mg, 0.45 mmol) 
and anhydrous Et3N (68 μL, 0.49 mmol) in anhydrous toluene (1.5 mL) at r.t. under Ar. The reaction 
was heated at 90 °C for 90 min after which the reaction was allowed to cool and was concentrated 
under reduced pressure. The oil was placed under Ar and BF3∙OEt2 (1.5 mL) was added and the 
reaction left stirring for 16 h at 50 °C. After cooling to r.t. the reaction was quenched with 2M 
NaOH(aq) to pH 10, diluted with EtOAc (5 mL) and left stirring at 50 °C for 4 h. After cooling to r.t. 
the organic layer was separated and the aqueous fraction washed with EtOAc (3 × 5 mL). The 
combined organic fractions were washed with sat. brine (10 mL), dried over Na2SO4, filtered and 
the solvent removed under pressure. After column chromatography [silica, PE: EtOAc: MeOH 
gradient column] the product 155 (50 mg, 40 %) was isolated as a white solid. 
Rf [PE:EtOAc, 50:50] 0.37;  
Mp [EtOAc] 202-205 °C;  
IR max (Thin film) 3417 (OH and NH), 2935 (CH) and 1651 (C=O);  
1H NMR δH(400 MHz, CDCl3) 12.67 (1H, brs, OH), 6.51 (1H, s, C(10)H), 6.23 (1H, t, J 2.5 Hz, C(1)H), 
5.93 (1H, brs, NH), 4.33-4.31 (1H, m, C(4a)H), 3.90 (3H, m, C(9)OCH3), 3.88 (3H, m, C(8)OCH3), 2.23-
2.41 (2H, m, C(2)H2), 2.10-2.14 (1H, m, C(4)H2), 1.88-1.92 (1H, m, C(3)H2) and 1.57-1.73 (2H, m, 
C(3)H2 and C(4)H2); 
13C NMR δC(100 MHz, CDCl3) 169.7– (C(6)q), 157.2– (C(9)q), 155.5– (C(7)q), 136.3– (C(8)q), 133.7– 
(C(10b)q), 130.4– (C(10a)q), 125.9+ (C(1)H), 104.3– (C(6a)q), 97.4+ (C(10)H), 60.7+ (C(8)OCH3), 56.0+ 
(C(9)OCH3), 50.7+ (C(4a)H), 29.6– (C(4)H2), 25.9– (C(2)H2) and 20.0– (C(3)H2);  
MS (+ESI) m/z 276 (100 %, [M+H]+) and 298 (13 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 298.1054, C15H17NNaO4, requires [M+Na]+ 298.1055.  
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Ethyl 3-(3’,4’-dimethoxyphenyl)-3-oxopropanoate (157) 
 
NaH (60 % dispersed in mineral oil) (1.20 g, 30 mmol) was added portion wise to a rapidly stirred 
solution of 3,4-dimethoxyacetophenone 156 (3.6 g, 20 mmol) in diethyl carbonate (40 mL) at 0 °C 
under N2. The reaction was heated to 80 °C for 90 min. Upon cooling to r.t. the reaction was 
quenched with sat. NH4Cl(aq) (20 mL), diluted with water (100 mL) and extracted with EtOAc (3 × 50 
mL). The combined organic fractions were washed with sat. brine (50 mL), dried over Na2SO4 and 
filtered. The solvent was removed under reduced pressure which was purified by column 
chromatography [silica, PE: EtOAc gradient column] giving the β-ketoester 157 (4.79 g, 95 %) as a 
yellow oil. 
1H NMR δH(400 MHz, CDCl3) 7.51 (1H, dd, J 8.0 and 2.0 Hz, C(6’)H), 7.49 (1H, d, J 2.0 Hz, C(2’)H), 6.85 
(1H, d, J 8.0 Hz, C(5’)H), 4.17 (2H, q, J 7.0 Hz, OCH2CH3), 3.91 (5H, s, OCH3 and C(2)H2), 3.89 (3H, s, 
OCH3) and 1.22 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 190.9– (C(1)q), 167.6– (C(3)q), 153.7– (C(3’ or 4’)q), 149.0– (C(4’ or 3’)q), 
129.2– (C(1’)q), 123.4+ (C(6’)H), 110.2+ (C(2’ or 5’)H), 110.0+ (C(5’ or 2’)H), 61.3– (OCH2CH3), 56.0+ 
(OCH3), 55.9+ (OCH3), 45.6– (C(2)H2) and 14.0+ (OCH2CH3). 
Spectroscopic data is consistent with that reported by Korsager et al.191 
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Ethyl 2-(3’,4’-dimethoxybenzoyl)-5-oxohexanoate (158) 
 
K2CO3 (800 mg, 5.8 mmol) was added to a rapidly stirred solution of ethyl 3-(3’,4’-
dimethoxyphenyl)-3-oxopropanoate 157 (1.34 g, 5.3 mmol) in anhydrous MeCN (20 mL) at 0 °C 
under Ar. After 10 min vigorous stirring MVK (470 μL, 5.8 mmol) was added drop wise and the 
reaction mixture was allowed to warm to r.t.. After 90 min the reaction was quenched with 
saturated sat. NH4Cl(aq) (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic 
fractions were washed with sat. brine (50 mL), dried over Na2SO4, filtered and the solvent removed 
under reduced pressure. After column chromatography [silica, PE: EtOAc gradient column] the 
product 158 (1.6 g, 94 %) was isolated as a yellow oil.  
Rf [PE:EtOAc, 50:50] 0.52;  
IR max (Thin film) 1731 (C=O), 1721 (C=O), 1673 (C=O) and 1594 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.71 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 7.60 (1H, d, J 2.0 Hz, C(2’)H), 6.91 
(1H, d, J 8.5 Hz, C(5’)H), 4.42 (1H, dd, J 8.0 and 6.0 Hz, C(2)H), 4.14 (2H, qd, J 7.0 and 2.0 Hz, 
OCH2CH3), 3.95 (6H, s, OCH3), 2.59 (2H, qt, J 18.0 and 7.0 Hz, C(4)H2), 2.29-2.13 (2H, m, C(3)H2), 2.13 
(3H, s, C(6)H3) and 1.18 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 208.0– (C(5)q), 193.8– (C(1)q), 170.0– (C(=O)q), 153.7– (C(4’)q), 149.1– 
(C(3’)q), 128.9– (C(1’)q), 123.6+ (C(6’)H), 110.6+ (C(2’)H), 110.0+ (C(5’)H), 61.3– (OCH2CH3), 56.1+ 
(OCH3), 56.0+ (OCH3), 52.2+ (C(2)H), 40.5– (C(4)H2), 30.0+ (C(6)H3), 22.9– (C(3)H2) and 14.0+ 
(OCH2CH3);  
MS (+ESI) m/z 345 (100 %, [M+Na]+) and 323 (29 %, [M+H]+);  
HRMS (+ESI) Found [M+H]+ 323.1491, C17H23O6, requires [M+H]+ 323.1495. 
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Ethyl 2-(3’,4’-dimethoxyphenyl)-4-oxocyclohex-2-ene-1-carboxylate (159) 
 
pTsOH.H2O (304 mg, 1.6 mmol) in toluene (40 mL) was stirred under Ar for 90 min with the oil bath 
at 143 °C with the azeotropic removal of water using Soxhlet equipment. Ethyl 2-(3’,4’-
dimethoxybenzoyl)-5-oxohexanoate 158 (1.26 g, 3.9 mmol) in toluene (15 mL) was added and the 
reaction heated for a further 24 h. After cooling the toluene was removed under reduced pressure 
to near dryness and loaded onto a column. After column chromatography [silica, PE: EtOAc gradient 
column] the purified product 159 (811 mg, 68 %) was isolated as a light yellow amorphous solid. 
Rf [PE:EtOAc, 50:50] 0.30;  
IR νmax (thin film) 1728 (C=O), 1661 (C=O) and 1518 (C=C);  
1H NMR δH(400 MHz, CDCl3) 7.10 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 7.04 (1H, d, J 2.0 Hz, C(2’)H), 6.86 
(1H, d, J 8.5 Hz, C(5’)H), 6.45 (1H, s, C(3)H), 4.11 (2H, q, J 7.0 Hz, OCH2CH3), 3.96-3.94 (1H, m, C(1)H), 
3.89 (3H, s, C(4’)OCH3), 3.88 (3H, s, C(3’)OCH3), 2.67-2.58 (1H, m, C(5)H2), 2.49-2.32 (3H, m, C(6)H2 
and C(5)H2) and 1.14 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 198.6– (C(4)q), 171.7– (C(=O)q), 154.8– (C(2)q), 150.9– (C(4’)q), 149.1– 
(C(3’)q), 130.1– (C(1’)q), 125.4+ (C(3)H), 119.6+ (C(6’)H), 110.9+ (C(5’)H), 109.1+ (C(2’)H), 61.4– 
(OCH2CH3), 55.9+ (C(3’)OCH3 and C(4’)OCH3), 43.3+ (C(1)H), 33.9– (C(5)H2), 26.5– (C(6)H2) and 14.0+ 
(OCH2CH3);  
MS (+ESI) m/z 305 (100 %, [M+H]+) and 327 (9 %, [M+Na]+);  
HRMS (+ESI) Found [M+Na]+ 324.1311, C17H20NaO5, requires 324.1208 [M+Na]+. 
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Ethyl 2-(3’,4’-dimethoxyphenyl)cyclohex-2-ene-1-carboxylate (160) 
 
NaBH4 (491 mg, 13 mmol) was added portion wise over 3 min to a rapidly stirred solution of TFA 
(2.4 mL), AcOH (2.4 mL) and anhydrous MeCN (2.4 mL) at 0 °C under Ar and effervescent was 
observed. The ethyl 2-(3’,4’-dimethoxyphenyl)-4-oxocyclohex-2-ene-1-carboxylate 159 (608 mg, 
2.0 mmol) in CH2Cl2 (15 mL) was added at 0 °C and the reaction was allowed to warm to r.t. and 
was stirred for 4 h. The reaction was quenched with 1M NaOH(aq) to pH 6 and extracted with EtOAc 
(3 × 15 mL). The combined organic fractions were washed with sat. brine (20 mL), dried over Na2SO4, 
filtered and the solvent removed under reduced pressure. After column chromatography [silica, PE: 
EtOAc gradient column] the product 160 (494 mg, 85 %) was isolated as a pale yellow amorphous 
solid. 
Rf [PE:EtOAc, 60:40] 0.57;  
IR max (Thin film) 2935 (CH), 1731 (C=O) and 1603 (C=C); 
1H NMR δH(400 MHz, CDCl3) 6.87 (1H, d, J 2.0 Hz, C(2’)H), 6.84 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 6.77 
(1H, d, J 8.5 Hz, C(5’)H), 6.12 (1H, td, J 4.0 and 1.5 Hz, C(3)H), 4.06-3.94 (2H, m, OCH2CH3), 3.86 (3H, 
s, OCH3), 3.84 (3H, s, OCH3), 3.66-3.63 (1H, m, C(1)H), 2.32-2.14 (2H, m, C(4)H2), 2.06-1.94 (2H, m, 
C(6)H2), 1.82-1.72 (1H, m, C(5)H2), 1.69-1.60 (1H, m, C(5)H2) and 1.06 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 174.7– (C(=O)q), 148.6– (C(3’ or 4’)q), 148.0– (C(4’ or 3’)q), 134.6– (C(1’ 
or 2)q), 134.3– (C(2 or 1’)q), 127.0+ (C(3)H), 117.6+ (C(6’)H), 110.8+ (C(5’)H), 109.0+ (C(2’)H), 60.4– 
(OCH2CH3), 55.8+ (OCH3), 55.7+ (OCH3), 43.6+ (C(1)H), 27.0– (C(6)H2), 25.5– (C(4)H2), 19.3– (C(5)H2) 
and 14.0+ (OCH2CH3);  
MS (+ESI) m/z 291 (93 %, [M+H]+);  
HRMS (+ESI) Found [M+H]+ 291.1593, C17H23O4, requires [M+H]+ 291.1596.  
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2-(3’,4’-Dimethoxyphenyl)cyclohex-2-ene-1-carboxylic acid (161) 
 
A rapidly stirred solution of ethyl 2-(3,4-dimethoxyphenyl)cyclohex-2-ene-1-carboxylate 160 (406 
mg, 1.4 mmol) in 1M NaOH(aq) : EtOH (1: 1, 16 mL) was heated at reflux for 6 h. The solution was 
then cooled to 0 °C, acidified to pH 2 using 6M HCl(aq) and extracted with EtOAc (3 × 15 mL). The 
combined organic fractions were washed with sat. brine (10 mL), dried over Na2SO4, filtered and 
the solvent removed under reduced pressure to give the product 161 (352 mg, 96 %) as a white 
solid without further purification. 
Mp [CHCl3] 102-106 °C;  
IR max (Thin film) 2935 (OH) and 1703 (C=O);  
1H NMR δH(400 MHz, CDCl3) 6.89 (1H, d, J 2.0 Hz, C(2’)H), 6.86 (1H, dd, J 8.5 and 2.0 Hz, C(6’)H), 6.79 
(1H, d, J 8.5 Hz, C(5’)H), 6.17 (1H, td, J 4.5 and 1.0 Hz, C(3)H), 3.86 (6H, s, OCH3), 3.69-3.67 (1H, m, 
C(1)H), 2.33-2.22 (2H, m, C(4)H2), 2.15-2.01 (1H, m, C(6)H2), 2.04-1.95 (1H, m, C(6)H2) and 1.83-1.62 
(2H, m, C(5)H2); 
13C NMR δC(100 MHz, CDCl3) 179.3– (C(=O)q), 148.9– (C(4’)q), 148.3– (C(3’)q), 134.3– (C(2)q), 133.6– 
(C(1’)q), 127.6+ (C(3)H), 117.6+ (C(6’)H), 111.1+ (C(5’)H), 109.2+ (C(2’)H), 55.9+ (OCH3), 55.8+ 
(OCH3), 42.8+ (C(1)H), 27.0– (C(6)H2), 25.5– (C(4)H2) and 19.4– (C(5)H2);  
MS (+ESI) m/z 285 (100 %, [M+Na]+) and 263 (44 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 263.1284, C15H19O4, requires [M+H]+ 263.1283. 
 
  




DPPA (366 μL, 1.7 mmol) was added dropwise to a rapidly stirred solution of 2-(3’,4’-
dimethoxyphenyl)cyclohex-2-ene-1-carboxylic acid 161 (445 mg, 1.7 mmol) and anhydrous Et3N 
(237 μL, 1.7 mmol) in anhydrous toluene (10 mL) at r.t. under Ar. The reaction was heated at 90 °C 
for 90 min after which the reaction was allowed to cool and was concentrated under reduced 
pressure. The oil was placed under Ar and BF3∙OEt2 (1.5 mL) was added and the reaction left stirring 
for 16 h at 50 °C. After cooling to r.t. the reaction was quenched with 2M NaOH(aq) to pH 10, diluted 
with EtOAc (5 mL) and left stirring at 50 °C for 4 h. After cooling to r.t. the organic layer was 
separated and the aqueous fraction washed with EtOAc (3 × 5 mL). The combined organic fractions 
were washed with sat. brine (10 mL), dried over Na2SO4, filtered and the solvent removed under 
pressure. After column chromatography [silica, PE: EtOAc: MeOH gradient column] the product 162 
(158 g, 36 %) was isolated as a white crystalline solid. 
Rf [EtOAc] 0.38;  
Mp [EtOAc] > 230 °C;  
IR max (Thin film) 3175 (NH), 2905 (CH) and 1659 (C=O);  
1H NMR δH(400 MHz, CDCl3) 7.56 (1H, s, C(7)H), 6.91 (1H, s, C(10)H), 6.16 (1H, s, C(1)H), 5.60 (1H, 
brs, NH), 4.36-4.38 (1H, m, C(4a)H), 3.95 (3H, s, OCH3), 3.94 (3H, s, OCH3), 2.35-2.41 (1H, m, C(2)H2), 
2.24-2.29 (1H, m, C(2)H2), 2.08-2.11 (1H, m, C(4)H2), 1.90-1.93 (1H, m, C(3)H2) and 1.63-1.75 (2H, 
m, C(3)H2 and C(4)H2); 
13C NMR δC(100 MHz, DMSO) 163.7– (C(6)q), 152.0– (C(9)q), 148.5– (C(8)q), 130.7– (C(10a or 10b)q), 
130.6– (C(10b or 10a)q), 123.8+ (C(1)H), 119.9– (C(6a)q), 109.1+ (C(7)H), 105.5+ (C(10)H), 55.7+ 
(C(9)OCH3), 55.4+ (C(8)OCH3), 50.3+ (C(4a)H), 29.2– (C(4)H2), 25.2– (C(2)H2) and 19.8– (C(3)H2); 
MS (+ESI) m/z 260 (100 %, [M+H]+) and 282 (33 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 260.1305, C15H18NO3, requires [M+H]+ 260.1281. 
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7-Hydroxy-8,9-dimethoxy-1,3,4,4a,5,10b-hexahydrophenanthridin-6(2H)-one (164) and 7-
hydroxy-8,9-dimethoxy-1,3,4,5-tetrahydrophenanthridin-6(2H)-one (165) 
 
Pd/C (10 % wt.) (24 mg) was added to a vigorously stirred solution of 7-hydroxy-8,9-dimethoxy-
3,4,4a,5-tetrahydrophenanthridin-6(2H)-one 155 (119 mg, 0.43 mmol) in EtOH (5 mL) under N2. The 
reaction was degassed and then placed under an atmosphere of H2 at r.t. for 3 h. Upon filtering the 
solvent was removed under reduced pressure and column chromatography [silica, CH2Cl2: Acetone 
gradient column] afforded 164 (64 mg, 54 %) and 165 (38 mg, 33 %) both as white crystalline solids. 
Lactam (164) 
Rf [EtOAc] 0.64;  
Mp > 230 °C;  
IR max (Thin film) 3430 (OH and NH) and 1649 (C=O); 
1H NMR δH(500 MHz, CDCl3, cis:trans, 59:41) 12.56 (1H, s, OH, trans), 12.47 (1H, s, OH, cis), 6.53 
(1H, brs, N(5)H, trans), 6.35 (1H, brs, N(5)H, cis), 6.32 (1H, s, C(10)H, trans), 6.24 (1H, s, C(10)H, cis), 
3.90 (3H, s, OCH3, trans), 3.88 (3H, s, OCH3, trans), 3.87 (6H, s, 2 × OCH3, cis), 3.87 (1H, m, C(4a)H, 
cis), 3.24 (1H, td, J 12.0 and 4.0 Hz, C(4a)H, trans), 2.68 (1H, m, C(10b)H, cis), 2.57 (1H, td, J 12.0 and 
4.0 Hz, C(10b)H, trans), 2.38 (1H, dd, J 12.5 and 2.5 Hz, C(1)H2, trans), 1.99-1.92 (2H, m, C(3)H2 and 
C(4)H2, trans), 1.88-1.83 (2H, m, C(3)H2 and C(4)H2, cis), 1.74-1.71 (1H, m, C(2)H2, trans), 1.69-1.65 
(1H, m, C(4)H2, cis), 1.62-1.55 (4H, m, C(1)H2 and C(2)H2, cis) and 1.54-1.51 (1H, m, C(4)H2, trans), 
1.44-1.35 (1H, m, C(3)H2, cis), 1.44-1.35 (2H, m, C(2)H2 and C(3)H2, trans) and 1.33-1.27 (1H, m, 
C(1)H2, trans); 
13C NMR δC(125 MHz, CDCl3, cis:trans, 59:41) 170.9– (C(6)q, cis), 170.2– (C(6)q, trans), 157.0– (C(8 or 
9)q, trans or cis), 156.9– (C(8 or 9)q, cis or trans), 155.9– (C(10a)q, trans or cis), 155.8– (C(10a)q, cis 
or trans), 140.7– (C(7)q, cis), 138.5– (C(7)q, trans), 135.1– (C(9 or 8)q, trans or cis), 134.9– (C(9 or 8)q, 
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trans or cis), 105.9– (C(6a)q, trans), 104.5– (C(6a)q, cis), 101.0+ (C(10)H, cis), 98.3+ (C(10)H, trans), 
60.6+ (2 × CH3, cis), 55.9+ (2 × CH3, trans), 55.6+ (C(4a)H, trans), 50.2+ (C(4a)H, cis), 41.5+ (C(10b)H, 
trans), 40.2+ (C(10b)H, cis), 32.0– (C(3 or 4)H2, trans), 29.8– (C(3 or 4)H2, cis), 29.4– (C(2)H2, cis), 
26.7– (C(1)H2, trans), 25.3– (C(4 or 3)H2, trans), 24.5– (C(2)H2, trans), 24.0– (C(4 or 3)H2, cis) and 
19.8– (C(1)H2, cis);  
MS (+ESI) m/z 577 (100 %, [2M+Na]+), 278 (78 %, [M+H]+) and 300 (34 %, [M+Na]+);  
HRMS (+ESI) Found [M+H]+ 278.1371, C15H20NO4, requires [M+H]+ 278.1392. Found [M+Na]+ 
300.1188, C15H19NNaO4, requires [M+Na]+ 300.1212. 
Lactam (165) 
Rf [EtOAc] 0.5;  
Mp [EtOAc] >230 °C;  
IR max (liquid film) 3400 (OH and NH), 2990 (CH) and 1649 (C=O);  
1H NMR δH(500 MHz, CDCl3) 13.00 (1H, s, OH), 10.85 (1H, brs, N(5)H), 6.43 (1H, s, C(10)H), 3.97 (3H, 
s, C(9)OCH3), 3.94 (3H, s, C(8)OCH3), 2.64 (2H, brt, J 5.5 Hz, C(4)H2), 2.59 (2H, brt, J 5.5 Hz, C(1)H2) 
and 1.87 (4H, m, C(2)H2 and C(3)H2);  
13C NMR δC(125 MHz, CDCl3) 165.7– (C(6)q), 158.3– (C(9)q), 154.5– (C(7)q), 136.0– (C(10a)q), 134.5– 
(C(4a)q), 133.8– (C(8)q), 111.3– (C(10b)q), 106.0– (C(6a)q), 93.7+ (C(10)H), 60.7+ (C(8)OCH3), 55.8+ 
(C(9)OCH3), 27.0– (C(4)H2), 23.4– (C(1)H2), 22.4– (C(2 or 3)H2) and 21.8– (C(3 or 2)H2);  
MS (+ESI) m/z 573 (100 %, [2M+Na]+), 276 (85 %, [M+H]+) and 298 (66 %, [M+Na]+);  
HRMS (+ESI) Found [M+H]+ 276.1200, C15H18NO4, requires [M+H]+ 276.1236. Found [M+Na]+ 
298.1026, C15H17NNaO4, requires [M+Na]+ 298.1055. 
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8,9-Dimethoxy-1,3,4,4a,5,10b-hexahydrophenanthridin-6(2H)-one (169) and 8,9-dimethoxy-
1,3,4,5-tetrahydrophenanthridin-6(2H)-one (163) 
 
Pd/C (10 % wt.) (27 mg) was added to a vigorously stirred solution of 8,9-dimethoxy-3,4,4a,5-
tetrahydrophenanthridin-6(2H)-one 162 (135 mg, 0.52 mmol) in MeOH (10 mL) under N2. The 
reaction was degassed and then placed under an atmosphere of H2 at r.t. for 4 h. Upon filtering the 
solvent was removed under reduced pressure and column chromatography [silica, CH2Cl2: Acetone 
gradient column] afforded lactam 169 (87 mg, 64 %) and lactam 163 (31 mg, 23 %) both as white 
crystalline solids. 
Lactam (169) 
Rf [EtOAc] 0.45;  
Mp [MeOH] > 230 °C;  
1H NMR δH(400 MHz, CDCl3, cis:trans, 58:42) 7.59 (1H, s, CH, trans), 7.56 (1H, s, CH, cis), 6.75 (1H, 
s, CH, trans), 6.65 (1H, s, CH, cis), 5.74 (1H, brs, NH, trans), 5.49 (1H, brs, NH, cis), 3.92 (6H, s, OCH3, 
trans), 3.92 (6H, s, OCH3, cis), 3.92 (1H, brs, CH, cis), 3.26 (1H, td, J 12.0 and 4.0 Hz, CH, trans), 2.69 
(1H, brs, CH, cis), 2.66 (1H, td, J 12.0 and 4.0 Hz, CH, trans), 2.40 (1H, dd, J 12.0 and 2.5 Hz, CH2, 
trans) and 1.95-1.29 (15H, m, CH2 trans and cis); 
13C NMR δC(100 MHz, CDCl3, cis:trans, 58:42) 152.3 (Cq), 152.2 (Cq), 147.9 (Cq), 147.7 (Cq), 136.0 
(Cq),110.4 (CH, trans), 110.2 (CH, cis), 108.9 (CH, cis), 106.0 (CH, trans), 56.1 (2 x OCH3, trans or B), 
56.0 (2 x OCH3, cis or A), 55.9 (CH, trans), 50.2 (CH, cis), 41.7 (CH, trans), 40.0 (CH, cis), 32.1 (CH2, 
trans), 30.3 (2 x CH2, cis), 29.2 (2 x CH2, cis), 27.0 (CH2, trans), 25.4 (CH2, trans) and 24.1 (CH2, trans); 
MS (+ESI) m/z 545 (100 %, [2M+Na]+), 284 (50 %, [M+Na]+) and 262 (44 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 262.1425, C15H20NO3, requires [M+H]+ 262.1443. Found [M+Na]+ 
284.1245, C15H19NNaO3, requires [M+Na]+ 284.1263. 
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Lactam (163)  
Rf [EtOAc] 0.25;  
Mp [EtOAc] > 230 °C;  
IR max (Thin film) 3735 (NH), 2918 (CH), 1637 (C=O) and 1609 (C=C);  
1H NMR δH(500 MHz, CDCl3) 10.07 (1H, brs, N(5)H), 7.79 (1H, s, CH), 6.92 (1H, s, CH), 4.01 (3H, s, 
OCH3), 4.00 (3H, s, OCH3), 2.66 (4H, brs, CH2) and 1.88 (4H, brs, CH2);  
13C NMR δC(125 MHz, CDCl3) 162.6– (C(6)q), 153.5– (C(9)q), 148.2– (C(8)q), 134.1– (C(4a)q), 133.8– 
(C(10a)q), 118.6– (C(6a)q), 109.3– (C(10b)q), 107.5+ (C(10)H), 102.3+ (C(7)H), 56.1+ (C(9)OCH3), 55.9+ 
(C(8)OCH3), 27.3– (C(1)H2), 23.3– (C(4)H2), 22.6– (C(2 or 3)H2) and 22.0– (C(3 or 2)H2); 
MS (+ESI) m/z 260 (100 %, [M+H]+) and 282 (9 %, [M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 260.1324, C15H18NO3, requires [M+H]+ 260.1281. 
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1,3,4,4a,5,11b-Hexahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one (103)  
 
Pd/C (10 % wt.) (17 mg) was added to a vigorously rapidly stirred solution of 3,4,4a,5-
tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one 148 (73 mg, 0.30 mmol) in MeOH (6 mL) 
under N2. The reaction was degassed and then placed under an atmosphere of H2 at r.t. for 4 h. 
Upon filtering the solvent was removed under reduced pressure and column chromatography 
[silica, CH2Cl2: Acetone gradient column] afforded lactam 103 (34 mg, 47 %).  
Lactam (103) 
Rf [EtOAc] 0.54;  
Mp [EtOAc] > 230 °C;  
IR max (Thin film) 3402 (NH), 2987 (CH) and 1664 (C=O);  
1H NMR δH(400 MHz, CDCl3, cis:trans, 54:56) 7.52 (1H, s, C(7)H, trans), 7.51 (1H, s, C(7)H, cis), 6.75 
(1H, s, C(10)H, trans), 6.62 (1H, s, C(10)H, cis), 5.99-5.98 (3H, m, OCH2O and NH, trans), 5.99-5.98 
(2H, m, OCH2O, cis), 5.72 (1H, brs, NH, cis), 3.87 (1H, brd, J 3.0 Hz, C(4a)H, cis), 3.22 (1H, td, J 11.5 
and 3.5 Hz, C(4a)H, trans), 2.67 (1H, brs, C(10b)H, cis), 2.60 (1H, td, J 11.5 and 3.5 Hz, C(10b)H, 
trans), 2.32 (1H, brdd, J 7.5 and 3.5 Hz, C(1)H2, trans), 1.95-1.91 (3H, m, C(3)H2 and C(4)H2 trans), 
1.87-1.81 (1H, m, CH2, trans), 1.78-1.64 (4H, m, 2 x CH2, cis), 1.62-1.53 (4H, m, 2 x CH2, cis) and 1.48-
1.27 (3H, m, C(1)H2 and C(2)H2, trans); 
13C NMR δC(100 MHz, CDCl3, cis:trans, 54:46) 166.2+ (C(6)q, cis), 165.6+ (C(6)q, trans), 151.1+ (C(9)q, 
trans), 150.9+ (C(9)q, cis), 146.7+ (C(8)q, cis), 146.4+ (C(8)q, trans), 140.0+ (C(6a)q, cis), 138.1+ (C(6a)q, 
trans), 123.3+ (C(10a)q, trans), 121.7+ (C(10a)q, cis), 108.1– (C(7)H, trans), 107.9– (C(7)H, cis), 106.6– 
(C(10)H, cis), 103.9– (C(10)H, trans), 101.5+ (OCH2O, trans or cis), 101.4+ (OCH2O, cis or trans), 55.7– 
(C(4a)H, trans), 50.0– (C(4a)H, cis), 41.9– (C(10b)H, trans), 40.3– (C(10b)H, cis), 32.0+ (C(4 or 3)H2, 
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trans), 30.1+ (CH2, cis), 29.9+ (CH2, cis), 29.1+ (CH2, cis), 27.0+ (C(1)H2, trans), 25.3+ (C(3 or 4)H2, 
trans), 24.0+ (C(2)H2, trans) and 19.8+ (CH2, cis); 
MS (+ESI) m/z 246 (39 %, [M+H]+) and 268 (8.4 %, [2M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 246.1128, C14H16NO3, requires [M+H]+ 246.1130. Found [M+Na]+ 
268.0939, C14H15NNaO3, requires [M+Na]+ 268.0949. 
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Ethyl 1-(benzo[d][1,3]dioxol-5-yl)-5-oxo-7-oxabicyclo[4.1.0] heptane-2-carboxylate (171) 
 
NaOH(aq) (240 μL, 10 %) and H2O2(aq) (480 μL, 36 %) was added to a rapidly stirred solution of cyclic 
ketone in EtOH at r.t.. After 20 h stirring the EtOH was removed under reduced pressure and the 
reaction mixture diluted with water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined 
organic fractions were washed with sat. brine (10 mL), dried over Na2SO4 and filtered. After column 
chromatography [silica, PE: EtOAc gradient column] the epoxide product 171 (56 g, 21 %) was 
isolated as a yellow oil. 
Rf [EtOAc] 0.67;  
IR max (Thin film) 1718 (C=O), 1173 (C-O) and 1109 (C-O);  
1H NMR δH(500 MHz, CDCl3) ) 6.83 (1H, dd, J 1.5 and 8.0 Hz, C(6’)H), 6.82 (1H, d, J 1.5 Hz, C(2’)H), 
6.76 (1H, d, J 8.0 Hz, C(5’)H), 5.96 (2H, s, OCH2O), 4.17-4.12 (2H, m, OCH2CH3), 3.59 (1H, s, C(6)H), 
3.49-3.47 (1H, m, C(2)H), 2.50-2.44 (2H, m, C(3)HaHb and C(4)HaHb), 2.37-2.32 (1H, m, C(4) HaHb), 
1.95-1.90 (1H, m, C(3) HaHb) and 1.20 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR (125 MHz, CDCl3) 203.8– (Cq), 171.9– (Cq), 148.0– (Cq), 147.9– (Cq), 130.5– (Cq), 120.7+ 
(C(6’)H), 108.3+ (C(5’)H), 107.2+ (C(2’)H), 101.3– (OCH2O), 62.9+ (C(6)H), 61.4– (OCH2), 44.7+ 
(C(2)H), 32.2– (C(4)H2), 20.4– (C(3)H2) and 14.0+ (CH3);  
MS (+ESI) m/z 631 (100 %, [2M+Na]+), 327 (57 %, [M+Na]+) and 305 (16 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 305.1010, C16H17O6, requires [M+H]+ 305.1025. Found [M+Na]+ 
327.0874, C16H16NaO6, requires [M+Na]+ 327.0845. 
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3',4',5'-Trimethoxy-[1,1'-biphenyl]-2-carboxylic acid (194) 
 
Acetic acid (0.3 mL) was added dropwise to a rapidly stirred mixture of 5-iodo-1,2,3-
trimethoxybenzene (882 mg, 3 mmol), benzoic acid (122 mg, 1 mmol), Pd(OAc)2 (38 mg, 5 mol %) 
and AgOAc (228 mg, 1.3 mmol) in a 2 dram vial. The sealed vial was then stirred at 130 °C for 24 h. 
Upon cooling to room temperature the solution was transferred to a round bottom flask with CH2Cl2 
and the solvent removed under reduced pressure. The reaction was then re-suspended in KOH(aq) 
(15 mL, 5 %) and extracted with CH2Cl2 (3 x 20 mL). The aqueous layer was then acidified to pH 2 
with 6M HCl(aq) and extracted with EtOAc (3 x 20 mL). The combined EtOAc was dried over Na2SO4, 
filtered and the solvent removed under pressure. Column chromatography [silica, PE: EtOAc 
gradient column] afforded the product 194 as an off-white solid (35 mg, 12 %). 
Mp [EtOAc] 138-140 °C [Lit.,192 136-137 °C];  
1H NMR δH(500 MHz, CDCl3) 7.91 (1H, dd, J 8.0 and 1.0 Hz, C(6)H), 7.56 (1H, dt, J 7.5 and 1.5 Hz, 
C(4)H), 7.43 (1H, dt, J 7.5 and 1.5 Hz, C(5)H), 7.39 (1H, dd, J 8.0 and 1.0 Hz, C(3)H), 6.56 (2H, s, C(2’)H) 
and C(6’)H), 3.89 (3H, s, OCH3) and 3.85 (6H, s, OCH3);  
13C NMR δC(125 MHz, CDCl3) 172.5– (Cq), 152.9– (2 x Cq), 142.9– (Cq), 137.5– (Cq), 136.5– (Cq), 131.9+ 
(C(4 or 5)H), 130.9+ (C(3 or 6)H), 130.4+ (C(6 or 3)H), 129.5– (Cq), 127.3+ (C(5 or 4)H), 105.8+ (C(2’)H 
and C(6’)H), 60.9+ (OCH3) and 56.1+ (2 x OCH3); 
MS (+ESI) m/z 599 (100 %, [2M+Na]+), 311 (26 %, [M+Na]+) and 289 (20 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 289.1070, C16H17O5, requires [M+H]+ 289.1076. Found [M+Na]+ 
311.0902, C16H16NaO5, requires [M+Na]+ 311.0895. 
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6.5. Synthesis of N ABC-ring analogues 
3,4,4a,5-Tetrahydro-6H-pyrido[1,2-a]quinazolin-6-one (198) 
 
Glutaraldehyde (50 % wt. in water) (1.9 mL, 10 mmol) was added dropwise to a stirred solution of 
anthranilamide 196 (1.36 g, 10 mmol) and MgSO4 (3.00 g, 25 mmol) in THF (30 mL) at r.t. under N2. 
NH4Cl (266 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc (150 mL) was 
added and the THF removed under reduced pressure. After filtering the solvent was removed under 
reduced pressure to give the enamine 198 (2.00 g, 100 %) as a light yellow solid in quantitative yield 
without further purification. 
Rf [EtOAc] 0.44;  
Mp [EtOAc] Sublimes 120 °C, melts 150 °C;  
IR max (KBr disc) 3415 (NH), 1680 (C=O) and 1650 (C=C);  
1H NMR δH(500 MHz, CDCl3) 7.98 (1H, dd, J 8.0 and 1.5 Hz, C(7)H), 7.40 (1H, dt, J 1.5 and 7.0 Hz, 
C(9)H), 6.93 (1H, t, J 8.0 Hz, C(8)H), 6.91 (1H, d, J 8.0 Hz, C(10)H), 6.60 (1H, dd, J 8.0 and 2.5 Hz, 
C(1)H), 6.13 (1H, brs, NH), 5.04 (1H, dd, J 10.0 and 4.0 Hz, C(4a)H), 4.94 (1H, brt, J 6.0 and 2.5 Hz, 
C(2)H), 2.31-2.28 (1H, m, C(3)H2) and 2.20-2.10 (3H, m, C(3)H2 and C(4)H2);  
13C NMR δC(125 MHz, CDCl3) 164.4– (C(6)q), 144.2– (C(10a)q), 134.0+ (C(9)H), 129.2+ (C(7)H), 124.6+ 
(C(1)H), 119.8+ (C(8)H), 116.9– (C(6a)q), 111.9+ (C(10)H), 103.1+ (C(2)H), 64.7+ (C(4a)H), 28.8– 
(C(4)H2) and 19.4– (C(3)H2);  
MS (+ESI) m/z 201 (100 %, [M+H]+), 423 (97 %, [2M+Na]+), 455 (88 %, [2M+Na]++MeOH) and 223 
(74 %, [M+Na]+); 
HRMS (+ESI) m/z Found [M+H]+ 201.1041, C12H13N2O, requires [M+H]+ 201.1028. Found [M+Na]+ 
223.0844, C12H12N2NaO, requires [M+Na]+ 223.0847. 
 




A solution of sodium periodate(aq) (NaIO4) (10 %, 10 mL) was mixed with RuCl3·×H2O (10 mg, 0.04 
mmol) and then added dropwise to a stirred solution of 4a,5-dihydro-3H-pyrido[1,2-a]quinazolin-
6(4H)-one 196 (200 mg, 1 mmol) in EtOAc (20 mL) at r.t.. After 150 min stirring the layers were 
separated and the aqueous layer extracted with EtOAc (3 × 20 mL). iPrOH (8 mL) was added to the 
combined organic fractions and stirred for 4 h. After filtering the black precipitate the reaction was 
washed with water (10 mL), sat. brine (10 mL), dried over Na2SO4 and filtered. Column 
chromatography [silica, CH2Cl2: Acetone gradient column] afforded the product 216 (53 mg, 26 %) 
as a white crystalline solid. 
Rf [EtOAc] 0.19;  
Mp [EtOAc] 148-154 °C;  
IR max (Thin film) 3580 (NH), 2963 (CH), 1670 (C=O) and 1632 (C=O);  
1H NMR δH(500 MHz, CDCl3) 8.25 (1H, dd, J 8.0 and 1.5 Hz, C(6)H), 7.75 (1H, ddd, J 8.5, 7.5 and 1.5 
Hz, C(8)H), 7.66 (1H, d, J 8.0 Hz, C(9)H), 7.45 (1H, ddd, J 8.5 and 1.0 Hz, C(7)H), 6.31 (1H, dd, J 6.5 
and 2.5 Hz, C(3a)H), 5.00 (1H, brs, N(4)H), 3.36 (1H, ddd, J 17.5, 9.5 and 8.0 Hz, C(2)H2), 3.05 (1H, 
ddd, J 18.0, 9.5 and 4.5 Hz, C(2)H2), 2.51 (1H, C(3)H2) and 2.23 (1H, dddd, J 12.5, 9.5, 4.5 and 3.0 Hz, 
C(3)H2);  
13C NMR δC(125 MHz, CDCl3) 161.7– (C(5)q), 158.4– (C(1)q), 149.6– (C(9a)q), 134.7+ (C(8)H), 127.0+ 
(C(9)H), 126.4+ (C(7)H), 126.4+ (C(6)H), 120.6– (C(5a)q), 83.1+ (C(3a)H), 29.8– (C(2)H2) and 27.6– 
(C(3)H2);  
MS (+ESI) m/z 225 (100 %, [M+Na]+), 203 (15 %, [M+H]+) and 427 (10 %, [2M+Na]+);  
HRMS (+ESI) Found [M+H]+ 203.0818, C11H11N2O2, requires [M+H]+ 203.0821. Found [M+Na]+ 
225.0666, C11H10N2NaO2, requires [M+Na]+ 225.0640. 
- 180 - 
 
General Procedure 4: 
1,1’-Carbonyldiimidazole (CDI) (324 mg, 2 mmol) was added to a stirred solution of benzoic acid (2 
mmol) in MeCN (10 mL) at r.t. under N2. The reaction was heated to 80 °C for 120 min then cooled 
to r.t. and NH3(aq) (35 %, 1 mL) was added. The reaction was stirred at r.t. for 18 h after which MeCN 
was removed under reduced pressure and 1 M NaOH(aq) (10 mL) added. The reaction was extracted 
with EtOAc (3 × 10 mL). The combined organic layers were washed with water (10 mL) followed by 
0.5 M FeSO4(aq) (2 × 10 mL) then sat. brine (10 mL), dried over Na2SO4, filtered and concentrated 
under reduced pressure to afford the product without the need for further purification. 
2-Amino-4,5-dimethoxybenzamide (219) 
 
Following the general procedure 4 using CDI (324 mg, 2 mmol) and 2-amino-4,5-dimethoxybenzoic 
acid (394 mg, 2 mmol) in MeCN (10 mL) followed by NH3(aq) (35 %, 1 mL) to give the benzamide 219 
(168 mg, 43 %) without further purification. 
Rf [EtOAc] 0.23;  
Mp [EtOAc] 139-142 °C [Lit.,193 138-140 °C];  
1H NMR δH(400 MHz, DMSO) 7.56 (1H, brs, CONH2), 7.11 (1H, s, C(6)H), 6.83 (1H, s, CONH2), 6.43 
(2H, brs, NH2), 6.28 (1H, s, C(3)H), 3.70 (3H, s, C(4)OCH3) and 3.66 (3H, s, C(5)OCH3);  
13C NMR δC(100 MHz, DMSO) 170.9– (C(=O)q), 153.0– (C(4)q), 146.8– (C(2)q), 138.9– (C(5)q), 113.0+ 
(C(6)H), 104.3– (C(1)q), 99.5+ (C(3)H), 56.6+ (C(5)OCH3) and 55.1+ (C(4)OCH3). 
Spectroscopic data is consistent with that reported by Stroganova et al. and Kanışkan et al.194,195  
 
  




Following the general procedure 4 using CDI (1.62 g, 10 mmol) and 2-amino-3-methylbenzoic acid 
(1.51 g, 10 mmol) in MeCN (50 mL) followed by NH3(aq) (35 %, 5 mL) to give the benzamide 233 (1.07 
mg, 71 %) without further purification. 
Rf [EtOAc] 0.41;  
Mp [EtOAc] 148-150 °C;  
1H NMR δH(400 MHz, DMSO) 7.72 (1H, brs, CONH2), 7.41 (1H, dd, J 8.0 and 1.0 Hz, C(4)H), 7.06 (2H, 
d, J 7.0 Hz, C(6)H and CONH2), 6.44 (1H, t, J 7.5 Hz, C(5)H), 6.39 (2H, brs, C(2)NH2) and 2.06 (3H, s, 
CH3);  
13C NMR δC(100 MHz, DMSO) 172.5– (C(=O)q), 149.0– (C(2)q), 133.4+ (C(4)H), 127.4+ (C(6)H), 123.8– 
(C(3)q), 114.9+ (C(5)H), 114.3– (C(1)q) and 18.4+ (CH3); 
MS (+ESI) m/z 173 (100 %, [M+Na]+) and 306 (16 %, [2M+Na]+ –NH3);  
HRMS (+ESI) m/z Found [M+Na]+ 173.0703, C8H10N2NaO, requires [M+Na]+ 173.0691. 
Spectroscopic data is consistent with that reported by Nathubhai et al.196 




Following the general procedure 4 using CDI (1.59 g, 9.8 mmol) and 2-amino-4-methylbenzoic acid 
(1.48 g, 9.8 mmol) in MeCN (50 mL) followed by NH3(aq) (35 %, 10 mL) to give the benzamide 234 
(993 mg, 67 %) without further purification. 
Rf [PE:EtOAc, 20:80] 0.41;  
Mp [EtOAc] 149-150 °C [Lit.,197 148 °C];  
1H NMR δH(400 MHz, DMSO) 7.41 (1H, brs, CONH2), 7.39 (1H, d, J 8.0 Hz, C(6)H), 6.92 (1H, brs, 
CONH2), 6.49 (2H, brs, NH2), 6.43 (1H, d, J 0.5 Hz, C(3)H), 6.26 (1H, ddd, J 8.0, 1.5 and 0.5 Hz, C(5)H) 
and 2.12 (3H, s, CH3);  
13C NMR δC(100 MHz, DMSO) 171.8– (C(=O)q), 150.9– (Cq), 142.1– (Cq), 129.3+ C(5)H), 117.0+ 
(C(6)H), 116.2+ (C(3)H), 111.6– (Cq) and 21.6+ (CH3);  
MS (+ESI) m/z 173 (100 %, [M+Na]+); 
HRMS (+ESI) m/z Found [M+Na]+ 173.0731, C8H10N2NaO, requires [M+Na]+ 173.0691. 
Spectroscopic data is consistent with that reported by Zhao et al.197 
  




Following the general procedure 4 using CDI (324 mg, 2.0 mmol) and 2-amino-5-methylbenzoic acid 
(303 mg, 2.0 mmol) in MeCN (10 mL) followed by NH3(aq) (35 %, 1 mL) to give the benzamide 235 
(184 mg, 61 %) without further purification. 
Rf [PE:EtOAc, 50:50] 0.40; 
Mp [EtOAc] 179-180 °C [Lit.,198 175-177 °C];  
1H NMR δH(400 MHz, DMSO) 7.72 (1H, brs, CONH2), 7.40 (1H, d, J 1.0 Hz, C(6)H), 7.05 (1H, brs, 
CONH2), 7.01 (1H, ddd, J 8.5, 2.0 and 0.5 Hz, C(4)NH2), 6.44 (1H, d, J 8.5 Hz, C(3)H), 6.38 (2H, brs, 
NH2) and 2.20 (3H, s, CH3);  
13C NMR δC(100 MHz, DMSO) 171.3– (C(=O)q), 147.9– (Cq), 132.7+ (C(4)H), 128.7+ C(6)H), 122.7– 
(Cq), 116.5+ (C(3)H), 113.7– (Cq) and 20.0+ (CH3);  
MS (+ESI) m/z 173 (100 %, [M+Na]+); 
HRMS (+ESI) m/z Found [M+Na]+ 173.0712, C8H10N2NaO, requires 173.0691 [M+Na]+. 
  




HCl(aq) (6 M, 0.5 mL) was added dropwise to a vigorously stirred solution of trimethoxyaniline 237 
(183 mg, 1 mmol) in diethyl ether (3 mL) r.t. until a precipitate was observed. The reaction was 
filtered and the solid washed with diethyl ether (2 x 5 mL) to give the HCl salt 251 (130 mg, 59 %) 
as a grey crystalline solid which was used without further purification. 
3,4,5-Trimethoxyaniline hydrochloride (58 mg, 0.26 mmol) was stirred in oxalyl chloride (150 μL) at 
160 °C in a sealed thick-walled pressure tube for 50 min. Upon cooling to r.t. MeOH was added and 
the reaction heated at reflux for 10 min. The solvent was removed under reduced pressure and 
column chromatography [silica, PE: EtOAc gradient column] afforded the product 252 (38 mg, 62 
%) as a red-brown crystalline solid. 
Salt (251) 
Mp [Et2O] 258 °C [Lit.,172 256 °C]  
Istatin (252) 
1H NMR δH(400 MHz, CDCl3) 7.72 (1H, brs, NH), 6.14 (1H, s, CH), 4.22 (3H, s, CH3), 3.96 (3H, s, CH3) 
and 3.77 (3H, s, CH3);  
13C NMR δC(100 MHz, DMSO) 178.6– (C(=O)q), 162.4– (C(=O)q), 160.4– (Cq), 152.8– (Cq), 148.9– (Cq), 
135.3– (Cq), 102.6+ (CH), 91.7– (Cq), 61.5+ (CH3), 60.9+ (CH3) and 56.7+ (CH3).  
Spectroscopic data is consistent with that reported by Mason et al.199 
  




Glutaraldehyde (50 % wt. in water) (190 μL, 1 mmol) was added dropwise to a stirred solution of 2-
amino-3-methylbenzamide 233 (150 mg, 1 mmol) and MgSO4 (300 mg, 2.5 mmol) in THF (3 mL) at 
r.t. under N2. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc (10 
mL) was added and the THF removed under reduced pressure. After filtering the solvent was 
removed under reduced pressure to give the crude enamine 285 which was used without further 
purification. 
1H NMR δH(400 MHz, CDCl3) 7.83 (1H, d, J 7.5 Hz, C(7)H), 7.30 (1H, dd, J 8.5 and 2.5 Hz, C(1)H), 7.18 
(1H, dd, J 7.5 and 1.0 Hz, C(9)H), 6.80 (1H, t, J 7.5 Hz, C(8)H), 5.16-5.12 (1H, m, C(2)H), 5.03-5.00 
(1H, m, C(4a)H), 2.23-2.19 (2H, m, C(3)H2), 2.17 (3H, s, CH3) and 2.16-2.10 (2H, m, C(4)H2); 
13C NMR δC(100 MHz, CDCl3) 160.5– (C(6)q), 144.7– (Cq), 134.4+ (C(9)H), 126.9+ (C(7)H), 122.4+ 
(C(1)H), 121.7– (Cq), 119.2+ (C(8)H), 116.1– (Cq), 107.6+ (C(2)H), 65.5+ (C(4a)H), 29.0– (CH2), 20.0– 
(CH2) and 16.3+ (CH3).  
 
  




Glutaraldehyde (50 % wt. in water) (190 μL, 1.0 mmol) was added dropwise to a stirred solution of 
2-amino-4-methylbenzamide 234 (150 mg, 1.0 mmol) and MgSO4 (360 mg, 3.0 mmol) in THF (5 mL) 
at r.t. under N2. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc 
(15 mL) was added and the THF removed under reduced pressure. After filtering the solvent was 
removed under reduced pressure to give the crude enamine 286 which was used without further 
purification. 
1H NMR δH(400 MHz, CDCl3) 7.85 (1H, d, J 8.0 Hz, C(7)H), 6.73 (1H, d, J 8.0 Hz, C(8)H), 6.71 (1H, s, 
C(10)H), 6.59 (1H, dd, J 8.0 and 2.5 Hz, C(1)H), 6.47 (1H, brs, NH), 5.00 (1H, dd, J 10.0 and 4.0 Hz, 
C(4a)H), 4.89-4.94 (1H, m, C(2)H), 2.34 (3H, s, CH3) and 2.06-2.17 (4H, m, C(3)H2 and C(4)H3);  
13C NMR δC(100 MHz, CDCl3) 165.8+ (C(6)q), 144.8+ (C(6a or 10a)q), 144.2+ (C(10a or 6a)q), 129.0– 
(C(7)H), 124.5– (C(1)H), 120.9– (C(8)H), 114.4+ (C(9)q), 112.2– (C(10)H), 102.9– (C(2)H), 64.7– 
(C(4a)H), 28.7+ (C(4)H2), 22.1– (CH3) and 19.3+ (C(3)H2);  
HRMS (+ESI) m/z Found [M+Na]+ 237.1044, C13H14NaN2O, requires [M+Na]+ 237.1004. 
 
  




Glutaraldehyde (50 % wt. in water) (190 μL, 1 mmol) was added dropwise to a stirred solution of 2-
amino-5-methylbenzamide 235 (150 mg, 1 mmol) and MgSO4 (300 mg, 2.5 mmol) in THF (3 mL) at 
r.t. under N2. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc (10 
mL) was added and the THF removed under reduced pressure. After filtering the solvent was 
removed under reduced pressure to give the crude enamine 287 which was used without further 
purification. 
1H NMR δH(400 MHz, CDCl3) 7.76 (1H, dd, J 0.5 and 1.5 Hz, C(7)H), 7.20 (1H, ddd J 0.5, 2.5 and 8.5 
Hz, CH), 6.80 (1H, d, J 8.5 Hz, CH), 6.55 (1H, dd, J 2.5 and 8.0 Hz, C(1)H), 4.99 (1H, dd, J 3.5 and 10.0 
Hz, CH), 4.90-4.86 (1H, m, CH) and 2.28-2.13 (7H, s, CH3 and m, 2 x CH2). 
  




A flask containing a vigorously stirring suspension of 4a,5-dihydro-3H-pyrido[1,2-a]quinazolin-
6(4H)-one 198 (200 mg, 1 mmol) and Pd/C (10 % wt.) (40 mg) in EtOH (10 mL) at r.t. was purged 
with N2. The flask was degassed and H2 introduced at atmospheric pressure. Vigorous stirring was 
continued at r.t. for 16 h. Upon filtering through a pad of celite the solvent was removed under 
reduced pressure and column chromatography [silica, PE: EtOAc gradient column] afforded the 
product 254 (137 mg, 68 %) as a white solid. 
Rf [EtOAc] 0.67;  
Mp [MeOH] 170-172 °C [Lit.,200 184-186 °C];  
IR max (Thin film) 3413 (NH), 1672 (C=O) and 1607 (C=C);  
1H NMR δH(500 MHz, CDCl3) 7.95 (1H, dd, J 7.5 and 1.5 Hz, C(7)H), 7.39 (2H, dt, J 7.0 and 1.5 Hz, 
C(9)H), 7.09 (1H, brs, NH), 6.90 (1H, t, J 7.5 Hz, C(8)H), 6.82 (1H, d, J 8.5 Hz, C(10)H), 4.46 (1H, dd, J 
10.5 and 3.0 Hz, C(4a)H), 3.74 (1H, brd, J 12.0 Hz, C(1)H2), 2.62 (1H, dt, J 12.5 and 3.0 Hz, C(1)H2), 
2.00-1.98 (1H, m, C(4)H2), 1.89-1.78 (3H, m, C(2)H2, C(3)H2 and C(4)H2), 1.69 (1H, qt, J 12.5 and 4.0 
Hz, C(2)H2) and 1.46 (1H, qt, J 13.0 and 3.5 Hz, C(3)H2);  
13C NMR δC(125 MHz, CDCl3) 164.7– (C(6)q), 149.7– (C(10a)q), 133.9+ (C(9)H), 128.7+ (C(7)H), 119.2+ 
(C(8)H), 117.7– (C(6a)q), 112.3+ (C(10)H), 68.2+ (C(4a)H), 45.5– (C(1)H2), 31.8– (C(4)H2), 24.2– 
(C(2)H2) and 21.9– (C(3)H2);  
MS (+ESI) m/z 427 (100 %, [2M+Na]+), 225 (58 %, [M+Na]+) and 203 (32 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 203.1196, C12H15N2O, requires [M+H]+ 203.1184. Found [M+Na]+ 
225.1035, C12H14N2NaO, requires [M+Na]+ 225.1004. 
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1,2,3,4,4a,5-Hexahydro-6H-pyrido[1,2-a]quinazolin-6-one (254) and 1-ethoxy-1,2,3,4,4a,5-
hexahydro-6H-pyrido[1,2-a]quinazolin-6-one (202) 
 
A flask containing a vigorously stirring suspension of 4a,5-dihydro-3H-pyrido[1,2-a]quinazolin-
6(4H)-one 196 (1.00 g, 5 mmol) and Pd/C (10 % wt.) (200 mg) in EtOH (25 mL) at r.t. was purged 
with N2. The flask was degassed and H2 introduced at atmospheric pressure. Vigorous stirring was 
continued at r.t. for 16 h. Upon the removal of H2 the reaction was heated to reflux for 2 h after 
which it was filtered through celite and further washed with hot EtOH until the crude mass was 
constant. The solvent was removed under reduced pressure and column chromatography [silica, 
PE: EtOAc gradient column] afforded the ethanol adduct 202 (77 mg, 6 %) as a yellow amorphous 
solid and product 254 (392 mg, 39 %) white crystalline solid. 
Ethanol Adduct (202)  
Rf [EtOAc] 0.76;  
IR max (KBr disc) 3420 (NH);  
1H NMR δH(400 MHz, CDCl3) 7.87 (1H, dd, J 7.5 and 1.5 Hz, C(7)H), 7.24 (1H, ddd, J 8.0, 7.0 and 1.5 
Hz, C(9)H), 6.77 (1H, ddd, J 8.0, 7.5 and 1.0 Hz, C(8)H), 6.53 (1H, dd, J 8.0 and 1.0 Hz, C(10)H), 6.01 
(1H, t, J 3.0 Hz, C(1)H), 5.11-5.09 (1H, m, C(4a)H), 4.09 (1H, brs, NH), 3.56-5.52 (2H, m, OCH2CH3), 
2.02-1.88 (2H, m, C(2)H2 and C(3)H2), 1.87-1.76 (2H, m, C(4)H2), 1.69-1.61 (2H, m, C(2)H2 and C(3)H2) 
and 1.18 (3H, t, J 7.0 Hz, OCH2CH3);  
13C NMR δC(100 MHz, CDCl3) 163.5– (C(6)q), 145.8– (C(10a)q), 133.7+ (C(9)H), 128.9+ (C(7)H), 118.5+ 
(C(8)H), 114.8– (C(6a)q), 113.6+ (C(10)H), 78.6+ (C(1)H), 64.0+ (C(4a)H), 63.4– (OCH2CH3), 33.5– 
(C(4)H2), 29.2– (C(2 or 3)H2), 17.1– (C(3 or 2)H2) and 15.2+ (OCH2CH3); 
MS (+ESI) m/z 515 (100 %, [2M+Na]+), 269 (52 %, [M+Na]+) and 201 (39 %, [M+H]+–EtOH);  
HRMS (+ESI) m/z Found [M+Na]+ 269.1294, C14H18N2NaO2, requires [M+Na]+ 269.1266. 
Analogue (254) 
Spectroscopic data are consistent with those previously reported for analogue 254.  
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1-Ethoxy-9-methyl-1,2,3,4,4a,5-hexahydro-6H-pyrido[1,2-a]quinazolin-6-one (256) and 9-
methyl-1,2,3,4,4a,5-hexahydro-6H-pyrido[1,2-a]quinazolin-6-one (257) 
 
Glutaraldehyde (50 % wt. in water) (190 µL, 1 mmol) was added dropwise to a stirred solution of 2-
amino-4-methylbenzamide 234 (150 mg, 1 mmol) and MgSO4 (480 mg, 4 mmol) in THF (5 mL) at r.t. 
under N2. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc (15 mL) 
was added and the THF removed under reduced pressure. After filtering the solvent was removed 
under reduced pressure to afford the crude enamine 286 without further purification. 
A vigorously stirred suspension of crude 9-methyl-3,4,4a,5-tetrahydro-6H-pyrido[1,2-a]quinazolin-
6-one 286 (214 mg, 1 mmol) in EtOH (20 mL) at r.t. was purged with N2 and Pd/C (10 % wt.) (100 
mg) was added. The flask was degassed and H2 introduced at atmospheric pressure. Vigorous 
stirring was continued at r.t. for 16 h. Upon filtering through a pad of celite the solvent was removed 
under reduced pressure and column chromatography [silica, PE: EtOAc gradient column] afforded 
the ethanol adduct 256 (62 mg, 24 %) and reduced product 257 (131 mg, 61 %) as a white solid. 
Reduced product (257) 
Rf [EtOAc] 0.32;  
Mp [CH2Cl2] Sublimes 195 °C, melts 215 °C;  
IR max (Thin film) 3420 (NH) and 1670 (C=O);  
1H NMR δH(400 MHz, CDCl3) 7.83 (1H, d, J 8.0 Hz, C(7)H), 6.94 (1H, brs, N(5)H), 6.71 (1H, dd, J 8.0 
and 0.5 Hz, C(8)H), 6.62 (1H, s, C(10)H), 4.42 (1H, ddd, J 10.0, 3.0 and 0.5 Hz, C(4a)H), 3.73 (1H, dd, 
J 12.0 and 2.0 Hz, C(1)H2), 2.61 (1H, dd, J 12.0 and 3.0 Hz, C(1)H2), 2.33 (3H, s, CH3), 1.99-1.93 (1H, 
m, C(4)H2), 1.89-1.74 (3H, m, C(2)H2, C(3)H2 and C(4)H2), 1.67 (1H, qt, J 13.0 and 3.0 Hz, C(2)H2) and 
1.44 (1H, qt, J 13.0 and 3.5 Hz, C(3)H2); 
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13C NMR δC(100 MHz, CDCl3) 164.8+ (C(6)q), 149.7+ (C(10a)q), 144.5+ (C(9)q), 128.6– (C(7)H), 120.3– 
(C(8)H), 115.2+ (C(6a)q), 112.8– (C(10)H), 68.2– (C(4a)H), 45.4+ (C(1)H2), 31.7+ (C(4)H2), 24.1+ 
(C(2)H2), 22.2– (CH3) and 21.8+ (C(3)H2); 
MS (+ESI) m/z 217 (100 %, [M+H]+) and 239 (69 %, [M+Na]+); 
HRMS (+ESI) m/z Found [M+H]+ 217.1327, C13H17N2O, requires [M+H]+ 217.1341. Found [M+Na]+ 








Glutaraldehyde (50 % wt. in water) (100 µL, 0.5 mmol) was added dropwise to a stirred solution of 
2-amino-5-methylbenzamide 235 (75 mg, 0.5 mmol) and NaSO4 (213 mg, 1.5 mmol) in THF (3 mL) 
at r.t. under N2. NH4Cl (27 mg, 100 mol %) was added and the reaction stirred at r.t. for 9 h, 
monitoring by TLC. EtOAc (10 mL) was added and the THF removed under reduced pressure. After 
filtering the solvent was removed under reduced pressure to afford the crude enamine 287 without 
further purification. 
A vigorously stirred suspension of 8-methyl-3,4,4a,5-tetrahydro-6H-pyrido[1,2-a]quinazolin-6-one 
287 (107 mg, 0.5 mmol) in EtOH (5 mL) at r.t. was purged with N2 and Pd/C (10 % wt.) (50 mg) was 
added. The flask was degassed and H2 introduced at atmospheric pressure. Vigorous stirring was 
continued at r.t. for 16 h. Upon filtering through a pad of celite the solvent was removed under 
reduced pressure and column chromatography [silica, PE: EtOAc gradient column] afforded the 
reduced product 258 (34 mg, 31 %) as a white solid. 
Rf [EtOAc] 0.5;  
Mp [CH2Cl2] 119 °C;  
IR max (Thin film) 3430 (NH) and 1650 (C=O);  
1H NMR δH(400 MHz, CDCl3) 7.75 (1H, d, J 2.5 Hz, C(7)H), 7.20 (1H, ddd, J 1.0, 2.5 and 8.5 Hz, C(9)H), 
7.08 (1H, brs, N(5)H), 6.73 (1H, d, J 8.5 Hz, C(10)H), 4.38 (1H, ddd, J 1.0, 3.0 and 10.5 Hz, C(4a)H), 
3.68 (1H, brd, J 12.0 Hz, C(1)H2), 2.58 (1H, td, J 3.0 and 12.5 Hz, C(1)H2), 2.27 (3H, s, CH3), 2.00-1.94 
(1H, m, C(4)H2), 1.89-1.78 (3H, m, C(2)H2, C(3)H2 and C(4)H2), 1.76-1.63 (1H, m, C(2)H2) and 1.44 
(1H, qt, J 3.5 and 12.5 Hz, C(3)H2);  
13C NMR δC(100 MHz, CDCl3) 165.0+ (C(6)q), 147.7+ (C(10a)q), 134.6– (C(9)H), 128.7– (C(7)H and 
C(8)q), 117.6+ (C(6a)q), 112.4– (C(10)H), 68.2– (C(4a)H), 45.6+ (C(1)H2), 31.5+ (C(4)H2), 24.2+ 
(C(2)H2), 21.8+ (C(3)H2), 20.2– (CH3); 
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MS (+ESI) m/z 215 (100 %, [M+H]+–H2), 237 (69 %, [M+Na]+–H2), 217 (48 %, [M+H]+) and 239 (34 %, 
[M+Na]+);  
HRMS (+ESI) m/z Found [M+H]+ 217.1327, C13H17N2O, requires [M+H]+ 219.1341. Found [M+Na]+ 
239.1146, C13H16N2NaO, requires [M+Na]+ 239.1160. 
  




Glutaraldehyde (50 % wt. in water) (67 μL, 0.35 mmol) was added dropwise to a stirred solution of 
2-amino-3-methylbenzamide 233 (53 mg, 0.35 mmol) and MgSO4 (105 mg, 0.88 mmol) in THF (2 
mL) at r.t. under N2. NH4Cl (9.0 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. 
EtOAc (10 mL) was added and after filtering the solvent was removed under reduced pressure to 
give the crude enamine 285 which was used without further purification. 
A flask containing a vigorously stirring suspension of crude 10-methyl-3,4,4a,5-tetrahydro-6H-
pyrido[1,2-a]quinazolin-6-one 285 (75 mg, 0.35 mmol) and Pd/C (10 % wt.) (35 mg) in EtOH (2.5 mL) 
at r.t. was purged with N2. The flask was degassed and H2 introduced at atmospheric pressure. 
Vigorous stirring was continued at r.t. for 18 h. Upon the removal of H2 the reaction was filtered 
through celite and further washed with warm EtOH until the crude mass was constant. The solvent 
was removed under reduced pressure and column chromatography [silica, PE: EtOAc gradient 
column] afforded analogue 260 (30 mg, 40 %) as a light yellow crystalline solid. 
Analogue (260) 
Rf [PE:EtOAc, 30:70] 0.43;  
Mp [CHCl3] 95-98 °C;  
IR max (Thin film) 1663 (C=O), 1518 (C=N) and 1239 (CN);  
1H NMR δH(400 MHz, CDCl3) 8.10 (1H, ddd, J 8.0, 1.5 and 1.0 Hz, C(7)H), 7.54 (1H, ddd, J 7.0, 1.5 and 
1.0 Hz, C(9)H), 7.29 (1H, t, J 7.5 Hz, C(8)H), 4.07 (1H, t, J 6.5 Hz, C(1)H2), 3.00 (1H, t, J 7.0 Hz, C(4)H2), 
2.58 (3H, s, CH3) and 2.03-1.90 (4H, m, C(2)H2 and C(3)H2); 
13C NMR δC(100 MHz, CDCl3) 162.5– (C(6)q), 153.4– (Cq), 146.0– (Cq), 134.8– (Cq), 134.5+ (C(9)H), 
124.2+ (C(8)H), 123.9+ (C(7)H), 120.3– (Cq), 42.1– (CH2), 32.1– (CH2), 22.1+– (C(2 or 3)H2), 19.4– (C(3 
or 2)H2) and 17.2– (CH3); 
MS (+ESI) m/z 215 (100 %, [M+H]+), 237 (67 %, [M+Na]+) and 451 (35 %, [2M+Na]+);  
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HRMS (+ESI) m/z Found [M+H]+ 215.1181, C13H15N2O, requires [M+H]+ 215.1184. Found [M+Na]+ 
237.0990, C13H14N2NaO, requires [M+Na]+ 237.1004; 
  
- 196 - 
 
2-(Piperidin-1-yl)benzamide (265) and 1,2,3,4,4a,5-hexahydro-6H-pyrido[1,2-a]quinazolin-6-one 
(254) and 1,2,3,4,4a,5-hexahydro-6H-pyrido[1,2-a]quinazolin-6-one (254) 
 
Glutaraldehyde (50 % wt. in water) (190 μL, 1 mmol) was added dropwise to a stirred solution of 
anthranilamide 196 (136 mg, 1 mmol) and MgSO4 (300 mg, 2.5 mmol) in MeOH (3 mL) at r.t. under 
Ar. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 60 mins. NaBH3CN (251 
mg, 4 mmol) was added and the reaction stirred at r.t. for 24 h. The reaction was quenched with 
NaHSO4 and extracted with EtOAc (3 x 10 mL). The combined organic fractions were washed with 
sat. brine (10 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
Column chromatography [silica, PE: EtOAc gradient column] afforded product 265 (10 mg, 5 %) and 
product 254 (trace) as a white crystalline solids. 
Compound (265) 
1H NMR δH(400 MHz, CDCl3) 9.80 (1H, brs, NH2), 8.16 (1H, ddd, J 7.5, 2.0 and 1.0 Hz, C(6)H), 7.44 
(1H, ddd, J 8.0, 7.0 and 2.0 Hz, C(3)H), 7.22-7.18 (2H, m, C(4)H and C(5)H), 5.82 (1H, brs, NH2), 2.93 
(4H, t, J 5.0 Hz, C(2’)H2 and C(6’)H2), 1.74 (4H, p, J 5.5 Hz, C(3’)H2 and C(5’)H2) and 1.62-1.58 (2H, m, 
C(4’)H2);  
13C NMR δC(100 MHz, CDCl3) 168.7 (C(=O)q), 152.9 (C(2)q), 132.4+ (C(3)H), 131.6+ (C(6)H), 127.3 
(C(1)q), 124.3+ (C(4 or 5)H), 120.4+ (C(5 or 4)H), 54.9 (C(2’)H2 and C(6’)H2), 26.7+ (C(3’)H2 and 
C(5’)H2) and 23.6 (C(4’)H2).  
Spectroscopic data is consistent with that reported by Sun et al.201 
Analogue (254) 
Spectroscopic data are consistent with those previously reported for analogue 254. 
 
  




Glutaraldehyde (50 % wt. in water) (190 μL, 1 mmol) was added dropwise to a stirred solution of 
anthranilamide 196 (136 mg, 1 mmol) in THF (3 mL) at r.t. under Ar. NH4Cl (27 mg, 50 mol %) was 
added and the reaction stirred at r.t. until the starting material had been consumed as determined 
by TLC spectroscopic analysis. Methanol was added (3 mL) and the reaction cooled to 0 °C. NaBH3CN 
(188 mg, 3 mmol) was added portion wise followed by AcOH until the pH was less than 7. The 
reaction was warmed to r.t. and stirred for 4 h. The reaction was quenched with H2O2(aq) (2 mL) and 
1M NaOH(aq) (5 mL) and stirred until two separate layers were visible. 0.5 M FeSO4(aq) (10 mL) was 
added and the reaction stirred overnight, extracted with EtOAc (3 x 10 mL) and the combined 
organic fractions were washed with sat. brine (10 mL), dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. Column chromatography [silica, PE: EtOAc gradient column] 
afforded product 254 (112 mg, 55 %) as a white crystalline solids. 
1H NMR δH(500 MHz, CDCl3) 7.95 (1H, dd, J 7.5 and 1.5 Hz, C(7)H), 7.39 (2H, dt, J 7.0 and 1.5 Hz, 
C(9)H), 7.09 (1H, brs, NH), 6.90 (1H, t, J 7.5 Hz, C(8)H), 6.82 (1H, d, J 8.5 Hz, C(10)H), 4.46 (1H, dd, J 
10.5 and 3.0 Hz, C(4a)H), 3.74 (1H, brd, J 12.0 Hz, C(1)H2), 2.62 (1H, dt, J 12.5 and 3.0 Hz, C(1)H2), 
2.00-1.98 (1H, m, C(4)H2), 1.89-1.78 (3H, m, C(2)H2, C(3)H2 and C(4)H2), 1.69 (1H, qt, J 12.5 and 4.0 
Hz, C(2)H2) and 1.46 (1H, qt, J 13.0 and 3.5 Hz, C(3)H2);  
13C NMR δC(125 MHz, CDCl3) 164.7– (C(6)q), 149.7– (C(10a)q), 133.9+ (C(9)H), 128.7+ (C(7)H), 119.2+ 
(C(8)H), 117.7– (C(6a)q), 112.3+ (C(10)H), 68.2+ (C(4a)H), 45.5– (C(1)H2), 31.8– (C(4)H2), 24.2– 
(C(2)H2) and 21.9– (C(3)H2). 
Spectroscopic data are consistent with those previously reported for analogue 254. 
 
  




Glutaraldehyde (50 % wt. in water) (100 µL, 0.5 mmol) was added dropwise to a stirred solution of 
2-amino-3-methylbenzamide 233 (75 mg, 0.5 mmol) and MgSO4 (180 mg, 1.5 mmol) in THF (3 mL) 
at r.t. under N2. NH4Cl (27 mg, 100 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc 
(10 mL) was added and the THF removed under reduced pressure. After filtering the solvent was 
removed under reduced pressure to afford the crude enamine without further purification. 
A solution of NaIO4(aq) (10 %, 5 mL) was mixed with RuCl3·×H2O (5 mg, 0.02 mmol) and then added 
dropwise to a stirred solution of crude 10-methyl-3,4,4a,5-tetrahydro-6H-pyrido[1,2-a]quinazolin-
6-one 285 (107 mg, 0.5 mmol) in EtOAc (10 mL) at r.t.. After 105 min stirring the layers were 
separated and the aqueous layer extracted with EtOAc (3 × 10 mL). iPrOH (8.0 mL) was added to 
the combined organic fractions and stirred for 18 h. After filtering the black precipitate the reaction 
was washed with water (10 mL), sat. brine (10 mL) and dried over Na2SO4 and filtered. Column 
chromatography [silica, CH2Cl2: Acetone gradient column] afforded the product 268 (36 mg, 33 %) 
as a white crystalline solid. 
Dione (268) 
Rf [CH2Cl2:Acetone, 50:50] 0.61;  
Mp [CH2Cl2] 135-139 °C;  
IR max (Thin film) 3585 (NH) 1665 (C=O) and 1632 (C=O);  
1H NMR δH(400 MHz, CDCl3) 8.12 (1H, dt, J 7.5 and 1.0 Hz, C(6)H), 7.60 (1H, dq, J 7.0 and 1.0 Hz, 
C(8)H), 7.34 (1H, t, J 7.5 Hz, C(7)H), 6.30 (1H, dd, J 7.0 and 3.0 Hz, C(3a)H), 4.49 (1H, brs, N(4)H), 
3.36 (1H, C(2)H2), 3.06 (1H, C(2)H2), 2.60 (3H, s, CH3), 2.50 (1H, C(3)H2) and 2.21 (1H, C(3)H2);  
13C NMR δC(100 MHz, CDCl3) 162.2– (C(5)q), 156.8– (C(1)q), 148.3– (C(9a)q), 135.5– (C(5a)q), 135.3+ 
(C(8)H), 125.8+ (C(7)H), 123.9+ (C(6)H), 120.4– (C(9)q), 83.1+ (C(3a)H), 29.8– (C(2)H2), 27.3– (C(3)H2) 
and 17.7+ (CH3); 
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MS (+ESI) m/z 239 (100 %, [M+Na]+) and 217 (39 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 217.0975, C12H13N2O2, requires [M+H]+ 217.0977. Found [M+Na]+ 
239.0792, C12H12N2NaO2, requires [M+Na]+ 239.0796. 
  




Glutaraldehyde (50 % wt. in water) (190 mL µL, 1 mmol) was added dropwise to a stirred solution 
of 2-amino-4-methylbenzamide 234 (150 mg, 1 mmol) and MgSO4 (300 mg, 2.5 mmol) in THF (5 mL) 
at r.t. under N2. NH4Cl (27 mg, 50 mol %) was added and the reaction stirred at r.t. for 24 h. EtOAc 
(10 mL) was added and the THF removed under reduced pressure. After filtering the solvent was 
removed under reduced pressure to afford the crude enamine without further purification. 
A solution of NaIO4(aq) (10 %, 10 mL) was mixed with RuCl3·×H2O (10 mg, 0.04 mmol) and then added 
dropwise to a stirred solution of crude 9-methyl-3,4,4a,5-tetrahydro-6H-pyrido[1,2-a]quinazolin-6-
one 286 (214 mg, 1 mmol) in EtOAc (20 mL) at r.t.. After 105 min stirring the layers were separated 
and the aqueous layer extracted with EtOAc (3 × 10 mL). iPrOH (20 mL) was added to the combined 
organic fractions and stirred for 18 h. After filtering the black precipitate the reaction was washed 
with water (10 mL), sat. brine (10 mL) and dried over Na2SO4 and filtered. Column chromatography 
[silica, CH2Cl2: Acetone gradient column] afforded the product 269 (56 mg, 26 %) as a white 
crystalline solid. 
Dione (269) 
Rf [EtOAc] 0.47;  
Mp [MeOH] 135-145 °C;  
IR max (Thin film) 3575 (NH), 1670 (C=O) and 1627 (C=O);  
1H NMR δH(400 MHz, CDCl3) 8.12 (1H, d, J 8.5 Hz, C(6)H), 7.44 (1H, s, C(9)H), 7.26 (1H, d, J 8.5 Hz, 
C(7)H), 6.30 (1H, dd, J 3.0 and 7.0 Hz, C(3a)H), 4.89 (1H, brs, N(4)H), 3.39-3.31 (1H, m, C(2)H2), 3.07-
2.99 (1H, m, C(2)H2), 2.49 (3H, s, CH3), 2.44-2.53 (1H, m, C(3)H2) and 2.17-2.25 (1H, m, C(3)H2);  
13C NMR δC(100 MHz, CDCl3) 161.7+ (C(5)q), 158.3+ (C(1)q), 149.7+ (C(9a)q), 145.8+ (C(8)q), 128.0– 
(C(7)H), 126.7– (C(9)H), 126.1– (C(6)H), 118.1+ (C(5a)q), 83.0– (C(3a)H), 29.7+ (C(2)H2), 27.4+ 
(C(3)H2) and 21.9– (CH3); 
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MS (+ESI) m/z 239 (100 %, [M+Na]+), 455 (21 %, [2M+Na]+) and 217 (19 %, [M+H]+);  
HRMS (+ESI) m/z Found [M+H]+ 217.0972, C12H13N2O2, requires [M+H]+ 217.0977. Found [M+Na]+ 
239.0794, C12H12N2NaO2, requires [M+H]+ 239.0796; 
  




Anthranilamide 196 (272 mg, 2 mmol) and D-lyxose (300 mg, 2 mmol) were stirred in MeOH (12 
mL). NH4Cl (54 mg, 100 mol %) was added and the reaction stirred at 60 °C for 18 h. The white 
precipitate was filtered and rinsed with MeOH (2 x 10 mL) affording the product 273 as a white solid 
(177 mg, 33 %) without further purification.  
Mp [MeOH] 215-216 °C;  
IR max (KBr disc) 3387, 3295, 3235, 1654, 1610, 1103; 
1H NMR δH(400 MHz, DMSO) 7.59 (1H, brs, NH), 7.58 (1H, dd, J 8.0 and 1.5 Hz, C(8)H), 7.23 (1H, ddd, 
J 8.0, 7.0 and 1.5 Hz, C(6)H), 6.84 (1H, dd, J 8.0 and 0.5 Hz, C(5)H), 6.64 (1H, td, J 7.5 and 1.0 Hz, 
C(7)H), 6.32 (1H, brs, N, 5.06 (1H, d, J 6.5 Hz, C(1’)OH), 4.89 (1H, d, J 6.5 Hz, C(3’)H), 4.57 (2H, m, 
C(2’)OH and C(4’)OH), 4.44 (1H, d, J 6.5 Hz, C(3’)OH), 3.76 (1H, m, C(3’)H), 3.64-3.57 (2H, m, C(2’)H 
and C(1’)H) and 3.50-3.46 (2H, m, C(4’)H2);  
13C NMR δC(100 MHz, DMSO) 163.7 (C(=O)q), 148.5 (C(4a)q), 132.8+ (C(6)H), 126.9+ (C(8)H), 116.2+ 
(C(7)H), 114.7 (C(8a)q), 114.2+ (C(5)H), 72.2+ (C(1’)H), 70.4+ (C(2’)H), 70.1+ (C(3’)H), 66.3+ (C(3)H) 
and 62.7– (C(4’)H2); 
MS (+ESI) m/z 157 (100 %, [Anthranilamide+Na]+–H2), 291 (24 %, [M+Na]+) and 559 (25 %, 
[2M+Na]+);  
HRMS (+ESI) m/z Found [M+Na]+ 291.0942, C12H16N2NaO5, requires [M+Na]+ 291.0957. 
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2-((E)-((2R,3R,4R)-2,3,4,5-Tetrahydroxypentylidene)amino) benzamide (274) 
 
Anthranilamide 196 (272 mg, 2 mmol) and D-lyxose (300 mg, 2 mmol) were stirred in EtOH (12 mL) 
at 60 °C for 18 h. The white precipitate was filtered and rinsed with EtOH (2 x 10 mL) affording the 
product 274 as a white solid (477 mg, 89 %) without further purification.  
Mp [MeOH] 178-185 °C; 
IR max (KBr disc) 3433, 3288, 3186, 1646, 1514, 1039;  
1H NMR δH(400 MHz, DMSO) 8.78 (1H, d, J 9.0 Hz, NH), 7.83 (1H, brs, NH2), 7.61 (1H, dd, J 1.5, and 
8.0 Hz, C(3)H), 7.31 (1H, dt, J 1.5 and 8.5 Hz, C(5)H), 7.16 (1H, brs, NH2), 6.87 (1H, d, J 8.0 Hz, C(6)H), 
6.67 (1H, dt, J 1.0 and 8.0 Hz, C(4)H), 4.93 (1H, d, J 6.0 Hz, C(2’)OH), 4.88 (1H, d, J 5.5 Hz, C(3’)OH), 
4.84 (1H, d, J 5.0 Hz, C(4’)OH), 4.83 (1H, brd, J 10.0 Hz, C(1’)H), 3.76 (1H, brddd, J 1.5, 3.5 and 5.5 
Hz, C(2’)H), 3.71-3.61 (2H, m, C(4’)H and C(5’)H2), 3.44-3.40 (1H, m, C(3’)H) and 3.15 (1H, dd, J 9.0 
and 10.5 Hz, C(5’)H2);  
13C NMR δC(125 MHz, DMSO) 171.1 (C(=O)q), 147.3 (C(1)q), 132.0+ (C(5)H), 128.7+ (C(3)H), 116.0 
(C(2)q), 115.5+ (C(4)H), 113.1+ (C(6)H), 81.3+ (C(1’)H), 74.1+ (C(3’)H), 70.3+ (C(2’)H), 66.5+ (C(4’)H) 
and 66.0– (C(5’)H2); 
1H NMR δH(400 MHz, DMSO-D2O shake) 7.57 (1H, dd, J 1.5 and 8.0 Hz, C(3)H), 7.32 (1H, ddd, J 1.5, 
7.0 and 8.5 Hz, C(5)H), 6.87 (1H, d, J 8.0 Hz, C(6)H), 6.69 (1H, dt, J 1.0 and 8.0 Hz, C(4)H), 4.82 (1H, 
d, J 1.5 Hz, C(1’)H), 3.77 (1H, brdd, J 1.5 and 3.5 Hz, C(2’)H), 3.71-3.66 (1H, m, C(5’)H), 3.64-3.60 (1H, 
m, C(4’)H), 3.43 (1H, dd, J 3.5 and 8.5 Hz, C(3’)H) and 3.15 (1H, dd, J 9.0 and 10.5 Hz, C(5’)H);  
13C NMR δC(125 MHz, DMSO-D2O shake) 171.1 (C(=O)q), 147.0 (C(1)q), 132.3+ (C(5)H), 128.7+ 
(C(3)H), 116.0+ (C(2)H), 115.6 (C(4)q), 113.2+ (C(6)H), 81.1+ (C(1’)H), 73.7+ (C(3’)H), 70.0+ (C(2’)H), 
66.4+ (C(4’)H) and 65.6 (C(5’)H2); 
MS (+ESI) m/z 291 (100 %, [M+Na]+) and 559 (58 %, [2M+Na]+);  
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HRMS (+ESI) m/z Found [M+Na]+ 291.0942, C12H16N2NaO5, requires [M+Na]+ 291.0957; 
  




Anthranilamide 196 (272 mg, 2 mmol) and L-lyxose (300 mg, 2 mmol) were stirred in MeOH (12 
mL). NH4Cl (54 mg, 100 mol %) was added and the reaction stirred at 60 °C for 18 h. The white 
precipitate was filtered and rinsed with MeOH (2 x 10 mL) affording the product 275 as a white solid 
(209 mg, 39 %) without further purification.  
Mp [MeOH] 213-215 °C;  
IR max (KBr disc) 3375, 3237, 1654, 1504, 1103; 
1H NMR δH(400 MHz, DMSO) 7.62 (1H, brs, NH), 7.57 (1H, dd, J 8.0 and 1.5 Hz, C(8)H), 7.30 (1H, brs, 
NH), 7.22 (1H, ddd, J 8.0, 7.0 and 1.5 Hz, C(6)H), 6.84 (1H, dd, J 8.0 and 0.5 Hz, C(5)H), 6.63 (1H, td, 
J 8.0 and 1.0 Hz, C(7)H), 6.38 (1H, brs, NH), 5.06 (1H, d, J 6.5 Hz, C(1’)OH), 4.89 (1H, d, J 6.5 Hz, 
C(3’)H), 4.64-4.57 (2H, m, C(2’)OH and C(4’)OH), 4.44 (1H, d, J 6.5 Hz, C(3’)OH), 3.76 (1H, q, J 6.0 Hz, 
C(3’)H), 3.64-3.57 (2H, m, C(2’)H and C(1’)H) and 3.50-3.46 (2H, m, C(4’)H2);  
13C NMR δC(100 MHz, DMSO) 163.7 (C(1)q), 148.5 (C(4a)q), 132.8+ (C(6)H), 126.9+ (C(8)H), 116.2+ 
(C(7)H), 114.7 (C(8a)q), 114.2+ (C(5)H), 72.2+ (C(1’)H), 70.4+ (C(2’)H), 70.1+ (C(3’)H), 66.3+ (C(3)H) 
and 62.7– (C(4’)H2); 
MS (+ESI) m/z 157 (100 %, [Anthranilamide+Na]+ – H2), 559 (25 %, [2M+Na]+) and 291 (24 %, 
[M+Na]+); 
HRMS (+ESI) m/z Found [M+Na]+ 291.0942, C12H16N2NaO5, requires [M+Na]+ 291.0957. Found 
[2M+Na]+ 559.2022, (C12H16N2O5)2Na, requires [2M+Na]+ 559.2016. 
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2-((E)-((2S,3S,4S)-2,3,4,5-Tetrahydroxypentylidene)amino) benzamide (276) 
 
Anthranilamide 196 (272 mg, 2 mmol) and L-lyxose (300 mg, 2 mmol) were stirred in EtOH (12 mL) 
at 60 °C for 18 h. The white precipitate was filtered and rinsed with EtOH (2 x 10 mL) affording the 
product 276 as a white solid (214 mg, 40 %) without further purification.  
Mp [MeOH] 173-175 °C; 
IR max (KBr disc) 3433, 3288, 3186, 1646, 1514, 1039;  
1H NMR δH(400 MHz, DMSO) 8.87 (1H, d, J 9.0 Hz, NH), 7.85 (1H, brs, NH2), 7.61 (1H, dd, J 8.0 and 
1.5 Hz, C(3)H), 7.31 (1H, dt, J 8.5 and 1.5 Hz, C(5)H), 7.21 (1H, brs, NH2), 6.87 (1H, d, J 8.5 Hz, C(6)H), 
6.67 (1H, d, J 7.5 Hz, C(4)H),4.97 (1H, d, J 6.0 Hz, C(2’)OH), 4.93 (1H, d, J 5.0 Hz, C(3’)OH),4.88 (1H, 
d, J 5.0 Hz, C(4’)OH),4.82 (1H, brd, J 10.0 Hz, C(1’)H), 3.77 (1H, brt, J 3.5 Hz, C(2’)H), 3.71-3.61 (2H, 
m, C(4’)H and C(5’)H), 3.44-3.40 (1H, m, C(3’)H) and 3.15 (1H, dd, J 9.0 and 10.5 Hz, C(5’)H);  
13C NMR δC(125 MHz, DMSO) 171.0 (C(=O)q), 147.3 (C(1)q), 132.0+ (C(5)H), 128.7+ (C(3)H), 115.9 
(C(2)q), 115.6+ (C(4)H), 113.1+ (C(6)H), 81.3+ (C(1’)H), 74.1+ (C(3’)H), 70.3+ (C(2’)H), 66.5+ (C(4’)H) 
and 66.0– (C(5’)H2); 
MS (+ESI) m/z 559 (100 %, [2M+Na]+) and 291 (70 %, [M+Na]+);  
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